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Abstract
Inherited retinal dystrophies constitute one of the most prevalent causes of bi­
lateral visual loss, affecting as many as 1 in 3000 people. Genetic therapies have been 
developed following the identification of disease-causing mutations, using an 
understanding of how these mutations cause retinal degeneration and improved viral 
vectors designed to give safe and efficient gene delivery. Hence a broad range of 
retinal disorders may be treatable with gene therapy, although many aspects of ocular 
gene therapy warrant further investigation.
The studies presented here aim to improve gene therapy in two well-characterised 
models of retinitis pigmentosa, the Prph2Rd2/Rdl mouse and the RCS rat. Gene 
replacement therapy can be effective in these and other models, mediating both 
structural and functional improvement. However, in many cases long-term rescue 
from degeneration is not achieved, as evidenced by a continuing loss of photoreceptor 
cells. These studies aim to improve adeno-associated virus (AAV)-mediated gene 
delivery to the murine retina by using novel promoters to investigate the 
consequences of gene replacement therapy. Additionally an alternative viral vector 
(AAV2/5) will be used to enhance gene replacement, which gives faster and stronger 
transgene expression than the AAV2/2 used in previous studies.
Cell death can also be prevented by administration of vectors expressing neurotrophic 
factors, but no study to date has identified such a factor that enhances gene 
replacement therapy; indeed, AAV-mediated CNTF expression has serious deleterious 
effects on retinal function. Hence here we have investigated these deleterious effects, 
and determined whether CNTF can be used to prevent photoreceptor death without 
the reduction in retinal function seen previously. In addition, the ability of AAV- 
mediated GDNF expression to enhance gene replacement therapy in both the 
Prph2Kd2fRd2 mouse and the RCS rat has been evaluated in detail. These studies show 
for the first time that neurotrophic factor delivery, when used in combination with 
gene replacement therapy, can enhance structural and functional improvement in 
models of retinitis pigmentosa.
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Abbreviation List
Below is a list of technical terms and common abbreviations used in this thesis. As far 
as is possible the terms are explained in full when first introduced, and subsequently 
used in abbreviated form.
AAV Adeno-associated virus
Ad Adenovirus
AMD Age-related macular degeneration
BDNF Brain-derived neurotrophic factor
cGMP cyclic guanosine monophosphate
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CNTF Ciliary neurotrophic factor
DMEM Dulbecco’s modified Eagle medium
ERG Electroretinogram
FGF Fibroblast growth factor
GDNF Glial cell line-derived neurotrophic factor
GFP Green fluorescent protein
HIV Human immunodeficiency virus
Lenti Lentiviral vector
MOPS Mouse opsin promoter fragment
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
PEDF Pigment epithelium-derived factor
Prph2 Peripherin 2
Rho Rhodopsin promoter (bovine)
RPE Retinal pigment epithelium
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1. Introduction
1.1 The eye — structure, function and genetic disease
Vital to the ability of higher organisms to sense, evaluate and interact with 
their environment, the eye is often referred to as the one of the most complex organ 
systems in biology. The primary function of the human eye is to respond to visual 
stimuli by transducing a response to light into neuronal signals that are interpreted by 
the brain. The eye carries out many disparate cellular and molecular processes to 
support the sensing of external stimuli; a tightly regulated microenvironment is 
maintained within the eye with regards to the differentiated status of its various cell 
types, vasculogenesis and modulation of the local immune system. This complexity of 
function arises from the variety of developmental origins of the cell types within the 
eye, and leads to a high degree of sensitivity to genetic and environmental factors. 
Slight changes in the finely balanced pattern of gene expression can lead to disease, as 
can subtle environmental insults and infections. The neurosensory retina, which 
responds to light entering the eye by initiating a neuronal signalling cascade, is the 
seat of many inherited genetic diseases, many of which result in blindness in one or 
both eyes and have been extensively researched in both clinical and laboratory 
settings. However, despite increased knowledge of aetiology and pathology of 
disease, many ocular conditions, especially retinal disorders, lack effective treatments.
1.2 Structure of the eye
The mammalian eye consists of concentric layers of tissue derived from two of 
the three embryological layers, the ectoderm and the mesoderm. An outer, fibrous 
casing, the sclera, forms a tough barrier that protects the eye; this layer originates in 
the mesoderm. Contiguous with the sclera, and also arising from the mesoderm, the 
anterior part of the eye’s outermost layer is the cornea (for schematic diagram see Fig. 
1.1). At the anterior opening of the eye, posterior to the cornea, lies the lens, which 
alters the refractive index of incident light by changing shape; this ectoderm-derived 
tissue enables images from varying distances to be focused onto the light-sensitive
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neuroretina. Encased inside the sclera is a vascular layer of tissues, amongst which the 
iris and choroid are found. Adjacent to this layer lies the neuronal tissue known as the 
neurosensory retina. This photosensitive tissue is where the capture, amplification and 
transduction of light signals to the visual cortex takes place [1], and the retina has 
evolved to carry out these primary functions of the eye as discussed below.
^ —  Corneal epithelium
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x Iridocorneal angle
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Iris -
C onjunctiva------
 Canal of SchlemmPosterior cham ber Lens
  Pars planaLens zon u les
Ciliary body r—  Ora serrata
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—  Subarachnoid sp a c e
—  Dura mater
Optic nerve
Fig. 1.1: Structure o f the eye; schematic diagram showing features of the human eye. [1]
1.3 T he retina -  structure and function
Consisting of several distinct layers of cells, the retina carries out the various 
functions required to achieve phototransduction -  the process by which light is 
received and converted into neuronal impulses. This neural layer of cells is generally 
viewed as two distinct tissue compartments: the inner, neurosensory retina, and the 
outer, supporting layer of cells, the retinal pigment epithelium (RPE).
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Fig. 1.2: H istological cross-section of the human retina; the various layers of cells are 
labelled on the right, cell types present in these layers identified on the left. OLM; outer 
limiting membrane. ONL; outer nuclear layer. OPL; outer plexiform layer. IPL; inner 
plexiform layer. GCL; ganglion cell layer. ILM; inner limiting membrane.
The neurosensory retina is a highly specialised tissue, comprising three principle cell 
types that perform the central functions in the phototransduction cascade and visual 
pathway: photoreceptor cells, bipolar cells and ganglion cells. The cells that respond 
to light entering the eye are the photoreceptor cells, of which the mammalian eye 
contains two different types: rods and cones. Rod- and cone-cell nuclei and cell 
bodies are found in the outer nuclear layer of the eye as seen in histological cross- 
section (Fig. 1.2), and rods dominate the photoreceptor cell population in the 
mammalian eye; there are around eighteen times as many rods as cones in an adult 
human eye. Rod and cone photoreceptors differ in the visual pigment they contain, 
and as a result they respond to different stimuli; rods contain the pigment rhodopsin 
whilst cones house different cone opsins depending on which sub-type of cone cell 
they belong to. Rods are sensitive to conditions of dim light and are responsible for 
scotopic (night) and peripheral vision, whereas cones respond to bright light of 
varying wavelengths allowing colour vision. In humans cone cells are also responsible 
for central visual acuity due to their spatial distribution (see below). Humans have
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three sub-types of cones, which respond to different wavelengths of light. Those that 
are maximally sensitive to long wavelengths of light (red light) are the L-cones, cones 
responsive to medium wavelengths of light (green light) are the M-cones, and cones 
that respond to short wavelengths of light (blue light) are the S-cones. Rodents and 
most other mammalian species are di-chromatic, meaning they only have cone cells 
that respond to medium- and short-wavelength light (M- and S-cones).
In the human eye, there is a central, pigmented portion of the retina, the macula, 
which is enriched for cone cells. Approximately 5 mm in diameter, and located 3 mm 
lateral to the optic disk (Fig. 1.1), the macula contributes most to visual acuity in 
humans, as it contains the greatest concentration of cone cells; there are 150,000 cone 
cells per mm in this region of the human eye. Within the macula, the central portion 
of retinal tissue is referred to as the fovea centralis. Here the inner retinal cells are 
displaced away from the underlying photoreceptors, allowing a greater proportion of 
incident light to be absorbed by the cells in this region (Fig. 1.3); this also contributes 
to the increase in acuity in this central retinal area. Rodents and other mammals (other 
than non-human primates) lack an anatomically defined macula, with cones 
distributed more evenly throughout the retina; this has implications for the study of 
retinal disease in animal models, as discussed below.
Photoreceptor cells have distinct cellular structures, comprising inner and outer 
segments, as well as a synaptic region and a cell body that contains the nucleus (Fig. 
1.4). The inner segments are densely packed with mitochondria, and provide a 
metabolic centre from which the energy required for the process of phototransduction 
is derived. A connecting cilium leads from inner to outer segment, which is intimately 
involved in the regulated transport of molecules into and out of the outer segment. In 
both rods and cones the outer segment is where their respective visual pigments are 
localised, which absorb light in a manner discussed below (Chapter 1.4). The outer 
segments in cone cells are made up of invaginations of the plasma membrane, known 
as lamellae. In rods these invaginations undergo further folding to form stacks of 
membranous discs discrete from the plasma membrane [2]. Inserted into cone 
lamellae and rod discs are the structural proteins peripherin-2 and rom-1 (see Chapter 
1.6), both of which are required for the formation and maintenance of outer segments.
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Fig. 1.3: Retinal cross-section of primate fovea; inner retinal cells are displaced from the 
foveal pit, allowing more light to reach cone photoreceptors located in the fovea centralis.
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Fig. 1.4: Rod and Cone photoreceptor cells; schematic diagram showing properties o f 
both types of photoreceptor cell. Taken from http: /  /anatomv.iupui.edu/
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Using connections at their innermost aspect, photoreceptor cells synapse with bipolar 
cells in the inner nuclear layer (Fig. 1.2), each of which receive stimuli from several 
photoreceptors. These bipolar cells in turn project axons into the inner plexiform layer 
of cells in the retina, and synapse with dendritic processes of ganglion cells (whose 
cell bodies lie in the ganglion cell layer, anterior to the inner plexiform layer -  see 
Fig. 1.2). The axons of the ganglion cells form the fibres of the optic nerve, and 
synapse with cells lateral geniculate nucleus; from here impulses are sent to the 
primary visual cortex.
Aside from these principal cell types, several other neuronal cells within the retina are 
required for processing of the visual signal, such as the amacrine association 
neurones. There are at least 20 morphologically distinct sub-classes of amacrine cell, 
which can be further classified according to the neurotransmitter they secrete 
(generally Gamma-Aminobutyric acid (GABA) or dopamine). Amacrine cells lack 
anatomically defined axons, but have dendrites that synapse with rod bipolars, from 
which they receive a signal in response to light which they then transmit to retinal 
ganglion cells (RGC); these represent horizontal connections between bipolar and 
ganglion cells, and serve to process the visual signal in addition to the direct 
connection between bipolar and ganglion cells themselves. As amacrine cells also 
make horizontal connections between rod- and cone-bipolar cells, they contribute to 
processing of the visual signal and add to the sensitivity to movement and contrast 
[3]. Muller cells, found in the inner nuclear layer, are a glial cell type that support 
both bipolar neurones and ganglion cells, providing survival factors and nutrients for 
these inner retinal cells. By surrounding blood vessels and insulating neuronal axons 
and cell bodies, they provide essential functions necessary for the maintenance of 
both the inner and outer retina.
Posterior to the photoreceptor outer segments lies the retinal pigment epithelium 
(RPE, see Fig. 1.2). The RPE comprises a monolayer of cuboid cells, the basal aspect 
of which lies on the connective tissue layer known as Bruch’s membrane. The RPE 
plays a vital role in the eye, providing much of the trophic support required to 
maintain the photosensitive retinal cells; components of the inter-photoreceptor 
matrix and various growth factors are produced by the RPE, which are essential for 
the development and support of rods and cones. In addition, RPE cells phagocytose
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photoreceptor outer segments, allowing them to be turned over and re-synthesised. 
The RPE is also involved in the visual cycle, essential for the uptake and turnover of 
by-products of the phototransduction cascade, as discussed in more detail later 
(Chapter 1.4). The RPE is thus crucial for effective maintenance of the neuronal 
component of the retina, and hence some diseases with retinal phenotypes in fact arise 
from primary defects in RPE function (Chapter 1.6).
Despite the lack of an anatomically defined macula in rats and mice, and the different 
spatial distribution and density of cone cells, the murine retina remains a useful model 
system in which human retinal dystrophies may be studied. Many of the genes that 
cause hereditary retinal disorders in humans either have naturally occurring 
counterparts in rodents, or have been modelled by using transgenic, knock-out or 
selective gene ablation technologies [4]. By studying the pathophysiology of such 
models, the mechanism of disease can be elucidated in many cases, and valuable 
insights into human disease have been obtained through investigations in animals. 
However, the differences between human and animal retinal biology must always be 
considered when applying conclusions from animal experiments to clinical contexts; 
the relevance of rodent disease mechanisms and responses to treatment is always open 
to question.
1.4 Phototransduction and the visual cycle
Neuronal signalling in response to an external stimulus is generally associated 
with a depolarisation of the actively maintained voltage across the cell membrane. 
This in turn results in secretion of a neurotransmitter that is detected by post-synaptic 
cells. In the case of photoreceptors, however, in the resting (un-stimulated) state the 
plasma membrane is depolarised, and the neurotransmitter glutamate is released into 
the synaptic space where it is bound by receptors on post-synaptic bipolar cells. This 
is an important consideration when discussing the phototransduction cascade; the 
‘ground state’ for rod and cone cells is one of a depolarised, actively secreting cell, 
which upon stimulation reverts to a hyperpolarised state, meaning that it is the 
reduction in neurotransmitter release that gives rise to subsequent signalling involved
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in perception of light by the brain. The depolarised ‘ground state’ and the 
hyperpolarised ‘excited’ state are shown schematically in Fig. 1.5. Once light enters 
the eye, it reaches the photoreceptor cells where it is absorbed by the visual pigment 
housed in membranous discs of the outer segments. In the case of rod cells, this 
pigment is rhodopsin; this is a G-protein coupled receptor (GPCR) that consists of a 
seven-pass transmembrane protein, rod opsin. As shown in Fig. 1.6, the seventh 
intradiscal domain is associated with the Vitamin A analogue 11 -cis retinal; this is the 
chromophore element of both rhodopsin and cone opsin, and when photons of light 
are absorbed by 11 -cis retinal, it isomerises to al\-trans retinol.
Rod
outer
segment
Rod
inner
segment
Fig. 1.5: Ion transport and membrane potential in photoreceptors in dark and light 
states; In the dark, cGMP-gated sodium channels allow an influx o f N a+ ions into the 
photoreceptor, maintaining a depolarised membrane potential (Dark, left panel). This 
depolarisation means that voltage-gated calcium channels (not shown) remain open in the 
dark. Upon light excitation, reduced levels o f cGMP lead to closure of the N a+ channels, 
and subsequent closure o f voltage-gated Ca2+ channels, hyperpolarising the photoreceptor 
(Light, right panel).
Dark
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Fig. 1.6: Tertiary structure of rhodopsin; Highlighted are 11 -cis retinal binding site 
(purple) phosphorylation sites used by rhodopsin kinase (green), glycosylation sites (red), 
and arrestin interaction sites (blue). From http://w ebvision.m ed.utah.edu/photol.htm l
The subsequent steps in the phototransduction cascade are summarised in Fig. 1.7. 
The isomerisation to al\-trans retinol causes rhodopsin to undergo a conformational 
change in its tertiary structure; this ‘activated’ form of rhodopsin is now able to 
activate the small G-protein, transducin, which is bound to the C-terminal end of 
rhodopsin. The activated transducin molecule then allows the y subunit of the 
phosphodiesterase (PDE) enzyme to hydrolyse cyclic guanosine monophosphate 
(cGMP) to 5’GMP. PDE is made up of three subunits, a, p and y. The decrease in the 
intracellular concentration of cGMP, caused by PDE-catalysed hydrolysis, closes 
cGMP-dependent Na+ channels. This prevents the influx of sodium ions into the rod 
cells, which in turn results in the voltage-gated Ca2+ channels closing. The 
photoreceptor cell is now hyperpolarised; as a result, the neurotransmitter glutamate, 
which is continuously released in unstimulated conditions, is prevented from being 
released. This drop in glutamate release by the photoreceptor cells upon light 
stimulation is sensed by the post-synaptic bipolar cells, which respond by either 
depolarising or hyperpolarising their own synaptic membranes, depending on whether 
they are ON- or OFF-bipolar cells. These bipolar cells then signal to retinal ganglion 
cells, whose axons project from the posterior pole of the eye at the optic disk to form 
the optic nerve; these axons extend along the optic tract and synapse with neurones in 
the lateral geniculate nucleus, from where impulses are sent to the primary visual 
cortex for interpretation of the image sensed initially by the retina.
19
disk membrane cytoplasm
Rhodopsin
photon
cations
cGMP
Fig. 1.7: Cartoon of major steps in phototransduction; Light induces structural change 
in rhodopsin; GTP binds to PDE; cGMP converted to 5’GMP; cGMP-gated Ca2+ channels 
close; glutamate release prevented.
From h ttp ://depts.washington.edu/ophthweb/KPgraphpic.html
Termination of the phototransduction cascade, along with the recycling of the many 
components involved, is required to prevent over-stimulation of the photoreceptors 
and also to ensure visual information can be continuously processed in conditions of 
prolonged stimulus. The all-trans retinol moiety of the rod cell visual pigment, 
synthesised by the isomerisation of the ‘resting’ 11 -cis retinal, cannot bind the opsin 
apo-protein. Instead, once the activated rhodopsin molecule has initiated transducin 
activation, the all-trans retinol dissociates from the transmembrane protein and is 
transported into the adjacent RPE cells by the transport protein ABCA4, formerly 
known as ABCR. In the RPE cells, a series of NADPH-dependent reactions drive the 
conversion of the al\-trans form back to 11 -cis retinal; this involves the microsomal 
protein RPE65, and the enzymes lecithin:retinol acetyl transferase (LRAT) and 11 -cis 
retinol dehydrogenase (11-cis RDH, see F ig . 1 .8). The 11 -cis retinal is then recovered 
to the photoreceptor outer segment; this step involves the inter-photoreceptor retinol 
binding protein (IRBP), which binds the retinal and shuttles it into the photoreceptor. 
Here it associates with rhodopsin molecules anchored to the outer segment discs.
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Fig. 1.8: Regeneration of visual pigm ent in retinal pigm ent epithelium cell; once light 
(hv) is absorbed by rhodopsin (Rh), the chromophore 11 -cis retinal isomerises to all-trans 
retinol. Following uptake o f this molecule into the RPE, enymatic reactions lead to the 
regeneration o f 11 -cis moiety via an ester intermediate. This molecule is then transported 
back into the photoreceptor by IRBP. Diagram adapted from one available at 
http://biophygics.bumc,bu .edu /faculty/ cornwall/index.html
In order to halt the phototransduction cascade upon light stimulation, and to return the 
photoreceptor cells to their ‘ground state’ of depolarisation, the cGMP-dependent 
Na+/Ca+ channels need to be closed. To achieve this, retinal guanylate cyclase 
(RetGC, encoded by the gene GUCY2D) is activated when cGMP levels fall; this 
activation is mediated by the calcium-binding proteins known as the Guanylate 
Cyclase Activating Proteins (GCAP), which are part of the calmodulin-like 
superfamily of calcium binding proteins [5]. RetGC converts 5’GMP back to the 
cyclic form, allowing cGMP-gated channels to re-open and stop the visual pathway 
from being activated. In addition to the action of RetGC, photorecovery is mediated 
by de-activation of rhodopsin at the outer segment disc membrane. The rhodopsin 
kinase (RK) enzyme, part of the G-protein receptor kinase (GRK) family, is a 
serine/threonine protein kinase whose phosphorylation activity is limited to the active
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form of its substrate, rhodopsin [6]. RK phosphorylates serine residues in the 
cytoplasmic loops of the activated rhodopsin protein, allowing a second 
photorecovery protein, arrestin, to bind (see Fig. 1.7). Binding of arrestin to rhodopsin 
prevents transducin from being bound, and so halts downstream signalling in the 
phototransduction cascade. These mechanisms prevent overstimulation of 
photoreceptor cells; the period of time following light-excitation where the cells 
return to their ground state is known as recovery.
Thus the phototransduction signalling cascade is initiated by the absorption of one 
photon of light by one rhodopsin molecule. One key feature of phototransduction is 
the amplification of signal that can be achieved during various steps in the cascade. 
Once one rhodopsin molecule is isomerised by the absorption of a photon, it is able to 
activate hundreds of transducin molecules. Activated transducin then allows PDE to 
hydrolyse several cGMP molecules, which leads to the hyperpolarisation of the 
photoreceptor of around 1 mV. Thus only a few photons of light need be absorbed for 
a rod cell to become hyperpolarised.
This is how light sensitive cells within the retina are able to convert the energy from 
photons of light into biochemical signals, resulting in neuronal excitation through to 
the visual cortex. Defects in genes encoding protein involved in many steps of the 
mechanism described above can lead to diseases that vary in severity and clinical 
symptoms. The most common outcome of these mutations is uni- or bi-lateral loss of 
vision. Many of these defects can be inherited, and it is on a family of these heritable 
retinal diseases that the current studies focus.
1.5 Inherited retinal degeneration
Inherited retinal disorders, including retinitis pigmentosa (RP), affect as many as 
1/3000 people worldwide [7], and currently there are no effective treatments 
available. These retinal dystrophies can be classified according to their clinical 
phenotype, and now according to their underlying molecular defects. Clinically the
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disorders present as either stationary or as progressive conditions; the former being 
caused by dysfunctional photoreceptors, the latter by the death of photoreceptors due 
to their underlying mutations. The different mutations causing these conditions are 
discussed below. These retinal dystrophies are further sub-classified according to the 
exact cell type affected. Rod cell dystrophies are caused primarily by the disruption of 
function and/or death of rod cells, whilst the cone population remains largely intact. 
Cone dystrophies affect only cones, with visual acuity and colour vision impaired but 
night vision remaining normal. Some inherited retinopathies involve loss of both cone 
and rod cells, and are called cone-rod or rod-cone dystrophies, depending upon which 
photoreceptor subtype is primarily affected. Of note is that many of these dystrophies 
involve both types of photoreceptors at advanced stages of disease, culminating in the 
loss of central visual acuity that is the primary cause of loss of quality of life in 
patients.
Characterised by loss of scotopic (night) vision, followed by peripheral visual loss 
and finally macular degeneration, retinitis pigmentosa is a term that encompasses a 
range of molecular defects affecting the structure, function and maintenance of 
(primarily) rod photoreceptors. Inherited as an autosomal recessive (arRP), autosomal 
dominant (adRP) or as an X-linked trait, a feature of RP is the extraordinary genetic 
heterogeneity seen in disease. Hundreds of different mutations in 36 photoreceptor- 
specific and RPE-specific genes (and 11 genetic loci) have been shown to segregate 
with incidence of disease in human pedigrees [8]; conversely, families in which the 
same mutation causes visual loss can show a range of clinical presentations, with 
variation in time of onset, penetrance and severity of visual loss.
The clinical signs of disease are varied, and particular symptoms of retinitis 
pigmentosa are associated with the mode of inheritance and sub-type of RP 
concerned. Fundus examinations of patients do, however, reveal clear common signs 
of disease, and the clinical course of RP can hence be followed non-invasively. 
Beginning with the narrowing of retinal arterioles, disease progression is confirmed 
with the appearance of ‘bone spicules’ (caused by proliferating RPE cells migrating 
into the retinal space vacated by dead photoreceptor cells, Fig. 1.9A, ref. [9]). The 
presence of dense hyper-pigmented regions throughout the fundus is characteristic of 
more advanced RP (Fig. 1.9B).
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Fig. 1.9: Fundus photographs from RP patients:
(a) Bone spicules in early RP (b) Dense pigmentation in advanced RP
Measuring the electrophysiological response of the retina to varying intensities of 
light provides an additional measure of retinal dystrophy. RP patients present with 
markedly reduced rod ERG amplitudes, as well as increased latency in cone b-waves 
in later stages of disease (Fig. 1.10) [10,11]. Poor sensitivity to low levels of light 
(often manifesting as night blindness) and narrowing of visual fields are often the first 
symptoms seen in patients with RP, whereas central visual acuity remains largely 
intact during the earlier stages of disease. This reflects the late onset of cone cell 
atrophy in RP pathology.
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Fig. 1.10: Electroretinogram (ERG) recordings taken from normal individual and 
from RP patient; Scotopic (a and b), photopic (c, d) and 30Hz flicker (e, f) responses from 
an individual with normal vision (a, c, e) and from and RP patient (b, d, f). Patient shows 
extinguished scotopic b-wave, greatly reduced photopic a- and b-wave, and gready reduced 
flicker response.
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The impaired scotopic vision seen in RP is also present in the various forms of 
congenital stationary night blindness (CSNB). However, CSNB patients’ reduced 
visual function does not deteriorate with time, and the secondary changes to retinal 
vasculature and pigmentation that characterise end-stage RP do not occur. This may 
reflect the potentially disparate pathology of CSNB-causing mutations versus RP- 
causing mutations, discussed in detail below.
The appearance and severity of RP symptoms vary greatly between patients. This 
variation reflects the heterogeneity in the genetics of RP, with different causative 
mutations giving rise to different phenotypes. For instance, X-linked RP is sub­
categorised into RP2 and RP3, diseases linked to two distinct genetic loci (see 
Chapter 1.6). Both forms present with nyctalopia (loss of night vision) as early as 10 
years of age [12], followed by loss of visual acuity in the thirties. Contrary to this, 
autosomal recessive forms of RP present with nyctalopia, poor night vision and 
peripheral visual loss from a later age, on average in the third decade of life; patients 
then go on to lose visual acuity, but not until their fifties. This clinical variation is 
compounded by syndromic RP-related conditions, where RP-like clinical presentation 
is coupled with non-related symptoms such as deafness in Usher’s syndrome.
1.6 Molecular Genetics of RP and related retinal dystrophies
As retinitis pigmentosa is inherited in all Medelian forms, mutations can be 
classified as to whether they cause dominant, autosomal recessive or X-linked forms 
of RP, as well as whether patients present with early- or late-onset vision loss. Table
1.1 summarises the various disease genes according to the sub-type of retinal 
degeneration they are associated with, and discussed below are some examples of 
disease-causing mutations that typify the broad sub-categories of RP.
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Disease Category
Cone or cone-rod dystrophy, autosomal
dominant
Cone or cone-rod dystrophy, autosomal
recessive
Cone or cone-rod dystrophy, X-linked
Leber congenital amaurosis, autosomal
dominant
Leber congenital amaurosis, autosomal
recessive
Retinitis pigmentosa, autosomal dominant 
Retinitis pigmentosa, autosomal recessive
Retinitis pigmentosa, X-linked
Mapped and Identified Genes
AIPL1, CRX, GUCA1A, GUCY2D, RIMS1,
SEMA4A, UNC119
ABCA4, CNGB3, RDH5
RPGR
CRX, IMPDH1
AIPL1, CRB1, CRX, GUCY2D, LRAT, RDH12, 
RPE65, RPGRIP1, TULP1 
CA4, CRX, FSCN2, GUCA1B, IMPDH1, NRL, 
PRPF3, PRPF8, PRPF31, RDS, RHO, ROM1, 
RP1, RP9, SEMA4A
ABCA4, CERKL, CNGA1, CNGB1, CRB1, 
LRAT, MERTK, NR2E3, NRL, PDE6A, 
PDE6B, RGR, RHO, RLBP1, RP1, RPE65, 
SAG, TULP1, USH2A 
RP2, RPGR
Table 1.1: Genes in which mutations are known to cause retinal dystrophies;
categorised here according to the disease they are associated with.
Taken from http://www.sph.uth.tmc.edu/Retnet/sum-dis.htm#B-diseases
1.6.1 Autosomal dominant RP
Mutations in the RHODOPS1N gene were first shown to cause autosomal dominant 
RP (adRP) in 1990, when Dryja et al. published a Pro-His substitution mutation in 
individuals with autosomal dominant RP [13]. Subsequent studies have revealed a 
large number of mutations in the RHODOPSIN gene, which in fact account for around 
25% of RP cases in total [14]; over 100 different mutations have now been described, 
with significant phenotypic variation between them [15]. Mutations in RHODOPSIN 
are classified according to the biochemical properties of the mutant protein. Some 
mutant forms of rhodopsin appear to be gain-of-function mutants that fold correctly 
and localise to the photoreceptor outer segment (Class I mutants), and these versions 
are able to bind 11 -cis retinal in vitro [16]. Class II mutants are generally misfolded 
and retained at the endoplasmic reticulum, leading to aggregation of the misfolded 
protein and the initiation of its ubiquitin-driven degradation. Indeed, this mislocalised 
and/or misfolded Rhodopsin protein may provide a distinct trigger for apoptosis in
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certain forms of RP (see Chapter 1.9). As both Class I and Class II mutations in 
RHODOPSIN lead to a severe alteration in photoreceptor function and /or structure, 
they lead to progressive degeneration seen in retinitis pigmentosa, as opposed to 
stationary night blindness (see Chapter 1.9 for further discussion).
Mutations in genes encoding photoreceptor-specific structural proteins also cause RP. 
Indeed, as rhodopsin is an integral membrane protein within rod outer segments, 
mutations in Rhodopsin can also affect photoreceptor structure. Mutations in Prph2, 
the gene encoding peripherin-2, also cause RP; according to one study of the 
prevalence of RP-causing mutations, around 8% of RP cases are caused by mutations 
in this gene [14]. Peripherin-2 is a glycoprotein localising to the outer segments of 
both rods and cones, providing structural stability to both types of photoreceptor. The 
first mutations in Prhp2 were found in patients with RP7, and were shown to be 
deletions of cysteine residues [17], or of a proline at position 219 [18] causing adRP. 
Subsequently other mutant Prph2 alleles have been described; patients with a P216L 
amino acid substitution present with late-onset dominant RP [18], and the deletion of 
codon 307 is known to cause dominant RP [19]. Because Prph2 forms tetramers that 
are inserted into the photoreceptor outer segment, the effect of many of these 
mutations are dominant-negative; although some wild-type protein is produced, the 
reduced ability to form functional tetramers results in the integrity of photoreceptor 
outer segments being compromised, leading to apoptotic cell death. In addition to 
these cases of monogenic RP, patients carrying mutant alleles for both Prph2 and 
another outer segment-specific gene, ROM1, suffer from digenic retinitis pigmentosa 
[20]. Another gene involved with outer segment disc morphogenesis, RP1, is mutated 
in autosomal dominant RP [21]. RP1 is located in the axoneme that forms part of the 
connecting cilium that links inner and outer segments in photoreceptors [22]. RP1 
protein is thought to stabilise nascent outer segments; hence, the absence of RP1 is 
believed to cause a failure of outer segment formation, leading to apoptotic cell death. 
RP10, a sub-class of autosomal dominant retinitis pigmentosa, has recently been 
shown to be caused by mutations in IMPDH1. Interestingly, this gene is expressed in 
a variety of tissues, including spleen, lung, ovary and testis, liver and the eye. Despite 
this patients with IMPDH1 mutations only present with retinal degeneration. 
IMPDH1 catalyses a key intermediary step in the synthesis of GTP, and it is thought 
that photoreceptors are particularly susceptible to disruptions in guanine nucleotide
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synthesis due to their reliance on GTP for the activation of transducin during 
phototransduction. Low levels of GTP, due to IMPDH1 mutations, prevent the retinal 
phosphodiesterase (PDE) from hydrolysing cGMP to 5’ GMP, which in turn leads to a 
constant influx of calcium ions through voltage-gated ion channels and eventually to 
cell death. Although patients with mutations in this gene present with early-onset, 
severe retinopathy, mice lacking Imdphl show progressive loss of retinal function 
without concomitant loss of photoreceptor cells [23]. Deletions, frameshifts and 
splice-site mutations in Prp/31 have also been shown to cause adRP with incomplete 
penetrance [24]. Prpf31 is a protein homologous to a yeast pre-mRNA splicing factor, 
and is ubiquitously-expressed. Prp/31 is one of several genes (including MERTK, 
discussed below, and the splicing factor genes hPrp3 and Prpc8 that are both 
implicated in retinitis pigmentosa), that are expressed in other tissues as well as in the 
eye, but which only give rise to ocular phenotype when mutated. There is currently no 
evidence that Prpf31, or hPrp3 and Prpc8, are involved in splicing of retina-specific, 
alternatively-spliced isoforms of genes, which could have explained how mutations in 
these genes only affect photoreceptors. Rather, it is proposed that photoreceptors are 
highly sensitive to mutations such as those in genes encoding splicing factors due to 
their high rate of protein synthesis, which is a result of the daily regeneration of outer 
segment disks [25].
Other genes mutated in adRP include those encoding transcription factors required for 
photoreceptor development, such as CRX and Nrl. These are both genes that encode 
transcription factors that are required for early photoreceptor development, acting 
together to drive transcription of photoreceptor-specific genes such as RHODOPSIN 
[26-28]. An A—>G substitution at position 121 of CRX was shown to cause adRP in 
one family [29], while other mutations in the same gene cause different forms of RP, 
as discussed below. A Ser—►Thr amino acid substitution at position 50 in the NRL 
protein,, caused by a T—»A base change in Nrl, also causes adRP; this mutation 
disrupts the transactivation domain of NRL, resulting in inappropriately high 
transcription of downstream genes, including RHODOPSIN [27]. Finally, it has 
recently been demonstrated that a gene expressed exclusively outside the neuroretina 
is involved in dominant RP. A R14W substitution in the carbonic anhydrase IV  gene 
(CA4), expressed in the choriocapilaris, is responsible for RP17 [30]. The authors of 
this study postulate that incorrectly folded CA4 protein causes the death of epithelial
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cells that lead to a disruption of the blood supply to the retina. A subsequent study 
suggested, however, that a disruption in the regulation of pH is a more plausible 
mechanism for photoreceptor cell death following on from mutations in CA4 [31].
1.6.2 Autosomal recessive RP and Leber Congenital Amaurosis (LCA)
Autosomal recessive retinitis pigmentosa (arRP) results from mutations in 
many different genes, summarised in Table 1.1. In general patients with recessive RP 
present with severe symptoms which in many cases have an early onset. This is most 
likely due to the fact that most recessive disease segregates with homozygous 
mutations in genes, often leading to a total absence of the protein encoded; as 
discussed below, this has severe consequences for photoreceptors that often manifest 
as a lack of vision from birth and a rapid loss of photoreceptors. Photoreceptor- and 
RPE-specific genes are known to be mutated in arRP. Cases of autosomal recessive 
RP have been shown to segregate with several mutations in the a- [32] and p- [33] 
subunits of the phosphodiesterase enzyme that cleaves cGMP; this prevents the 
hydrolysis of cGMP, leaving cGMP-gated ion channels permanently open which 
leads to cell death by calcium overload. Also, some cases of RP are attributed to 
premature stop codons within the gene encoding the a-subunit of cGMP-gated 
calcium channels [34], and to various missense mutations in gene encoding the p- 
subunit [35]. The gene encoding tubby-like protein-1 (TULP-1), a photoreceptor- 
specific gene that is a member of the tubby family of genes [36,37] has also been 
shown to be mutated in arRP [38,39], and its homologue tub causes syndromic retinal 
degeneration, deafness and obesity when mutated in tub~f~ mice [40]. Other 
photoreceptor-specific genes are mutated in more severe forms of recessive RP, as 
discussed below. Mutations in the Mertk gene, expressed in the RPE, cause early- 
onset autosomal recessive RP [41]. Patients present with nyctalopia in their early 
teens and only a small central portion of visual field remaining by their thirties; as 
such this represents one of the most severe forms of recessive RP. Mertk is known to 
be expressed in kidney, liver, nerve ganglia in the brain and phagocytic cells such as 
macrophages; despite this wide expression profile, patients with mutations in this 
gene only present with ocular symptoms.
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The most severe recessive retinitis pigmentosa cases are described as Leber 
congenital amaurosis (LCA), a sub-category of arRP that is characterised by severe 
visual loss in the first decade of life, and patients have little or no retinal function in 
terms of electrophysiological response to light. As LCA progresses patients develop 
the narrowing of retinal blood vessels and pigmentary changes in the RPE seen in 
other forms of RP, but it is the severe, early-onset visual loss and undetectable ERG 
accompanied by largely normal fundus appearance that is characteristic of LCA [42]. 
Many RPE-specific genes encoding proteins that form part of the visual cycle, 
whereby the 11 -cis retinal moiety of the photoreceptor visual pigment is regenerated 
in the RPE, are known be mutated in LCA. Mutations such as those in the RLBP1 
gene, which encodes cellular retinaldehyde binding protein (CRALBP) [43], and in 
the genes coding for proteins that participate in the conversion of all-trans retinol to 
11 -cis retinal such as LRAT, [44] cause LCA. Mutations in the RPE65 gene are also 
associated with LCA [45]. As discussed in Chapter 1.12, patients with mutations in 
RPE65 will be the first to receive AAV-mediated gene therapy as part of a clinical 
trial to treat LCA. Mutations in photoreceptor-specific genes that lead to LCA have 
been identified, such as those in Aipll [46], which encodes a chaperone protein 
expressed exclusively in rod cells [47]. In addition, mutations in the Gucy2d gene, 
which encodes the photoreceptor-specific enzyme that catalyses cGMP synthesis 
(RetGC) also cause LCA [48]; a missense mutation and two single-base deletions 
leading to frameshifts were shown to segregate with disease in patients with early 
onset visual loss and absent ERG. Interestingly, missense mutations elsewhere in the 
same gene cause dominant cone-rod dystrophy; E837D and R838C amino acid 
substitutions cause a early-onset loss of central visual acuity, a ‘bull’s eye’ 
maculopathy followed by peripheral fundus abnormalities, and cone ERG ablation by 
7 years of age followed by a decline in rod function by the fourth decade of life [49]. 
It is proposed that the LCA-causing mutations in Gucy2d affect the catalytic domain 
of the enzyme encoded by this gene, causing recessive retinal degeneration; the 
E837D and R838C substitutions occur in a putative dimerisation domain, which could 
interfere with the formation of functional dimmers of RetGC-1 and act as dominant- 
negative alleles. LCA is also caused by mutations in RPGRIP. Following the 
description of mutations in the gene encoding the retinitis pigmentosa GTPase 
regulator (RPGR) that cause X-linked RP (Chapter 1.6.3), the role of the 
photoreceptor connecting cilium in RP was further elucidated when mutations in
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RPGRIP were described. Initially identified through yeast two-hybrid screening for 
proteins that associate with RPGR [50,51], RPGRIP is mutated in patients with LCA 
[52,53] and was elegantly shown to be the primary resident of the photoreceptor 
connecting cilium, anchoring RPGR to the cilium; RPGR is absent from the cilia of 
RPGRIP'1' mice, but not the other way around, suggesting RPGR depends on RPGRIP 
for its correct sub-cellular localisation [54,55].
1.6.3 X-linked retinitis pigmentosa
Retinitis pigmentosa can be inherited in an X-linked form, and thus far 
mutations in two genes have been identified as causing X-linked RP. The X-RP2 
locus was first identified through restriction polymorphism analysis of X-linked RP 
patients [56], and was subsequently shown to encode a 350 amino acid protein that is 
expressed in spleen, liver, lung, kidney and photoreceptors [57]; insertion of an LI 
retrotransposon element, amino acid substitutions and ffameshifts leading to 
premature truncation of RP2 protein segregate with disease. Mutations in RPGR, 
which encodes an RCCl-like guanosine exchange factor, have been shown to be 
mutated in X-RP3, the most prevalent form of X-linked retinitis pigmentosa [58]. 
RPGR was subsequently shown to be an integral part of the photoreceptor protein 
transport mechanism in mice, through its interaction with the gamma sub-unit of the 
photoreceptor phosphodiesterase enzyme [59]; its precise function in other 
mammalian species remains uncertain, although RPGR is located in the connecting 
cilium in human and in mouse, suggesting the human RPGR has a similar function to 
its murine orthologue. RPGR is expressed in many cell types, including in the kidney, 
testis, spleen and liver [60]. ORF 15, a splice variant of RPGR preferentially 
expressed in the retina, appears to be a ‘mutation hot-spot’ in which many disease- 
causing mutations reside [60]; this alternatively spliced isoform is created by the 
skipping of a splice site that causes the extension of exon 15 by translation of intron 
15. Subsequently other mutations in RPGR have been shown to cause a form of X- 
linked cone dystrophy (COD1) [61].
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The genes responsible for inherited retinal degenerations have been identified in 
patients through linkage studies and positional cloning strategies, and have provided 
some insight into the pathology of the various sub-types of retinitis pigmentosa. Both 
naturally occurring and genetically modified animal models have been used to better 
understand the complex molecular events leading from mutation of the gene described 
above to the death of photoreceptors.
1.6.4 Stationary night blindness
Stationary night blindness is caused by a variety of mutations in photoreceptor- 
specific genes that cause a disruption in function, without the concomitant death of 
photoreceptors seen in RP. Many cases of autosomal dominant CSNB are caused by 
an amino acid substitution mutation in the rod-specific GNAT1 gene [62], whereas 
several mutations in a calcium channel found in photoreceptors cause X-linked CNSB 
[63]. Mutations in PDE6fi also lead to CSNB [64]. The putative mechanisms behind 
why these mutations lead specifically to stationary disease, as opposed to progressive 
retinal degeneration seen in RP, are discussed in Chapter 1.9.
1.7 Animal models of retinal degeneration
Several animal models of disease show genetic and biological similarity to 
various forms of RP and have been invaluable in developing gene therapy strategies. 
These models are generally well-characterised and usually better-understood than 
their human equivalents in terms of their molecular pathology. Although rodent and 
large animal retinae differ from human retinae in many aspects, animal models still 
serve as valid systems in which mechanisms of and treatments for disease can be 
studied. One major difference between rodent and human retinae is the lack of an 
anatomically defined macula, or indeed any cone-rich region in the retina. Many 
animal models of disease differ in some aspects from their human counterparts, and 
hence the study of therapeutic strategies needs to account for these differences before
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conclusions from animal studies can be applied to clinical disease. Thus mutations 
leading to macular degeneration may be harder to study in rodents. Animal models 
have recently been developed that do mimic some features of AMD; laser-induced 
focal disruption of Bruch’s membrane leads to choroidal neovascularisation in mice 
that resembles CNV seen in AMD patients [65], as does ectopic expression of hPKl 
[66]. However, these models only reflect individual pathological processes found in 
AMD, and do so in isolation from the other features of disease seen in humans. Mice 
with targeted disruption of the gene encoding either macrophage chemoattractant 
protein-1 (MCP1) or its cognate receptor, C-C chemokine receptor-2 (Ccr-2), do show 
drusen and lipofuscin accumulation from 15 months of age onwards, thus resembling 
many features of AMD [67]. These knock-out mice represent the most accurate 
models of and AMD-like phenotype; nonetheless, as these features of AMD only 
develop in very old mice, and with an apparent inconsistent penetrance, they are 
difficult to study as a disease paradigm. As such, it is easier to study retinitis 
pigmentosa in animal models, as many features of clinical disease are modelled in 
rodents and large animals.
As well as the animal models that mimic features of AMD (above) and those that 
reflect the pathology seen in RP (below), animal models with mutant CSNB-causing 
alleles have also been described. Mutations in the murine orthologues of GNAT1, 
CACNAF1 and PDE6p all cause loss of rod-cell function without concomitant 
photoreceptor degeneration, and the putative mechanisms behind this are discussed in 
Chapter 9.
1.7.1 Naturally-occurring animal models of retinal degeneration
Genes encoding enzymes of the phototransduction cascade, structural proteins and 
proteins involved in transport of pigments to photoreceptor outer segments are all 
found to be mutated in various animal models of RP [4,68]. The first naturally 
occurring murine model of retinal degeneration to be described was the retinal 
degeneration (rd) mouse [69], which was subsequently shown to have an early onset 
retinal phenotype due to an insertional mutation in the Pde6b gene [70]. This encodes 
the p-subunit of the PDE enzyme, which hydrolyses cGMP as part of the
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phototransduction pathway (see Chapter 1.4); the elevated levels of cGMP in the 
mutant lead to continuous influx of calcium ions through the cGMP- and voltage-
I
gated Ca channels, and this leads to apoptotic cell death in photoreceptor cells due 
to calcium overload [71]. In contrast to human arRP, the rd mouse has an early onset 
rapid degeneration, with rod cell loss complete by post-natal day 20 [72]; RP patients 
with mutations in p-PDE (the human orthologue of Pde6b) present later in life, well 
into their third decade. This discrepancy may well be due to the fact that whilst the 
disease-causing mutation in the rdl mouse is a null mutation resulting in no 
functional protein being produced, a large proportion of patients with PDE6/3 
mutations have missense mutations affecting the catalytic domain of the mature 
protein, resulting in reduced but not abolished activity [70,73].
Recently the Rpe65Rdl2/M12 mouse was characterised, which is a naturally-occurring 
model for LCA caused by a homozygous nonsense mutation in the Rpe65 gene [74]. 
The Rpe65Rdl2/Rdn mouse has distinctive white dots visible on fundus examination at 
five months of age, and severely reduced ERG b-wave amplitudes (around 50 pV) at 
one month of age. The two most widely-studied naturally-occurring rodent models of 
RP, the Prph2Kd2/Kd2 mouse and the RCS rat, are discussed in more detail below. 
There are also large-animal models of human retinal degeneration. Mutations in the 
canine equivalent of the Pde6b gene cause retinal degeneration in a dog model of RP, 
wherein Irish setter dogs have an early-onset retinal degeneration phenotype that 
segregates with the locus designated rod-cone dysplasia 1 {rcdl). This was shown to 
be a mutant allele of the gene encoding the P-subunit of canine rod cGMP 
phosphodiesterase; a stop codon created by a single base substitution at codon 807 
leads to a loss of functional PDE-P protein [75], which is analogous to the rdl mouse 
described above. The rcdl dog is another model used for investigating the progression 
of disease and possible treatments for RP, and has an early onset of retinal 
degeneration (around 25 days after birth) followed by loss of photoreceptors over one 
year [75]. A further naturally-occurring large animal model of RP is caused by a T4R 
mutation in rhodopsin found in English mastiff dogs, which causes abnormal 
photorecovery following light excitation [76]; this phenotype is similar to that seen in 
patients with a T4K amino acid substitution, and thus this naturally occurring dog 
model of RP may prove useful in the evaluation of therapeutic strategies for this form 
of RP. A canine model for X-linked RP has also been described, known as X-linked
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progressive retinal atrophy (XLPRA); Siberian husky dogs suffer from an X-linked 
rod-cone dystrophy that was initially mapped to a region of the X chromosome that 
has homology to the human RP3 locus [77]. The two sub-categories of this canine 
retinal dystrophy, XLPRA 1 and XLPRA2, were subsequently shown to be caused by 
two different mutations in the RPGR gene [78]. Deletion of five nucleotides in exon 
ORF15 of RPGR, leading to premature stop codon that truncates RPGR ORF15 by 
230 amino acids, causes XLPRA 1. This form of XLPRA is characterised by normal 
photoreceptor development and onset of ERG abnormalities and photoreceptor loss at 
one year of age. XLPRA2 was shown to segregate with a two base-pair deletion 
further downstream within exon ORF15, which leads to the inclusion of 34 extra basic 
amino acids in RPGR and causes photoreceptors to develop abnormally; XLPRA2 
retinae have greatly reduced ERG response from an early age, and a rapid loss of 
photoreceptors such that 50% of the ONL is lost within seven months of life [78]. 
Thus, rodents and dogs that have naturally-occurring mutations have been extensively 
studied in order to understand the mechanisms underlying human retinitis pigmentosa; 
transgenic technology has also been used in rats and mice to study the pathology of 
RP, as discussed below.
1.7.2 Light-induced, transgenic and knock-out rodent models of 
retinal degeneration
Photoreceptor death has been modelled in rodents by using constant light 
exposure (or exposure to short bursts of high levels of light) to induce damage. There 
are advantages to inducing photoreceptor death in this manner; the cells die by 
apoptosis so some insights into mechanisms of photoreceptor death can be gained be 
studying light-damage models. Also the photoreceptor death is acute and rapid, with 
exposure to 2 hours of 13,000 lux light causing complete loss of photoreceptors in 10 
days, such that therapeutic strategies take less time to evaluate than in some genetic 
models of disease. Nonetheless, there are major discrepancies between such light- 
induced models of cell death and RP seen in genetic models of disease and in the 
clinic. Firstly, although photoreceptors die by apoptosis, the mechanisms that trigger 
this programmed cell death (see Chapter 1.9) may be very different to those in
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genetic models of RP, which means treatment strategies that show efficacy in these 
acute models of disease may not be appropriate to clinically-relevant models. Also, 
the acute nature of photoreceptor death in these models means that there is a very 
small ‘window’ in which to intervene with a therapy; often therapies need to be 
applied as prophylaxis in advance of light-induced damage, an option not available in 
the clinic. Hence the studies presented here, and the majority of studies into potential 
therapies for RP, use genetic models of disease.
Transgenic technology, whereby a mouse strain is engineered to harbour a disease- 
causing allele of a gene implicated in RP, and targeted disruption of endogenous 
murine genes, have both been used extensively to study the pathology of RP. A mouse 
harbouring a Q344ter mutation in the rhodopsin gene has a naturally occurring stop 
codon that truncates the rhodopsin protein by five amino acids, resulting in 
mislocalised rhodopsin and a more latent response to a light stimulus [79]. Rodents 
expressing transgenes carrying many other mutations in the rhodopsin gene, 
equivalent to those mutations found in patients, show photoreceptor degeneration [4]. 
For instance, rats carrying an S334Ter transgene undergo rapid retinal degeneration, 
losing most of their photoreceptors within three weeks [80]. The proline-to-histidine 
substitution at position 23 was the first rhodopsin amino acid substitution to be 
described in patients [13], and rats carrying a P23H rhodopsin transgene are perhaps 
the most widely studied transgenic model of RP. These P23H rats undergo a slower 
photoreceptor degeneration than the S334Ter rats; rats heterozygous for the P23H 
opsin allele lose around 50% of their photoreceptors at three months of age [81]. In 
addition to transgenic rodents carrying mutant versions of rhodopsin, other dominant 
disease alleles have been used to study RP in mice. A mouse strain carrying a Prph2 
transgene that encodes a P216L amino acid substitution has been shown to lose 
photoreceptors and retinal function in a manner consistent with patients that have the 
P216L mutation [82]. The mutant Prph2 allele causes photoreceptor degeneration due 
to a reduced ability to form functional peripherin-2 tetramers in photoreceptor outer 
segments. This loss of photoreceptors is dependent on the level of transgene 
expression in different lines of P216L transgenic mice (high-expressing lines have 2 
rows of photoreceptor nuclei in their outer nuclear layer at seven months of age, 
compared with five rows in lower-expressing lines), and on the genetic background of 
the mice with respect to the Prph2 gene (on a Prph2Rd2l+ heterozygote background,
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mice carrying a P216L Prph2 transgene have 5 rows of photoreceptor nuclei at three 
months of age). Knock-out mice, created by targeted disruption of a gene by a 
selective marker, have also been generated to mimic mutations that lead to RP; for 
instance, targeted disruption of the rhodopsin gene has been used to study RP, with 
rhodopsin /_ mice losing all their photoreceptors within the first three months of life 
[83]. Mice carrying one functional allele of rhodopsin (,rhodopsin/+) have a normal 
outer nuclear layer at this time point, although individual rod cells express 50% of the 
normal level of rhodopsin [84]. Mice lacking the Tulpl gene serve as a model of 
recessive RP [85]. In tulpl"A mice there is mislocalisation of rod- and cone-opsins, 
accumulation of vesicles in the inter-photoreceptor matrix, and photoreceptor 
degeneration that reaches end-stage at 5 months of age. Mice lacking RPGR and 
RPGRIP, which encode proteins found in photoreceptor connecting cilia, serve as 
models for X-linked and LCA respectively [54,86]. RPGR'A mice show normal 
photoreceptor development, followed by cone opsin mislocalisation to inner segments 
and a reduction in amount of rhodopsin present in rod outer segments. Functionally 
the lack of RPGR protein leads to a 25% reduction in rod-specific ERG at 6 months of 
age, and a concomitant loss of cone function, and structurally the outer nuclear layer 
is reduced by two rows of photoreceptor nuclei at this time point [86]. Mice lacking 
RPGRIP show a much more severe phenotype than those lacking RPGR; RPGRIP'f' 
photoreceptors have abnormal outer segments and pyknotic nuclei from a very early 
age (PND 15), and photoreceptor loss is complete by three months of age [54]. RPGR 
protein was shown to be absent in connecting cilia of RPGRIP'f' mice, but RPGRIP is 
present as normal in mice lacking RPGR; this indicates that RPGRIP localises to the 
connecting cilium first, recruiting RPGR subsequently, and that a lack of RPGRIP 
gives rise to a more severe, early-onset phenotype which is analogous to clinical 
findings [54].
In selecting models of retinal degeneration in which to test therapeutic strategies, 
several considerations need to be made. Firstly, models which resemble human 
disease, both in terms of the mutation that causes disease and in the pathology that 
follows, are desirable in order that any successful treatment could be considered for 
use in the clinic. Secondly, a model that shows an intermediate rate of photoreceptor 
degeneration is ideal; models that lose their photoreceptors slowly enough to allow 
therapeutic intervention (as opposed to the rdl mouse, for instance), and yet not so
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slowly that evaluating the efficacy of the therapy becomes difficult (e.g. RPGR'f' 
mice). Thirdly, a rodent model of retinal degeneration that has an absence of a given 
gene product, as opposed to those caused by dominant negative alleles, may prove 
more amenable to treatment as discussed in Chapter 1.13. The studies presented here 
focus on two models of retinitis pigmentosa that, by virtue of their relevance to 
disease found in humans, the favourable kinetics of photoreceptor loss and the 
homozygous null nature of the mutations, are invaluable tools in elucidating the 
mechanisms involved in retinal degeneration.
1.8 Biology of the Prph2Kd2/Rd2 mouse and RCS rat
Formerly known as the retinal degeneration slow (rds) mouse, the Prph2Rd2/Rdl 
mouse has much in common with cases of RP in humans, with an intermediate rate of 
photoreceptor cell loss compared with other models of disease [68]; degeneration 
proceeds slower than models such as the rdl mouse (in which one layer of 
photoreceptor cells remain at three weeks of age), but faster than models such as 
RPGR'f' mice -  in Prph2Rd2IRd2 mice the ONL is reduced by 50% by two months of 
age, and continues to atrophy over the next six months. It is not clear why different 
models of RP show such variable rates of photoreceptor loss, although some putative 
mechanisms are discussed in Chapter 9. However, one major difference between this 
naturally occurring model and human disease is that the Prph2Rd2IRd2 mouse has 
negligible rod function and greatly reduced cone function from birth (see below), 
whereas many patients retain scotopic vision until the fifth or sixth decade of life. 
While the inheritance mode in this mouse model is semi-dominant, the kinetics of 
photoreceptor degeneration resembles that seen in dominant RP in humans. Disease is 
caused by an insertional mutation in the Peripherin (Prph2) gene that encodes 
peripherin-2, a structural protein found in the outer segments of photoreceptors [87]. 
Peripherin-2 is a major structural component of the membranous disks within the 
outer segments that house the visual pigment in both cones and rods. Failure to 
produce these disks, due to the null mutation in the Prph2 gene, causes absence of 
outer segments from birth (see Fig. 1.11). As outer segments are not formed, and the 
rhodopsin pigment cannot be correctly localised to the outer segment,
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phototransduction takes place at greatly reduced levels than in wild-type mice. The 
mechanisms that link the absence of outer segments to photoreceptor cell death are 
unclear. Previous studies have established that cell death in the Prph2Rd2/Rdl mouse 
(and other rodent models of retinitis pigmentosa) occurs by apoptosis, and that in the 
case of the Prph2RdirRd2 mouse this programmed death peaks at post-natal day 18 [72]. 
The particular kinetics of photoreceptor cell death in the Prph2Rd2IRdl mouse model 
has implications for the type of treatment that might be tested, and this will be 
discussed in more detail in Chapter 1.9.
(a) Prph^/mi mouse
Rd2.ftet2 untreated J » pm
Fig. 1.11: Outer segm ents in Prpb2Kd2/Kd2 and wild-type CBA mice; mice homozygous 
for a null mutation in Prph2 do not develop outer segments and have disorganised inner 
segments (a) when compared to wild-type mice (b).
In the Prph2Rdl/R<n mouse some residual electrophysiological activity is detectable in 
terms of a scotopic ERG b-wave in the first weeks after birth. In the absence of outer 
segments, the rhodopsin produced by rods and cones is localised in the connecting 
cilium. This reduced, mislocalised pigment does give some activation of 
phototransduction, which provides enough electrical activity to generate a small 
response to a light stimulus. It remains unclear, however, whether Prph2Rd2/Rdl mice 
have residual vision, even before the large scale death of their photoreceptors. The 
earliest recordings of young Prph2RdirRdl mice show a b-wave amplitude of 40 pV at a 
rod-specific stimulus intensity. This functional deficiency worsens over the first few 
weeks after birth, with no detectable b-wave present at six months of age [88].
(b) CBA mouse
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Mice heterozygous for the insertional mutation in Prph2 (Prph2Rd2l+) also have an 
RP-like phenotype, although the kinetics of retinal degeneration is altered from that 
seen in homozygous mice. Prph2Rd2l+ heterozygotes have largely normal retinal 
development, although electron microscopy reveals ‘whorls’ in the photoreceptor 
outer segments caused by a reduction in the amount of Peripherin-2 protein being 
produced. Prph2Rdll+ mice retain largely wild-type ERG responses into their third 
month, following which there is a gradual decline in b-wave amplitude. This is 
reflected in the relatively slow progression of apoptosis in the rod cells, with 50% of 
the outer nuclear layer lost by eighteen months in heterozygote mice as opposed to 
two months in the Prph2Rd2!Rd2 homozygote [89]. It may be that Prph2Rd2l+ mice lose 
their photoreceptors due to different mechanisms than those seen in the homozygous 
null Prph2Rd2fRd2 mouse, although this remains to be determined experimentally.
The Royal College of Surgeons (RCS) rat completely loses its outer nuclear layer by 
around three months of age, even though the mutated gene is not expressed in 
photoreceptor cells. The RCS rat has a deletion of 409 bp in the gene encoding the 
receptor tyrosine kinase gene Mertk [93], which corresponds to the second exon of 
that gene; expressed in the retinal pigment epithelium (as well as monocytes), Mertk 
encodes a proto-oncogene, constitutively active mutants of which are implicated in 
tumourigenesis [90]. Lack of Mertk protein prevents the RPE cells from 
phagocytosing the outer segments of photoreceptors [95], which are shed as part of 
the circadian cycle and accumulate as debris in the sub-retinal space. This prevents 
oxygen and nutrients reaching the photoreceptor cells, leading to complete loss of 
cells in the outer nuclear layer by three months after birth.
There are several advantages in using the Prph2Rd2IRdl mouse and the RCS rat as 
models for retinal gene therapy. Primarily, as the Prph2Rd2IRdl mouse is one of the 
best characterised models of RP in terms of its biology, some of the most extensive 
gene therapy work to date involves this strain of mice. The rate of degeneration in 
both of these rodent models is favourable; treatments can be assessed relatively 
quickly after administration as the rate of ERG loss and of photoreceptor loss is fast 
enough to determine efficacy. Moreover, the rate of degeneration is somewhat slower
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than in the rd mouse or light-induced models of disease, and this in turn allows for a 
time window in which treatments can be applied and assessed before retinal structure 
and function is ablated completely. In order that such gene therapy applications are 
successful, it is necessary to determine the mechanisms underlying apoptotic 
photoreceptor loss in models of retinal degeneration, as discussed below.
1.9 Mechanisms of photoreceptor death in inherited retinal 
degeneration
The mutations discussed above have been associated with retinitis pigmentosa 
through genetic linkage studies in humans, and are known to cause retinal 
degeneration through studying animal models of disease. It has also been previously 
shown that the cell death seen in these models is caused by apoptosis [72]. However, 
little is known about the link between the genetic defects know to cause disease in 
models of RP, and the death of retinal cells by programmed cell death. Several 
hypotheses on the mechanisms of photoreceptor death have been proposed, with many 
different pathways discussed. By understanding the way in which mutations in the 
genes mentioned above cause the apoptosis seen in RP, it may be possible to 
intervene in the appropriate pathways, slowing or even preventing this cell death.
1.9.1 Overview of apoptotic signalling
Programmed cell death, or apoptosis, is an essential process required to control cell 
numbers in multicellular organisms, and is involved in normal embryological 
development. However apoptosis is a common consequence of disparate disease- 
causing mutations, and this controlled cell death leads to loss of photoreceptors in 
retinitis pigmentosa. Apoptosis is mediated by a signalling cascade involving the 
activation of caspase enzymes by proteolytic cleavage. Synthesised as pro-enzymes 
(pro-caspases), caspases cleave their downstream target molecules at specific aspartic
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acid residues, using a critical cysteine residue in their active site (Fig. 1.12). The 
initial stimulus for the activation of this caspase cascade can be intracellular (i.e. in 
response to damage within the cell) or extracellular (i.e. in response to signalling from 
other cells). The intracellular triggers for apoptosis are varied, and centre on the 
mitochondrion; this pathway is discussed in more detail below. In the case of 
extracellular triggers of apoptosis, receptor-mediated signalling initiates the cleavage 
of activator caspases by causing the aggregation of adaptor proteins, molecules that 
recruit specific pro-caspases into a multi-protein complex with proteolytic activity. 
The receptors used to trigger apoptosis share common intracellular domains, known 
as death domains, which bind to adaptor proteins only when their ligand is bound to 
their extracellular domain; for example, the Fas ligand-mediated activation of the Fas 
receptor mediates Caspase-8 cleavage through its intracellular death domain during 
apoptosis of T-cells [91].
Aggregated pro-caspases such as Caspase-8 undergo ‘mutual cleavage’ (i.e. each 
Caspase-8 molecule cleaves another Caspase-8 molecule in the aggregate), rendering 
many active molecules of this activator caspase. These active enzymes then cleave 
their specific target caspases, stimulating their proteolytic activity. This caspase 
activation pathway terminates in fragmentation of the nuclear envelope, DNAse 
digestion of chromosomal DNA and degradation of cellular lipids in a systematic 
dismantling of the cell (Fig. 1.13).
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Fig. 1.12: Schematic diagram showing activation o f caspase activity; Following 
cleavage by an activator caspase, an inactive procaspase molecule becomes and active 
caspase (A), and is able to cleave its downstream target caspases to initiate a proteolytic 
cascade that terminates in breakdown o f  nuclear laminin proteins, degradation o f cytosolic 
proteins and cell death (B).
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Fig. 1.13: Intra- and extra-cellulat stimulation of caspase cleavage cascade during 
apoptosis; an example o f  extra-cellular initiation of apoptosis is the Fas-ligand mediated cell 
death induced by killer lymphocytes o f T-cells that express Fas-receptor (A); binding o f Fas- 
ligand leads to accumulation o f  Caspase 8 molecules recruited by death-domain binding of 
adaptor molecules, and mutual cleavage within the Caspase 8 aggregate leads to initiation of 
a caspase cascade. Intracellular stimuli can also initiate apoptosis, and this commonly 
involves injury to the mitochondria (B); injured mitochondria release Cytochrome C, which 
bind to the activator molecule Apaf-1. The subsequent activation of procaspase 9 leads to 
the proteolytic caspase cascade described previously.
1.9.2 Apoptosis in inherited retinal dystrophies
Before considering the ways in which RP-causing mutations cause cell death, it is 
worth discussing the failure of CSNB-causing mutations to cause photoreceptor 
death. As detailed in Chapter 1.6.4, mutations in (amongst others) GNAT1, 
CACNAF1 and PDE6f lead to disruption in photoreceptor function, without causing 
the mutant cells to die. This may be related to how the mutations affect photoreceptor 
function. It appears that mutations leading to CSNB modify photoreceptor function in 
a more subtle manner than those leading RP, either by altering the synaptic signalling 
between photoreceptors and bipolar cells (in the case of CACNAF1 mutations, which 
lead to intact photoreceptor function but reduced ERG b-wave and hence reduced
aggregation 
and daavaga of 
procaspase 8 
molecule*
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higher visual function), or by altering the regulatory mechanisms in the 
phototransduction cascade (i.e. point mutations in GNAT1 and/or PDE6p). As neither 
type of CSNB-causing mutation would be predicted to result in a prolonged reduction 
in intracellular calcium, nor would they cause severe structural or metabolic 
disruption to the mutant photoreceptors, these subtle insults seem to reduce visual 
function without committing photoreceptors to apoptosis.
It is axiomatic that the programmed cell death described above is the predominant 
cause of photoreceptor loss in RP [72], but it is not fully understood how apoptosis is 
initiated in rods and cones harbouring disease-causing mutations. One possible 
pathway related to photoreceptor death involves phagocytic cells that form part of the 
immune system. In the microenvironment of the degenerating retina, cells from the 
inner nuclear layer (INL) produce chemokines that, acting via Muller cells, induce the 
apoptotic programme in rod cells [92]. It had been proposed that activated microglia, 
myeloid cells found in the eye and throughout the CNS, are involved in apoptosis in 
the outer nuclear layer of dystrophic retinae; because numbers of activated microglia 
peak at the same time as apoptosis peaks in the RCS rat, an hypothesis emerged 
suggesting that microglia play an active role in photoreceptor cell death. However, 
recent work in the Prph2Rd2IRd2 mouse shows that although microglia are present in 
the degenerating retina, neither their gene expression profile nor their temporal 
distribution supports this theory as microglial presence peaked 5 days after apoptosis 
had done so and the microglia were also iNOS-negative [93], suggesting the absence 
of cytotoxic signalling molecules that could kill photoreceptors.
Another theory of cell death in RP concerns the constitutive activation of the 
phototransduction cascade, caused by aberrant expression of genes required to prevent 
over-stimulation of photoreceptors. Fain and Lisman first proposed a mechanism by 
which photoreceptors die in response to vitamin A deprivation and inherited RP 
mutations [94]. They suggested that the cell death seen in these circumstances could 
be similar to that seen in light damage models of RP. In such models, retinae exposed 
to either short bursts of high-intensity light or prolonged low intensity light suffer loss 
of photoreceptors. Their ‘equivalent light hypothesis’ suggests that many of the 
mutations that cause RP, as well as dietary vitamin A deprivation, may cause 
constitutive stimulation of the phototransduction cascade, resulting in signals being
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sent to the inner retina that are ‘equivalent’ to those sent in response to the detection 
of incident light. It has been proposed this may lead to cytotoxicity by two 
mechanisms; one in which insufficient calcium influx leads to cell death (see below), 
and another whereby the post-synaptic bipolar cells, acting as if constantly exposed to 
light, initiate signalling events that lead to photoreceptor cell death. Evidence has 
since emerged to suggest that this may be a major contributing factor to the 
degeneration seen in some forms RP. For instance, data from CNGB1'1' mice, which 
produce no p-subunit of the cGMP-gated calcium channels, support the theory that 
continuous activation of phototransduction leads to cell death. Consider that light 
capture by rhodopsin leads to activation of PDE via transducin, and that this leads to 
closure of the Ca2+ channels, hyperpolarising the cell and preventing the glutamate 
release that forms the constitutive ‘dark signal’. Disruption of the CNGB1 gene that 
leads to lack of CNGB1 protein results in calcium influx being permanently 
prevented, because CNGB1 is required to correctly target the CNGA1 protein to the 
rod plasma membrane and to form functional CNG heterotetramers with a-subunits. 
Due to the lack of functional cGMP-gated calcium channels at the plasma membrane, 
calcium is no longer transported into the cell to maintain a depolarised ‘ground state’ 
and there is a permanent state of hyperpolarisation in the photoreceptor inner 
segment; glutamate is never released from the photoreceptors, and the bipolar cells of 
the inner retina respond as though they are receiving signals from light-activated rods 
all the time.
Evidence from other models of RP also supports the equivalent light hypothesis. 
Some mutant forms of rhodopsin are known to constitutively activate transducin, 
independent of excitation by photons of light [95,96]. There is some difficulty in 
directly assaying the constitutive activity of such mutants in vivo, but if transducin is 
activated even in the absence of light the inner retina would receive an equivalent 
light signal as before. Mutations in the retinal guanylyl cyclase enzyme, RetGC, have 
also been described [49]. The expected consequence of this would be the lack of 
cGMP synthesis, leading to permanently closed calcium channels and a signal 
equivalent to light being sent to bipolar cells and beyond in the visual pathway. In 
addition, a study using mice that lack functional arrestin protein and are defective in 
the shut-off of rhodopsin signalling showed that activation of phototransduction by 
normal levels of light can cause degeneration of the outer nuclear layer over a period
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of one year; this is because the phototransduction cascade is not correctly shut off, 
supporting the equivalent light hypothesis [97]. Perhaps the most convincing evidence 
to support the equivalent light hypothesis comes from a transgenic mouse model of 
Leber's congenital amaurosis (LCA). Woodruff and colleagues showed that a null 
mutation in the Rpe65 gene, known to cause LCA by disrupting 11 -cis retinal 
reconstitution from recycled alWraws-retinol, causes degeneration of photoreceptors 
in a manner consistent with the equivalent light hypothesis; photoreceptors from 
Rpe65'A mice have reduced circulating current in response to light stimulation, 
reduced light sensitivity, and accelerated turn-off of photoresponse [98]. Moreover, 
they provide direct evidence that the lack of RPE65 protein causes photoreceptor 
death through accumulation of opsin that is not bound to 11 -cis retinal and the 
constitutive activation of the phototransduction cascade; by crossing the Rpe65~f~ mice 
with mice homozygous for a null mutation in transducin, and showing a retardation of 
cell death, they showed that the Rpe65 null mutation causes photoreceptors apoptosis 
mediated by activation of the phototransduction cascade [98]. Thus, new, more direct 
evidence suggests that a constitutive signal equivalent to that sent on light exposure 
may cause cell death in RP.
To elaborate upon this hypothesis, the mechanisms through which such constitutive 
activation of the phototransduction cascade causes apoptosis need to be elucidated. 
Two possibilities arise; one is a cell-autonomous, intracellular pathway to cell death, 
another implicates other cell types associated with apoptotic photoreceptors. 
Intracellular responses from within cells that harbour mutations leading to an 
equivalent light signal could be responsible for triggering apoptosis, possibly related 
to calcium levels within the photoreceptors. The permanent closing of calcium 
channels, through any of the mechanisms mentioned above, would lead to a drop in 
intracellular calcium levels. Neuropathology in various systems is associated with 
elevated Ca2+ levels, through mitochondrion-mediated caspase activation that follows 
signalling from glutamate receptors [99]; the degeneration in the rd mouse could be 
caused by elevated intracellular calcium, produced by the constitutively high cGMP
^ I
levels keeping the Ca channels open. However, some studies suggest that 
neurotoxicity may arise if calcium levels are too low as well. In vitro experiments 
show that the gating of calcium channels, leading to an increase in intracellular Ca2+, 
protects cultured neurones from apoptosis [100]. Another way in which cells may die
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in response to an equivalent light signal could involve secondary messengers being 
released by cells in the inner retina. Bipolar cells, as well as Muller cells and ganglion 
cells, secrete neurotrophic factors that promote the survival of photoreceptors under 
normal circumstances. It may be that on receiving a constant light signal, real or 
equivalent, these cells alter their gene expression and either secrete factors that trigger 
an extrinsic apoptotic pathway in the photoreceptors, or stop secreting factors that 
otherwise promote photoreceptor survival.
It is likely that the evidence supporting the equivalent light theory applies better to 
certain models and forms of RP than others. In particular, several forms of RP are 
caused by mutations that give rise to disease mechanisms considerably different from 
constitutive activation of the phototransduction cascade; mutations -  particularly 
homozygous null mutations -  that ablate photoreceptor function totally are likely to 
cause cell death due to the abolition of photoresponse in the rods and cones, as 
opposed to the constitutive activation of phototransduction proposed in the equivalent 
light hypothesis. As such these mutations would represent an ‘equivalent dark’ 
hypothesis, whereby lack of phototransduction is a characteristic consequence of the 
gene defect concerned. By understanding the alternative disease mechanisms leading 
to apoptotic photoreceptor death, therapeutic intervention to prevent the loss of cells 
in the outer retina may be possible. For instance, healthy photoreceptors are known to 
die in the presence of mutant cells; this ‘by-stander effect’ suggests a non cell- 
autonomous mechanism for cell death, possibly involving secondary cells and their 
secreted factors [101]. Direct evidence for this by-stander effect comes from chimeric 
mice generated from albino Prph2R<n/Rd2 mice and pigmented mice that were wild- 
type at the Prph2 locus; photoreceptors were found to die not only in the regions 
overlying non-pigmented RPE, but also in regions overlying pigmented RPE, 
indicating that photoreceptors that are genetically normal die in the presence of 
photoreceptors carrying RP-causing mutations [102]. The involvement of inner retinal 
cell types in the death of otherwise healthy photoreceptors has not yet been shown, 
and this remains a plausible theory of cell death in RP. However, evidence that a by­
stander effect mediated by the loss of rods is responsible for the cone cell death has 
emerged from a series of studies on retinal explants from rod-deficient rd mice. The 
rod-derived cone viability factor (RdCVF) was isolated by screening a cDNA library 
from a wild-type mouse retina for a secreted factor that enhances the survival of chick
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cone cells and cone-rich retinal explants from rdl mice in culture [103,104]. This 17 
KDa protein is secreted by rods, and, when delivered as a GST-tagged fusion protein 
into the sub-retinal space of rd mice, supports enhanced survival of cones. RdCVF is 
the first example of a factor that is secreted by rods that appears to be required for 
cone survival. It is not known how RdCVF acts on cone cells to enhance their 
survival, but it has been established that removal of the factor from rod-conditioned 
medium by blocking antibodies abrogates the ability of the conditioned medium to 
enhance murine cone cell survival in explants [103]. As RdCVF is secreted by rods 
and acts on the survival of cones, there is at least a component of photoreceptor death 
that is not cell autonomous; it is as yet unclear whether RdCVF plays a role in 
photoreceptor death following insults such as continuous light or equivalent genetic 
mutations, and because many of the experiments described using RdCVF were done 
in vitro using either chick cells of murine retinal explants, it is unclear whether this 
molecule is relevant to cone survival in situ in either the murine or human retina. It is 
yet to be determined whether gene therapy using this rod-derived survival factor 
would enhance cone cell survival.
In addition to the effect of rod death on cone survival, another way in which other cell 
types may be implicated in photoreceptor death is through a change in the expression 
of survival factors that are secreted by inner retinal cells. It is known that in order to 
prevent neuronal cells from undergoing apoptosis, glial cells and neurones themselves 
express many protein growth factors that are neurotrophic -  factors that promote the 
survival of neuronal cells. Such neurotrophic factors are secreted by the cells that 
neurones grow towards (their target cells), and binding of the neurotrophic factor to 
its cognate receptor leads to signalling that prevents apoptosis in the neurone, as well 
as growth of the neurone towards the source of the factor along a concentration 
gradient [105]. Following the identification of nerve growth factor (NGF), seen as the 
prototypical neurotrophin, several proteins have been shown to promote neuronal 
survival in the CNS, including NGF itself [106], brain-derived neurotrophic factor 
(BDNF) [107], ciliary neurotrophic factor (CNTF) [108], basic fibroblast growth 
factor (bFGF) [109] and glial cell line-derived neurotrophic factor (GDNF) [110]. 
These studies demonstrated the potential of neurotrophic molecules in promoting 
neuronal cell survival; the term neuroprotection refers to this survival effect on 
neuronal cells exerted by neurotrophic growth factors. Withdrawal of these growth
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factors is sufficient to initiate photoreceptor apoptosis, although this may not be the 
only mechanism involved in retinal degeneration.
In a review of mechanisms involved in apoptosis of photoreceptors in models of RP, 
Travis proposed that mutations that cause equivalent light signals, and those that 
disrupt photoreceptor function, may lead to cell death through an increase in oxidative 
stress [111]. When expression of the anti-apoptotic gene Bcl-2 was shown to improve 
photoreceptor survival in Prph2R<n/Rdl mice [112], this notion was given credence. It 
is proposed that the unusually high density of mitochondria in photoreceptors makes 
rod and cone cells unduly sensitive to mutations that alter their metabolic 
requirements. Mutations such as that of the Peripherin gene in the Prph2Rd2/R<n mouse 
lead to photoreceptors being less metabolically active than wild-type photoreceptors. 
This may lead to an increase in mitochondrial free radical production in the form of 
reactive oxygen species (ROS). This is because, whilst other tissues are able to 
modulate their blood supply by vaso-constriction, the choriocapilaris that serves the 
retina is largely unable to constrict, meaning the same level of oxygen is supplied to 
photoreceptors despite their altered metabolic state. In many cell types, in both 
normal processes such as embryological development and in the pathology of various 
diseases, apoptosis occurs when various stimuli trigger intracellular signalling 
cascades through mitochondria. The role of mitochondrial responses to oxidative 
damage in apoptotic cells in general is well-established; the release of Cytochrome-c 
from the mitochondrion (in response to, amongst other stimuli, oxidative stress) and 
the subsequent activation of caspase proteins via Apaf-1 is seen as a major control 
point in the intracellular pathway to programmed cell death [91]. Hence, a rise in 
mitochondrial ROS through a mutation that causes a reduction in metabolic activity 
would then lead to increased apoptosis, as ROS are known to induce damage to DNA, 
lipids and proteins within mitochondria [113,114], leading to mitochondrial inner 
membrane disruption and subsequent cytochrome-c release.
This receptor-independent response to internal sensing of apoptotic stimuli such as 
oxidative stress is likely to be a predominant cell death pathway in the Prph2Rd2/Rdl 
mouse, particularly when considered alongside a mathematical model for retinal 
apoptosis [115]. Clarke et al. describe how the probability that any given rod cell will 
die by apoptosis declines exponentially over time, and that this can only be explained
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by a ‘one-hit model’ of cell death whereby a mutation leaves cells susceptible to a 
single apoptotic insult. This is in contrast to, for instance, a ‘cumulative damage’ 
model for cell death, where a steadily increasing probability of apoptosis would be 
seen. The authors of this regression analysis study demonstrated that the one-hit 
model also applies to other animal models of retinal degeneration, including the 
nervous (nr/nr) mouse, the purkinje cell degenerationipcd/pcd) mouse, and the rdl 
mouse [115]. Following this analysis it has been proposed that the kinetics of 
apoptosis seen in the Prph2R<nm2 retina, and in other models of retinal degeneration, 
suggests that mutations affecting the integrity and functional status of outer rod 
segments leave cells vulnerable to increased oxidative stress, and that this oxidative 
stress leads to an exponentially decreasing loss of rod cells by programmed cell death.
Within this ‘oxidative stress’ theory of retinal cell death, the accumulation of reactive 
oxygen species is crucial; mitochondria in cells with mutant outer segments are more 
likely to produce free radical species that go on to damage mitochondrial and cellular 
components. The natural cellular defence against ROS is the manganese superoxide 
dismutase enzyme, MnSOD; this enzyme is the major mitochondrial member of the 
superoxide dismutase gene family, and is encoded by the nuclear SOD2 gene [116]. 
SOD2 converts ROS to H2O2 , removing a free radical in the process. Although the 
half-life of oxygen free radicals in situ are very short, making the ROS themselves 
difficult to quantify, proximate markers of ROS damage such as peroxidated lipids, 
DNA lesions and protein peroxidation can be measured to assess the involvement of 
ROS-mediated damage in cells. Considering that SOD2+l~ heterozygotes show 
increased ROS presence and increased oxidative damage to mitochondrial DNA 
[117], overexpression of SOD2 in models of RP in which absence or paucity of outer 
segments is believed to reduce rods' oxygen utilisation should prevent or slow 
apoptotic death. Conversely, a mouse that is heterozygous for null mutations in both 
SOD2 and Prph2 (SOD2+/‘ Prph2Rdll+ mice) might produce accelerated apoptotic 
photoreceptor cell death as shown by thickness of the outer nuclear layer.
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1.10 Treatment strategies for RP
1.10.1 Pharmacological treatments for RP
Pharmacological treatments are available for many ocular diseases, and range 
from systemically to locally administered compounds. However, none of the forms of 
retinitis pigmentosa that have been discussed thus far benefit from pharmacological 
interventions. Some RP-like syndromic conditions may be ameliorated by dietary 
regulation, such as gyrate atrophy of the retina and choroids [118]. However, any 
improvements seen are reversible, and some reports suggest that certain patients may 
not respond to treatment at all [119]. Drug therapies have been largely ineffective in 
animal models of RP. A study in the rd mouse suggesting a (transient) amelioration of 
phenotype following systemic administration of calcium channel blockers [120] was 
contradicted by another study in the same model [121] whereas oral administration of 
9-ds-retinal in Rpe65'/' mice is thought to mediate therapeutic benefit, albeit only 
when assessed at short-term time points [122,123]. A more common pharmacological 
approach, however, involves attempts to prevent photoreceptor cell loss without 
addressing the underlying causative mutations. As discussed previously, neurotrophic 
factors exert an anti-apoptotic effect by suppressing pro-apoptotic signalling in 
various neurones. These neurotrophic proteins have been assessed for their ability to 
protect neuronal cells in the eye from apoptotic cell death. Intraocular injections of 
recombinant growth factor proteins, such as CNTF, bFGF and BDNF exert a 
neuroprotective effect by promoting the survival of photoreceptor cells in the 
degenerating retina [124,125]. However, the results from these early studies in the eye 
were varied; some of the neurotrophic factors tested only promoted photoreceptor 
survival in certain models of RP, whereas some models showed no increased survival 
of photoreceptors after injection of any of the factors [125]. Cayouette et al. showed 
that a neurotrophic factor originally isolated from RPE cells, pigment epithelium- 
derived factor (PEDF), protects to some extent against the apoptosis seen in the rd 
mouse and the Prph2Rd2fRd2 mouse [126]. Following intravitreal delivery of 
recombinant PEDF protein (rPEDF), a transient reduction in apoptotic cell loss was 
shown in both models evaluated; three days after treatment significantly more 
photoreceptors remained in rPEDF-injected eyes when compared to /?-Gal treated
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controls, but this difference was no longer apparent six days later. Nonetheless, these 
were the first studies to show any efficacy of pharmacological intervention in models 
of inherited retinal dystrophies. An effective anti-apoptotic treatment regimen has the 
potential advantage that it could be applied to a wide spectrum of retinal 
degenerations with unrelated causative mutations, by enhancing photoreceptor 
survival. However, delivering the neurotrophic factors as recombinant protein is not 
ideal; without repeated administrations, the relatively short half-life of the proteins 
means that any functional improvement is short-lived. Moreover, it seems that 
neurotrophic factor administration alone may not suffice in models of disease where 
the absence of a gene product commits photoreceptors to die unless this underlying 
defect is also corrected. Neuroprotection via delivery of genes encoding these 
neurotrophic factors, however, would allow for long-term therapeutic effects of the 
likes of BDNF and GDNF, and this has been made possible by advances in viral gene 
therapy.
1.10.2 Cellular therapy for retinal degeneration
As pharmacological therapy is largely ineffective for most inherited retinal 
degenerations, novel treatment strategies have been developed that address the 
mutations underlying disease, or that attempt to stably deliver factors that enhance 
photoreceptor survival in mutation-independent approaches. Although the studies 
presented here focus on gene therapy using viral delivery of therapeutic nucleic acids, 
some forms of inherited retinal dystrophy may also be amenable to cellular therapy 
(Chapter 1.12).
Cellular therapy is a term that describes three broad therapeutic approaches; replacing 
the diseased cell type with healthy tissue; treatment with an ectopic cell type that 
provides trophic support for degenerating photoreceptors; or treatment with a cell type 
engineered to secrete a growth factor that enhances photoreceptor survival. An 
example of the first strategy would be the transplantation of healthy RPE cells to treat 
disease caused by RPE-specific mutations. This has been shown to be effective in 
models of RP, and in patients with AMD. In particular, the photoreceptor
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degeneration in the RCS rat may be slowed to a certain extent by transplantation of 
immortalised human RPE cells (ARPE19), with an improvement in behavioural 
function correlating to some preservation of photoreceptors [127,128]. In addition, 
engraftment of a healthy region of RPE underneath a diseased macula improves visual 
function in some AMD patients [129], although other studies carried out indicate that 
the occurrence of proliferative vitroretinopathy [130] and/or secondary geographic 
atrophy [131] may hinder functional recovery following such procedures. In addition, 
these and other studies using RPE translocation require autologous cell transfer, or 
require the recipients to be immuno-suppressed in order to avoid graft rejection.
An ideal cellular therapy would be the use of stem, progenitor, or precursor cells to 
regenerate tissue that is damaged in disease. With the discovery of neural stem cells in 
mature mammalian eyes [132], the possibility of transplanting progenitor cells into 
the eye to repopulate the degenerating retina arose. Early work using GFP-positive 
donor cells transplanted into degenerating recipient retinae showed limited integration 
of transplanted cells into the outer nuclear layer, with most cells that survived the 
graft doing so in the plexiform layers or the inner nuclear layer of the retina [133]. 
Enhanced survival of host photoreceptors and a modest improvement in visual 
function was reported. However, the transplanted cells used in this study were isolated 
from neonatal mice and included many different cell types at various stages of 
development. It is therefore likely that the improvements seen resulted from engrafted 
cells secreting soluble trophic factors as opposed to integrated and differentiated 
donor cells replacing degenerating photoreceptors. Subsequent studies have attempted 
to restore structure and function to degenerating retinae using transplantation of 
various populations of retinal progenitor cells. To date many such studies have 
attempted to use actively dividing retinal progenitor cells transplanted into 
degenerating recipient eyes. This was based on these transplanted cells receiving the 
appropriate developmental cues from the environment into which they integrate and 
developing into functional rods and cones. However, it has now been shown that 
although precursor cells from an immature donor eye can integrate and develop into 
functional rods, these donor cells have to be post-mitotic cells committed to a 
photoreceptor fate for this integration to be successful. This was determined using 
donor cells from mice in which a GFP gene is driven by the Nrl promoter, which is 
the earliest rod-specific transcription factor expressed in post-mitotic rod precursors
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[26]. Using cells from post-natal Nrl.GFP mice, it has been shown that only non­
dividing, post-mitotic (and hence GFP-positive) precursor cells are able to integrate 
into an adult recipient retina, although actively-dividing cells do survive engraftment 
in the sub-retinal space [134]. In many studies of this nature, the precursor cells are 
generally taken from the ciliary margin, a region of the anterior retina near the ciliary 
body. The presence of these ‘stem-like’ cells in the adult has been described as a 
‘niche’ for cells that could potentially repopulate damaged areas of the host retina; 
however, in mammals although these precursor cells have the ability to differentiate 
when removed from their native environment, they do not appear to do so in situ 
during the course of disease. This, together with the results described by Maclaren 
and Pearson et al. [134], suggests that although the adult retina can host engrafted 
retinal precursors, early and undifferentiated stem/precursors are unable to integrate 
and subsequently develop into mature photoreceptors, presumably as the adult retina 
lacks the requisite developmental cues in the form of transcription factors and other 
signalling molecules [134]. Another cellular therapy approach is to use cells such as 
Schwann cells to provide trophic support to degenerating retinae. Initially Schwann 
cells were shown to aid regeneration of CNS lesions in rats [135]; subsequently 
Schwann cell have been used to aid neuronal regeneration in a contusion model of 
spinal chord injury in rats [136] and to promote retinal ganglion cell survival 
following optic nerve transection [137,138]. It has been shown that the ability of 
Schwann cells to promote axonal regeneration and neuronal cell survival depends on 
the secretion of neurotrophic factors such as NGF [136]; it follows that Schwann 
cells, or indeed many other cell types, engineered to over-express neurotrophic genes 
could exert a similar neuroprotective effect. This is supported by evidence from 
studies in which Schwann cells transduced ex vivo to produce brain-derived 
neurotrophic factor (BDNF) promote axonal regeneration across a spinal chord 
transaction [139]. In the eye, Schwann cells transfected ex vivo with plasmids 
encoding BDNF and glial cell line-derived neurotrophic factor (GDNF) prolong 
photoreceptor survival and provide some modest behavioural improvement in the 
RCS rat, although untransduced Schwann cells also provide some transient 
improvements [140]. Cellular implants that are engineered to secrete CNTF have been 
used to treat patients of retinitis pigmentosa, and this will be discussed in further 
detail in the context of AAV-mediated CNTF delivery in a rodent model of RP 
(Chapter 5). Aside from using cellular therapies for inherited retinal degenerations,
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the use of gene therapy strategies holds much promise and it is the aim of these 
studies to develop existing approaches to ocular gene therapy.
1.10.3 Gene therapy for retinal degeneration
Gene therapy refers to a range of molecular techniques designed as rational 
strategies to treat disease by delivery of nucleic acids. There are several approaches 
that can be used to deliver nucleic acids to a target organ using a vector. The vector 
used can be viral or non-viral, with greater efficacy associated with the former whilst 
the latter offers greater safety. For most ocular gene therapy applications, viral vectors 
are preferred; this is because highly efficient transduction of cells is required to 
mediate functional benefit, and cell-specific expression can often be critical. Which 
particular viral vector is used depends on the cell type to be treated.
The eye is regarded as a good target organ for gene therapy. Primarily this is due to 
the ease of access, both for delivery of gene therapy agents and with regards to non- 
invasive follow up. Administering therapeutic agents through intraocular or sub- 
retinal injections is not disruptive beyond the level of procedures carried out routinely 
in ophthalmic surgery. Ophthalmoscopy or electroretinography, used to assess post­
treatment retinal function, are non-invasive and easily standardised. Furthermore, the 
eye contains cell types from different embryological origins and with diverse 
functions, and hence can be a valuable resource for testing gene delivery to several 
tissue types. Moreover, the blood-retina barrier allows the expression of ectopic genes 
to be targeted to specific cell types and systemic spread of virus and transgene can be 
limited [141]. The blood-retina barrier, composed of tight junctions between RPE 
cells and between corneal epithelial cells, also prevents the entry of large pathogens 
into the eye through the blood supply. Additionally, the eye carries out many more 
immuno-modulatory functions in order to avoid inappropriate inflammatory responses 
to antigens (reviewed by Streilein, ref. number [142]), which in itself can cause much 
damage to the cells in the eye; these include down-regulation of MHC Class I 
expression in corneal antigen-presenting cells (APCs); cytokines present in the 
aqueous humour that suppress both T cell differentiation and their secretion of pro- 
inflammatory signalling molecules; the inhibition of T cells and complement by cell-
56
surface proteins expressed constitutively by comeal and retinal pigment epithelium. 
Together these measures serve to modulate the immune response to pathogens (and, 
potentially, gene therapy vectors) that, if left uncontrolled, would damage the 
neurosensory retina. These characteristics of the mammalian eye make it an attractive 
target organ for gene therapy, and to date a number of vectors have been used to 
deliver genes to the eye with varying degrees of success.
1.11 Gene delivery vectors
1.11.1 Non-viral gene delivery
At its most basic, gene delivery to target tissues can be achieved by 
electroporating or even injecting cells in situ with naked plasmid DNA, as reviewed 
by Prud’homme et al [143]; the route of administration of plasmid DNA prior to 
electroporation plays an important role in determining which cell types are 
transduced, which will also be discussed in the context of viral gene delivery below. 
Short-lived (less than two weeks) localised reporter gene expression has been reported 
using direct injection into the comeal stroma [144]. Following anterior chamber 
injection of plasmid DNA followed by electroporation, reporter gene expression in 
comeal endothelium is maximal just three days post-treatment, and is undetectable 
three weeks after injection [145]. Sub-retinal injection of plasmid DNA followed by 
electroporation results in transient RPE-specific transgene expression, although this 
expression reaches a peak three days post-treatment and is undetectable 21 days post­
treatment [146]. The transient nature of reporter gene expression using this technique 
could be because host enzymes such as DNAse break down naked DNA, leading to 
poor transduction rates. Neonatal gene transfer using electroporation appears more 
efficient, with up to 80% of rod cells transduced by a reporter gene expression 
cassette following treatment at post-natal day 0 [147]. Rather than electroporating 
naked plasmids, DNA can be delivered to cells in liposomes, an approach that has 
been used in tissues such as muscle [148,149]. In the eye, lipofection can lead to 
transient reporter gene expression, but lasts no longer than 21 days. Cationic polymers
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have been assessed for their ability to deliver DNA to target cells; advances are being 
made using this approach, with improvements in transduction efficiency a priority 
[150]. Because the DNA remains episomal, in dividing cell the transgene is lost 
during cell division, which also reduces the longevity of expression following non- 
viral gene delivery; nonetheless as many cell types in the eye are post-mitotic, 
therapeutic levels of transgene expression may be achieved using these vectors. Novel 
transfection agents that incorporate ligands for specific cell-surface receptors have 
also been developed, allowing receptor-mediated endocytosis of cationic polymer- 
DNA complexes to increase transfection efficiency and specificity of cell types 
transduced; for instance, by incorporating the protein transferring into PEI/DNA 
complexes, highly specific gene transfer to hepatic tumours can be achieved, although 
it is not clear whether this expression would persist beyond the one week time-point 
assessed in this study [151]. Despite these advances, in vivo gene delivery using these 
non-viral techniques remains of low efficiency and are of most use when transient 
gene expression is sufficient to mediate a treatment effect [152]. This is possibly 
because the DNA introduced into host cells using electroporation and/or lipofection 
remains episomal. Recently Chalberg et al. have shown that electroporation leads to 
persistent reporter gene expression (at least 4.5 months) in rat RPE following sub- 
retinal injection of naked plasmid DNA, if co-injected with a plasmid encoding the 
integrase gene from the phiC31 bacteriophage [129]. Essentially these latest strategies 
used in developing non-viral gene therapy vectors have attempted to mimic 
mechanisms used by viruses to incorporate DNA into host cells and provide long­
term, stable gene expression.
1.11.2 Viral gene delivery vectors
Viruses are naturally capable of delivering nucleic acids to the nucleus of their 
target cells, and viruses engineered to deliver therapeutic transgenes have been 
extensively studied in cell culture and animal models of disease, and to some extent in 
humans. The choice of which viral vector is used can be crucial to the success or 
otherwise of a gene therapy strategy; viruses suited for a particular cell type or a 
particular disorder may not be applicable to other contexts. Discussed below are the
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candidate viral vectors that have been considered for use in gene therapy applications 
in the eye as well as in other systems.
Herpes Simplex virus (HSV)-based vectors
HSV is widely used in gene transfer experiments in organs other than the eye. A 
large double stranded DNA virus that naturally infects neuronal cell types, gene 
therapy strategies for Parkinson’s disease [153] and Alzheimer’s disease [154] have 
been based on this virus. A major advantage of using HSV to deliver therapeutic 
genes is the large coding capacity of the HSV genome; by replacing non-essential 
elements of the wild-type genome, viruses can package up to 30 kb of transgenes 
within multi-cistronic expression cassettes. HSV is able to establish latent infection by 
persisting as episomal DNA as part of its life cycle. Once this latency is established, 
the only viral transcripts that are produced are the latency-associated transcripts, or 
LATs [155]. The expression of these transcripts, which as of yet have unknown 
function, is driven by the LAT promoters; active during the latent phase of the HSV 
life cycle, these promoters can be used to drive stable transgene expression over long 
periods of time -  in neuronal tissue stable transgene expression lasting at least six 
months has been demonstrated [156]. There are three ways in which recombinant 
HSV particles can be used as gene therapy vectors, which are applicable in different 
disease paradigms. Firstly, HSV can be engineered to harbour mutations in viral genes 
that are essential for nucleic acid synthesis, which renders the virus replication- 
deficient in non-dividing cell types. These mutations can be in the HSV thymidine 
kinase gene, and the ribonucleotide reductase gene [157], or in a gene that shuts off 
host-cell protein synthesis (IPC34.5) [158]. These viruses are then able to replicate in 
cells that have up-regulated host functions that complement those of the mutated viral 
gene, such as malignant tumour cells (that have re-entered the cell cycle and are in 
Gl/S phase) [159]. Once these mutant HSV virions replicate in tumour cells, they lyse 
the host cells and have been shown to be well tolerated and to have anti-tumour 
efficacy in patients that have high grade glioma [160]. Hence HSV that replicates only 
in tumour cells constitutes one form of oncolytic viral gene therapy, whereby viruses 
are used to lyse malignant tissue; recombinant adenoviruses can also be used as 
oncolytic agents (see below). As gene delivery to neuronal cells such as 
photoreceptors could be used as a therapeutic strategy for treating RP, HSV would be
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a candidate vector for delivery of therapeutic genes to the eye. Following intravitreal 
injection of recombinant HSV, 25% of retinal ganglion cells are transduced, but 
transgene expression lasts for less than two weeks; RPE expression also seen for two 
weeks following intravitreal HSV injection, but photoreceptors are not transduced 
using any route of administration [161]. This is likely to be a function of the large size 
of HSV virions (around 200nm), preventing virions from penetrating the inter­
photoreceptor matrix and entering photoreceptors cells. Coupled with HSV’s high 
natural immunogenicity and the difficulty of making high-titre, pure viral stock makes 
recombinant HSV of limited use for ocular gene transfer. A novel HSV-based gene 
delivery system may be of some utility in the treatment of acute ocular conditions, 
and is based on amplicons that can contain transgene expression cassettes of up to 150 
kb. HSV amplicons are essentially plasmids which contain the HSV ori sequence 
(origin of replication) and the HSV pac (packaging) sequence and an expression 
cassette carrying the gene of interest. To produce an amplicon-based recombinant 
HSV stock, the amplicon plasmid is transfected into a permissive cell line, and is 
either packaged into mature HSV particles using replication-defective HSV in which 
the packaging signal has been deleted, or by providing the necessary HSV capsid 
proteins in trans using a cosmid or BAC vector (for review see ref. [162]). Rapid 
RPE-specific transgene expression was reported following administration of an HSV 
amplicon-based vector following sub-retinal delivery [163], which was nonetheless 
transient. In around 10% of cells this may have been because the promoter activity 
from the episomal transgene expression cassette was shut off. The majority of cells 
appeared to have lost their episomal amplicon, possibly through an immune response 
to the vector preparation. Therefore where acute transgene delivery would be able to 
mediate a therapeutic effect, these amplicon vectors may play a role.
Adenoviral vectors (Ad)
Adenovirus (Ad) was the vector of choice for many early in vivo gene transfer 
experiments, and has shown to mediate effective therapeutic gene expression in 
several species [164]. Clinical trials using Ad-based vectors have also been carried 
out, with diseases such as cystic fibrosis [165] and cancer [166] being treated. A 
major advantage of using Ad-based vectors is that a relatively large amount of DNA 
can be incorporated into their genome; transgenes of up to 48 kb can be delivered to
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host cells using recombinant adenovirus, whereas the lower coding capacity of other 
vector systems can be a limiting factor for gene delivery. Much work has been carried 
out to develop safer and more efficient adenoviral vectors, with progressively fewer 
and fewer viral genes being included within the mature recombinant virion [167]. The 
first Ad-based vectors were made replication-deficient by deletion of the El region of 
the adenoviral genome, which contains genes involved in regulation of early phase of 
the infectious cycle. ‘Second-generation’ Ad vectors are further deleted in the E4 or 
E2 regions, preventing transcriptional control of viral gene expression and viral 
genome replication respectively. In the eye, as with other viral and non-viral gene 
delivery vectors, the route of administration determines which cell types are 
transduced by adenoviral vectors. Following anterior chamber injection of an 
adenoviral vector, reporter gene expression is seen in the corneal endothelium, iris 
epithelium, and trabecular meshwork, whereas sub-conjunctival injection results in 
conjunctival fibroblasts being transduced and sub-retinal injection results in 
exclusively the RPE being transduced [168]. However, the utility of first and second 
generation adenoviral vectors for ocular gene delivery is limited due to the aggressive 
immune response initiated by adenovirus in the eye; T-cell mediated immune 
responses lead to abolition of transgene expression as early as three weeks after 
administration to the retina, whereas mice lacking a T-cell repertoire maintain high 
levels of transgene expression for at least four months [168], In retinal gene therapy 
applications where long-term, therapeutic gene expression is required, therefore, Ad- 
based vectors are extremely limited in their utility. The clinical use of this vector 
system has been questioned following the death of a patient during a phase I trial for 
adenoviral vectors in omithne trascarbamylase deficiency (OCD) [169]. In retrospect, 
the phase I clinical trial may have been poorly planned due to a relative paucity of in 
vivo studies in animal models of OCD. Given that some of the early studies involving 
adenoviral vectors in models of OCD had been carried out in neonatal mice, which 
have no cellular immune response, it is possible that the investigators underestimated 
the potential adverse effect this adenoviral vector could have following high-dose 
hepatic administration. It was an aggressive systemic immune response to a high dose 
of adenoviral vector that caused the lethal complications seen in this clinical trial 
Despite a small study in non-human primates demonstrating that this vector is well- 
tolerated at low-to medium level doses (up to 6x1011 particles per kg) [169], this same 
dose range resulted in severe and lethal inflammatory side effects in the phase I trial.
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This lead to the suspension of all gene therapy trials by the United States Food and 
Drug Administration (USFDA), and to a more cautious approach to adenoviral gene 
therapy. Despite this major setback, clinical trials for gene therapy applications are 
now being approved for a range of diseases and vectors [170], and in China an 
adenoviral construct encoding p53 has recently been approved as a licensed treatment 
for head and neck squamous cell carcinoma (HNSCC) [171]. Gendicine, an Ad-5 
serotype vector, has been used to treat in excess of 2600 HNSCC patients. Indeed, the 
development of safer, less immunogenic helper-dependent adenoviral vectors [172] 
have allowed gene therapy for OCD to be investigated once again, with longer-term 
disease correction and less of a deleterious immune response in mice [173].
In the eye, adenoviral vectors have been used for a Phase I clinical trial for the 
choroidal neovascularisation (CNV) associated with age-related macular degeneration 
(AMD). This open-label trial demonstrated that adenovirus-mediated PEDF 
expression is well tolerated in patients with severe neovascular AMD, although very 
low doses of adenovirus were used [174]; studies in which monkeys were injected 
with increasing doses of the Ad.PEDF vector had identified lx l0 9 particles as being 
the maximum tolerated dose, beyond which an adverse immune reaction to the vector 
was noted [175] -  in the clinical trial doses between lxlO6 and lxlO9 were used. Data 
relating to efficacy of this treatment in ameliorating vision needs to be interpreted 
with caution due to the small scale of the trial, in which 28 patients were treated. This 
is particularly applicable to this trial, as the natural history of AMD patients’ visual 
acuity is such that some month-on-month improvement in outcome measure can be 
expected without intervention, and also because visual acuity may not always be the 
most appropriate way of assessing functional vision. Despite the potentially beneficial 
effects of PEDF in protecting retinal neurones from apoptosis, delivery using Ad- 
based vectors appears to be counter-productive due to the high likelihood of 
inflammatory responses to the vector itself. It may well be that gutted or helper- 
dependent Ad-based vectors are appropriate when transient gene expression allows 
long-term disease correction; in order to mediate effective gene therapy in most ocular 
diseases, however, vectors need to drive stable, long-term gene expression in the 
absence of immune responses and other deleterious effects.
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‘Third-generation’ or ‘gutted’ Ad vectors have recently been developed, and are 
deleted for all viral genes. They therefore offer two major advantages; the host 
immune response seen with earlier Ad vectors is greatly diminished, and the gutted 
vectors also have a capacity to deliver larger expression cassettes. This increased 
cloning capacity is of particular interest, especially with respect to multi-cistronic 
approaches to gene therapy. The use of gutted Ad vectors results in longer-term 
transgene expression in mice, and is well tolerated because little immune response is 
provoked; in a model of muscular dystrophy, intramuscular delivery of a gutted 
adenovirus encoding murine dystrophin gene results in efficient expression of 
dystrophin protein in the absence of vector- or transgene-mediated immune response 
[176]. This gene replacement therapy continues to rescue 50% of muscle fibres in the 
dystrophin-deficient (mdx) mouse one year post-injection from contraction-mediated 
injury [177]. In the eye, Ad-mediated transgene product persists in the form of mRNA 
for at least 18 weeks post-treatment and protein for up to five months in rdl mice 
treated with sub-retinal delivery of Ad.pPDE [178]. Although the latest Ad vectors 
that are deleted for all viral genes are promising in terms of their ability to drive high 
levels of transgene expression without eliciting a host immune response, there remain 
technical barriers to large-scale, clinical grade adenovirus production.
Retroviral vectors
A third group of viral gene transfer vectors based on retroviruses have been developed 
that mediate long-term, highly efficient transgene expression. Retroviruses are RNA- 
based viruses that integrate their reverse-transcribed proviral DNA into host cell 
chromosomes, and are classified into seven distinct genera according to their 
sequence similarity (Table 1.2a); these genera share common features, such as a ~10 
kb RNA genome that encodes gag, pol and env genes (see Table 1.2b and Fig. 1.14 
for details), and their overall genomic organisation whereby the integrated provirus 
has 3’- and 5’-long terminal repeat (LTR) sequences flanking these genes.
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Fig. 1.14: (a); Illustration o f  major features common to retroviral genomes, (b); genes other 
than gag, pol and env found in lentiviral genomes. These are all deleted in retro- and lenti- 
viral vectors, rendering them replication-deficient. Taken from diagrams available at 
http://www.virology.net and from ref. number [179]
Genus: Type Species:
Avian type C retroviruses avian leukosis virus (ALV)
BLV-HTLV retroviruses bovine leukaemia virus (BLV)
Lentivirus human immunodeficiency virus (HIV-1)
Mammalian type B retroviruses mouse mammary tumor virus (MMTV)
Mammalian type C retroviruses murine leukaemia virus (MLV)
Spumavirus human spumavirus (HSRV)
Type D retroviruses Mason-Pfizer monkey virus (MPMV)
Table 1.2a: Classification of retroviruses into genera according to sequence 
similarity. Type species, right column; example o f a retrovirus belonging to the genus 
shown in left column. Table available at http://www.virologv.net
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Name 
R Region
U5
Primer Binding Site 
Env
Central Polypurine Tract (cPPT) 
U3
Feature
A short (18-250nt) sequence which forms a 
direct repeat at the both ends of the genome, 
which is therefore 'terminally redundant'.
A unique, non-coding region of 75-250nt 
which is the first part of the genome to be 
reverse transcribed, forming the 3' end of the 
provirus genome.
18nt complementary to the 3' end of the 
specific tRNA primer used by the virus to 
begin reverse transcription.
Encodes a 160 kd precursor protein, which is 
cleaved posttranscriptionally into two 
envelope glycoproteins. The first env protein 
is gpl20, a highly charged glycoprotein that 
binds to cell-specific viral receptors (e.g., 
CD4+ T cell receptor in the case of HIV) and 
ancillary coreceptors (e.g., chemokine 
receptors for HIV-1). There are five highly 
variable domains of the env gene - VI 
through V5 -  which are responsible for viral 
evasion from host immune response. The 
second env protein, gp41, is a hydrophobic 
transmembrane glycoprotein that anchors 
gpl20 to the virus envelope.
~10 A/G residues responsible for initiating 
(+) strand synthesis during reverse 
transcription.
A unique non-coding region of 200-1,200nt 
which forms the 5' end of the provirus after 
reverse transcription; contains the promoter 
elements responsible for transcription of the 
provirus.
Gene encoding the MA, CA, and NC
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proteins, which are group-specific structural 
antigens
pro Gene encoding the viral protease. For most
retroviruses, the pro ORF is -1 with respect to 
the gag ORF and a Gag-Pro polyprotein is 
expressed by a -1 fiameshift during 
translation.
pol Gene encoding the viral reverse transcriptase
and integrase proteins. In  most cases (except 
spumaviruses), the gene product is 
synthesized as a 180-kD Gag-Pro-Pol 
precursor polyprotein. In  mammalian type-C, 
HTLV/BLV, lentiviruses, WDSV, and
Gypsy, the pol ORF is in-frame and
contiguous with the pro ORF producing 
equimolar amounts of Pro and Pol proteins.
Table 1.2b: Features of retroviral genomes common to all viruses in this genus.
Adapted from http:// w o t . virology.net
Vectors based on type-C retroviruses such as Moloney murine leukaemia virus 
(MoMLV) have shown considerable promise in gene therapy [180]. Vectors based on 
MoMLV, a 100 nm single-stranded RNA virus with a genome of 8.3 kb, are the most 
commonly used retroviral vectors in animal trials of gene transfer. To generate 
recombinant retroviruses the gene of interest is normally cloned into a plasmid 
containing 3’- and 5’ long terminal repeat (LTR) sequences and the 350 bp \|/
sequence required to package this recombinant genome; the gag and pol genes
required to generate virus capsid are provided in trans, in helper plasmids that are \|/- 
negative. Packaging cell lines stably transfected with plasmids harbouring mutations 
in both the vj/ sequence required for packaging and complementary mutations in the 
gag and pol genes are now used; this avoids the possible formation of replication 
competent retrovirus during virus production, by ensuring that in the rare occasions 
where the \j/-negative helper plasmid is packaged into retroviral virions, they are not 
replication competent [181]. Sustained therapeutic efficacy has been demonstrated 
using an MoMLV vector in human clinical trials of gene therapy for X-linked severe
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combined immune deficiency (X-SCID), an immune disorder caused by a mutation in 
the gene encoding the y-chain common to cytokine receptors (IL2RG) [182]. X-SCED 
patients fail to develop NK and T-cells due to a block in the differentiation of T-cells 
in early haematopoiesis. The result is a severely compromised cellular immune 
system that is lethal without allogenic bone marrow transplant [183]. The first clinical 
trial to use gene delivery using MoMLV-based vectors demonstrated effective disease 
correction in five X-SCID patients. They had received autologous bone marrow grafts 
that had been transduced ex vivo with an MoMLV vector expressing the y-chain gene, 
which conferred a selective advantage upon the transduced cells when grafted into the 
host patients. This allowed effective repopulation of T-cells, and allowed the 
restoration of a normal T- and B-cell repertoire that lead to these previously immuno­
compromised patients having a much improved quality of life [184]. Indeed, a longer- 
term follow up of these patients revealed no significant adverse events, and a second 
trial using a similar study design was undertaken using a separate patient cohort. This 
second trial also showed sustained disease correction in X-SCID patients after ex vivo 
retrovirus-mediated gene transfer, and six years after treatment no serious side effects 
have been reported. However, as with Ad-based gene transfer vectors, efficacy of 
retroviral vectors in the clinic has been accompanied by serious adverse events in the 
first trial described above. Three of the twenty patients treated to date developed 
clonal expansion of transduced T-cells, resulting in acute lymphoproliferative disease 
following treatment with a MoMLV vector [185]. The neoplastic transformation in 
these patients was ascribed to vector-mediated insertional mutagenesis, due to the 
integration of the vector provirus in the promoter region upstream of the LM 02  gene 
[185]. Although the patients concerned were treated with chemotherapeutic agents, 
two have this was viewed as a severe adverse event caused by aberrant 
overexpression of an oncogene directed by proviral integration. As such, the need to 
develop vectors that carried less risk of insertional mutagenesis was highlighted; 
despite the long-term reconstitution of a normal repertoire of T-cells, the potential for 
deleterious effects caused by gene transfer vectors is of major concern. One study in 
mice lacking the y-chain receptor (.IL2RG4 mice) seems to suggest that the 
therapeutic transgene itself is oncogenic. They claim that because IL2RG'' mice only 
develop lymphoma after ex vivo transduction of bone marrow with an MoMLV vector 
encoding the IL2RG gene, but not a vector encoding a GFP reporter gene, that the 
IL2RG gene is what causes transformation of T-cells and not insertional mutagenesis
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per se [186]. However, their data does not support this conclusion. The authors did 
not treat IL2RG’A mice with wild-type bone marrow that had been transduced with 
MoMLV expressing the IL2RG gene and check for lymphoma formation, nor did they 
treat wild-type mice with a vector encoding a reporter gene. Therefore possibility that 
insertional mutagenesis is the principle cause of lymphoma formation, but only in the 
context of cells that are able to proliferate and expand (i.e. in the presence of the y- 
chain receptor), cannot be excluded. Two further severe, early-onset immune 
disorders have been successfully treated with retroviral vector-mediated gene therapy, 
the adenosine deaminase deficient form of severe combined immunodeficiency 
(ADA-SCID) and chronic granulomatous disease (CGD). In the case of ADA-SCID, 
although patients may benefit from delivery of the adenosine deaminase enzyme itself 
[187] or from HLA-matched bone-marrow transplants [188], in many cases neither 
treatment is applicable. The first clinical trials of ADA-SCID involved a retroviral 
vector encoding the ADA gene, and showed that long-term reconstitution of immune 
repertoire in treated patients [189,190]. A more recent report of a patient previously 
refractory to enzyme replacement therapy benefiting from retrovirus-mediated gene 
replacement therapy reinforces the efficacy of this approach for ADA-SCID [191]. 
Gene delivery to bone-marrow in patients with chronic granulomatous disease has 
also been studied, with adeno-associated virus initially being used as a potential 
therapeutic agent [192,193]. Clinical trials of gene therapy for CGD, however, have 
used retroviral vectors encoding components of the NADPH-oxidase multi-enzyme 
complex (which is deficient in CGD patients), and have shown that patients’ anti­
microbial capability is significantly improved following such gene replacement 
therapy [194,195]. In the case of the latter study, retroviral insertion was shown to up- 
regulate expression of three genes that drove clonal expansion of the gene-corrected 
granulocytes. This unexpected augmentation of the treatment effect of gene 
replacement is in stark contrast to the findings in the X-SCID trial, where viral 
insertion lead to leukaemogenesis. This is likely due to the fact that retroviral 
expression of gp91phox confers no selective advantage to transduced cells, such that 
even in the event of insertional activation of growth-promoting genes (as is seen in the 
CGD trial), no abnormal tumourigenic cell division is seen. In the case of X-SCID 
gene therapy, however, cells transduced to over-express the IL2RG gene (and hence 
have a selective expansion advantage over non-transduced cells) can be seen as being 
primed, or sensitised, to the oncogenic insertional activation of LM02. Thus
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leukaemogenesis following gene therapy of haematopoietic cells can be seen as a 
multi-step process, in which insertional activation of oncogenes is only truly 
oncogenic in cells possessing a selective advantage by nature of the therapy itself. The 
continued concern over insertional mutagenesis causing inappropriate activation of 
oncogenes is being addressed by the development of vectors that do not integrate their 
proviral genomes into host DNA, as described below. Vectors based on retroviruses 
are not appropriate for diseases of the retina, as they cannot transduce non-dividing 
cell types; for efficient transduction of cells in the retina, vectors based on a sub­
category of retroviruses are used.
Lentiviral vectors
Vectors based on a sub-group of retroviruses, the lentiviruses, are currently 
being used in gene therapy and provide greater promise for ocular applications. 
Whilst lentiviruses are similar to retroviruses in that they use RNA as their genomic 
nucleic acid, there are many features that distinguish lentiviruses from retroviruses. 
Firstly, lentiviruses are diploid viruses, meaning they carry two copies of positive- 
sense RNA within each mature virion. In addition, lentiviral genomes encode 
additional genes (such as rev, tat, v if and vip, see Fig. 1.14) that code for proteins 
involved in regulation of proviral gene expression and are called ‘accessory proteins’. 
Whereas retroviruses only transduce dividing cell types, thereby preventing the use of 
vectors based on MoMLV being used to treat the terminally differentiated cell types 
in the eye, lentiviruses mediate transgene expression in quiescent or terminally 
differentiated cells as well [196]. Another advantage of lentiviral vectors is that self-
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inactivating vectors (see below) that are deleted for all viral genes can be made. This 
allows a completely replication-deficient virus to be used, providing a safe way of 
preventing lytic infections of host cells. In addition, recent developments in lentiviral 
production methods allow the prevention of previously encountered systemic immune 
responses; producing recombinant lentivirus using serum-free medium, and purifying 
the vector by sucrose gradient ultracentrifugation, abrogates the immune response 
seen following injection into mouse brain, demonstrating that the immune response 
previously seen is due to contaminating immunogenic components in the viral 
preparation rather than the lentiviral particles per se [197].
The surface glycoproteins on lentiviral envelopes determine their tropism towards 
given cell types; the natural tropism of wild-type lentiviruses such as human 
immunodeficiency virus (HIV) is restricted to CD4+ T-lymphocytes, and by altering 
the expression of the glycoproteins on the viral envelope, lentiviral vectors can be 
engineered to infect a broader range of cell types. This is known as pseudotyping, and 
results in lentiviruses expressing envelope proteins from other viruses on their 
surface; striatal and hippocampal neurons [196], muscle , liver [198] and RPE [199] 
can be transduced by altering lentiviral tropism in this way. Pseudotyping vectors 
based on equine immuno-deficiency virus (EIAV) alters the transduction profile of 
this non-primate lentivirus. EIAV vectors pseudotyped with the varicella simplex 
virus surface protein (VSV-G protein) result in efficient transduction of corneal 
endothelium and some expression in the trabecular meshwork following anterior 
chamber injection; when pseudotyped with the rabies-G protein, however, there is no 
transduction of these cell types, but neuronal cells in the cornea and iris appear 
transduced. EIAV.VSV-G vectors do give some expression in photoreceptors, 
although this occurs with greatly reduced transduction efficiency than in RPE cells, 
which show very high levels of reporter gene expression [200]. Thus far, RPE cells 
appear to be the only cell type transduced with high enough efficiency for therapeutic 
purposes in the context of retinal dystrophies; however, this does not preclude the use 
of lentiviral vectors in disease paradigms in which photoreceptors die. This can be 
achieved by direct treatment of the RPE, whereby an RPE-specific gene that is 
mutated in a model of retinal degeneration is delivered by a lentivirus, or by 
transducing the RPE with a lentivirus encoding a secreted growth factor to provide 
neuroprotection to dying photoreceptors; both possibilities will be discussed below.
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Another feature of the latest lentiviral vectors prevents them from activating 
inappropriate transcription of genes downstream of the integration site. As discussed 
above for retroviruses, lentiviruses reverse transcribe their diploid RNA genome, and 
the reverse-transcribed cDNA is integrates into the host genome essentially at random 
using the viral integrase enzyme. The genomic RNA contains promoter and enhancer 
elements in the U3 region of the 3’ Long Terminal Repeat (LTR) sequence, which are 
only transcriptionally active when transferred to the 5’ LTR during integration of the 
provirus. Thus the latent provirus has transcriptional activity in its 5’ LTR which can 
trigger transcription of genes downstream of the integration site that otherwise would 
be silent. This is undesirable in the case of most gene therapy applications, as 
demonstrated in the X-SCID trial, and so late-generation retro- and lenti- viral vectors 
that carry deletion mutations in their 3’ LTR regions circumvent this potential risk by 
preventing promoter activity from this modified LTR. Both retroviral [201] and 
lentiviral [201] vectors modified in this manner are referred to as self-inactivating, as 
deletions in the 3’ viral LTR result in the 5’ proviral LTR promoter activity being 
abolished. Another strategy for avoiding insertional mutagenesis following lentivirus- 
mediated gene transfer has been to develop vectors that do not integrate their proviral 
DNA into the host genome. Initial work using a feline immunodeficiency virus (FIV)- 
based vector showed that by incorporating a point mutation in the integrase gene that 
encodes a D66V amino acid substitution, in vivo transduction of RPE was abrogated 
[202]; in the absence of evidence showing that this vector was able to reverse 
transcribe its genome and drive any transgene expression (from non-integrated 
episomes), it is unclear whether this mutation was pleiotropic and hence ablated viral 
transgene expression altogether. However, subsequent in vitro data using integrase- 
deficient vector based on HIV-1 showed efficient transgene expression using an 
SV40-on promoter sequence in the presence of the SV40 Large T antigen [203]. 
Whereas previously it was considered that lentiviral vector-mediated expression could 
only be achieved from integrated proviral genomes, this study provided evidence for 
episomal lentiviral genomes mediating stable transgene expression in the absence of 
integration into host DNA, albeit in vitro and at short-term time points in vivo. These 
vectors were rendered integrase-deficient by the introduction of a point mutation in 
the integrase gene, giving rise to a D116N amino acid substitution; expression of 
reporter genes using the SV40 ori promoter was demonstrated in permissive cell lines. 
Following this short-term in vitro study, we have shown that integrase-deficient
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vectors are able to mediate stably maintained transgene expression in the RPE in vivo 
for up to nine months [204]. We also evaluated the ability of such non-pleiotropic 
integrase mutants to mediate therapeutic gene delivery in models of retinal 
degeneration (see Chapter 3). Thus the newest lentiviral vectors incorporate 
additional safety features that may facilitate their use in the clinic; this generation of 
self-inactivating, pseudotyped and now integrase-deficient lentiviral vectors are very 
effective in animal gene transfer trials, although their use in gene therapy for 
photoreceptor-specific disorders remains limited to gene correction in the RPE, and to 
transducing the RPE to produce neurotrophic factors that can prevent photoreceptor 
apoptosis. Tschemutter et al. demonstrated histological and electrophysiological 
disease correction in the RCS rat, a model in which defects in the phagocytosis of 
photoreceptor outer segment material leads to rod and cone cell death [205]. 
Lentivirus-mediated Mertk expression was shown to maintain outer nuclear layer 
thickness, improve rod function as assayed by ERG, and restore phagosomes to the 
RPE cells as shown by electron microscopy. This was the first example of a lentiviral 
vector mediating structural and functional improvement in a model of retinal 
degeneration. As several retinal dystrophies are caused by mutations in genes 
expressed in the RPE, there are many forms of RP that could potentially benefit from 
lentivirus-mediated gene replacement therapy. Given the role of the RPE in providing 
trophic support for the neurosensory retina, and the highly efficient transduction of 
RPE seen with lentiviral vectors, mutation-independent treatment strategies for RP 
may involve the use of vectors based on HIV-1. This type of treatment strategy 
involves administration of vectors that encode secreted growth factors and/or anti- 
apoptotic factors that prevent photoreceptor apoptosis; given the highly efficient 
transduction of RPE achieved by HIV-1-based vectors, using the RPE to produce 
ectopic factors of this nature may aid RP gene therapy. Currently, however, the 
relative difficulty of producing clinical grade lentiviral vectors, which can be 
produced on a large scale and to standards approved by regulatory bodies such as the 
Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, means 
that alternative vector systems are being developed for use in the clinic.
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Adeno-associated vims (AAV)-based vectors
Possibly the most promising viral vector for gene therapy directed towards 
photoreceptors is based on the Adeno-Associated Virus (AAV). A dependovirus that 
is naturally replication-deficient and non-pathogenic, AAV has a 4.8 kb single­
stranded DNA genome that consists of two multi-cistronic genes, rep and cap, flanked 
by two inverted terminal repeat sequences (Fig. 1.15). The genome of naturally 
occurring, wild-type AAV is known to integrate into host chromosomal DNA in a 
site-specific manner; the AAV gene rep mediates this integration, at a locus on human 
chromosome 19 [206]. The integration or otherwise of recombinant AAV (rAAV)- 
based vectors remains to be established, although it is believed that low-efficiency 
integration does occur at multiple, non-specific sites [207]. Within the virion the 
AAV genome is encapsidated by a 20 nm icosahedral capsid, which is made of three 
viral proteins (VP1, 2 and 3) encoded by the cap gene. AAV has a wide tropism, 
infecting many cell types depending on the particular serotype concerned; the 
serotypes differ from each other in the sequence of their capsid proteins. It is the exact 
configuration of these surface proteins that determines the specificity with which 
AAV serotypes infect cells; each of the eight serotypes used to generate recombinant 
gene delivery vectors to date show different cell-type specific transduction profiles 
[208].
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Fig. 1.15: Diagtam representing adeno-associated virus genome; (a) Wild-type AAV  
has inverted terminal repeat (ITR) sequences at both the 5’- and 3’ ends, which flank the rep 
and cap genes. p5 and p i9 indicate the promoters that initiate the transcription o f  rep that 
result in the production o f  Rep78, Rep68, Rep52 and Rep40; p40 is the promoter that drives 
expression o f  the three cap proteins VP1, VP2 and VP3. (b) shows the hairpin-stem 
secondary structure o f  both ITRs, generated by Watson-Crick base-pairing within the single­
stranded genome, (c) As the ITRs are the only viral sequences required for packaging into 
mature virions, the entire 4.8 kb genome can be replaced by expression cassettes (in this case 
a multi-cistronic construct) driven by ectopic promoters (black arrows).
The most widely used serotype in gene therapy applications is AAV2, as this was the 
first human serotype described and due to the relative ease of production of high-titre, 
pure virus; AAV2 binds with high affinity to heparin, making purification of virus 
from packaging cells relatively simple by use of heparin/agarose columns [209]. 
Recombinant AAV (rAAV) has been used as a gene transfer vector in various tissue 
types [210], and indeed has been used in clinical trials for alpha-1 antitrypsin 
deficiency [211] and for cystic fibrosis [212].
When delivered into the sub-retinal space, recombinant AAV2 efficiently transduces 
photoreceptors and RPE cells [213,214], but this tropism can be altered by using a cap 
plasmid that encodes the capsid of another serotype in trans during virus production. 
This method of pseudotyping virus produces hybrid virions, containing genomes 
based on AAV2, and the capsid of, for instance, AAV4. So, while AAV2 vectors 
transduce ganglion cells following intravitreal injection and both photoreceptors and 
RPE following sub-retinal injection, AAV2/4 transduces only RPE after sub-retinal 
delivery. As well as tropism towards given cell types, the kinetics of transgene 
expression are also determined to some extent by the serotype; AAV2/5 gives faster 
onset of gene expression - around one week after sub-retinal injection [215] - 
compared with the slower and ultimately weaker expression from AAV2 that is not 
maximal until six weeks post injection [214]. These tissue-specific expression 
patterns, together with the replication-deficient nature of AAV, make this vector a 
safer alternative to other vectors available; in addition, no significant immune
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response is noted following gene delivery to the retina with recombinant AAV 
vectors. Hence transgene expression lasts longer after delivery with rAAV than with 
other vectors [214], and the safe nature of AAV allows it to mediate structural and 
functional improvements in several models of retinitis pigmentosa, and to be the 
vector of choice in clinical trials for retinal degeneration. Considering the advantages 
of pseudotyped AAV vectors, we decided to evaluate AAV2/5 as a gene replacement 
vector in three models of retinal degeneration as part of the studies presented here 
(Chapter 4).
One drawback of the rAAV system is that relatively small expression cassettes need 
to be used; the virions only package genome-sized lengths of DNA, meaning no more 
than 4.8Kbp can be cloned between the Inverted Terminal Repeat (ITR) sequences. 
The latest AAV vectors have an even smaller coding capacity, but have many 
advantages that may be of use for gene therapy applications. Self-complementary 
AAV (scAAV) vectors have been used in vivo to mediate strong transgene expression 
[216], and have recently been shown to be effective in gene therapy for a murine 
model of haemophilia B and in macaques [217]. Although an expression cassette of 
only 2.4 kb can be used, for many applications in the eye this may be sufficient. Initial 
data from our group shows faster initiation of gene expression in eyes that received 
sub-retinal injection of scAAV than titre- and serotype- matched single-stranded AAV 
(Dr. M. Rajah, personal communication). This approach may increase further the 
efficiency of AAV-mediated gene delivery to the retina, which using single-stranded 
AAV has been shown to be highly efficient and safe.
1.12 Gene therapy approaches animal models of inherited 
retinal degeneration
Two broad strategies have been used to ‘rescue’ retinal cells from 
degeneration -  one is gene correction, which may be achieved by gene replacement or 
ablation of a ‘poisonous’ message, and the other is known as neuroprotection. In gene 
replacement strategies, a functional copy of the gene known to be mutated in a given
75
form of RP is introduced to ameliorate the pathology caused by the mutation; in order 
to reduce the expression of mutant genes that cause toxicity, several techniques can be 
used to ablate mRNA, as discussed below. Neuroprotection involves delivery of genes 
that do not necessarily relate to the underlying causative mutation, but that prolong 
photoreceptor survival. Gene therapy approaches using viral vectors have been shown 
to ameliorate disease in various models using both strategies, including the 
Prph2M2ml mouse and RCS rat.
1.12.1 Gene correction -  ablation of toxic message
Gene replacement is essentially only useful in the case of truly recessive 
disorders or those involving haploinsufficiency; cases where expressing a functional 
allele would provide sufficient protein levels to restore function. Disorders that 
incorporate any element of dominance, or in which mutant (dominant negative) alleles 
interfere with native wild-type alleles, would benefit less from gene replacement. 
Such disorders would require ablation of the mutant allele either by a mutation- 
independent approach (whereby all transcripts of the gene of interest are ablated, then 
replaced by a non-silenced version), or an approach where only mutant transcripts are 
ablated, leaving wild-type message uncleaved. Both mutation-independent and 
mutation-specific approaches can be mediated by the use of ribozymes or RNA 
interference. Ribozymes are catalytic RNA molecules that bind to specific mRNA 
sequences and catalyse the cleavage of the target message; naturally-occurring 
ribozymes are found in plant viroids, and ‘hammerhead’ ribozymes can be engineered 
to ablate specific messenger RNA sequences that are associated with disease [218]. 
No in vivo data is available at the time of writing that validates the use of ribozymes 
to silencing mutant transcripts in models of inherited retinal degeneration, although in 
vitro data has demonstrated that ribozymes directed against the 5’ untranslated region 
of rhodopsin mRNA could cleave all rhodopsin transcripts, mutant or wild-type, and 
that a rhodopsin gene designed not to be cleaved by these ribozymes could replace the 
ablated gene product [219]. In a mutation-specific approach, a hammerhead ribozyme 
directed specifically against the P23H rhodopsin allele, known to cause retinal 
degeneration in mice and humans, was shown to reduce levels of P23H mutant
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transcript by 40% in vitro [220]. In vivo delivery of an AAV vector encoding this 
ribozyme was shown to reduce mutant transcript by around 15%, reduce loss of 
photoreceptors by up to 45% (compared to uninjected eyes, 20% compared with non- 
catalytic ribozyme) and enhance average ERG b-wave by up to 100% (although the 
non-catalytic ribozyme does improve b-wave by around 60%, probably by binding to 
the mRNA as an anti-sense oligonucleotide) [221]. Indeed, ribozyme therapy against 
the P23H mutant rhodopsin transcript results in protection from apoptotic loss of 
photoreceptors up to eight months-post-injection, although improvements in retinal 
function are difficult to interpret due to small numbers of rats being treated [222]. 
Another way of ablating a dominant negative mutant transcript is to use RNA 
interference (RNAi); this approach exploits the site-specific cleavage of a target 
mRNA molecule catalysed by a double-stranded RNA, with homology to the target, 
that recruits proteins such as Dicer to a multi-protein complex termed RNA-induced 
silencing complex (RISC) (for extensive review of RNAi and the mechanisms 
involved, see [223]. siRNA molecules, 21-23 nucleotide molecules that initiate RISC 
formation and cleavage of a target message, can be delivered directly as 
oligonucleotide ‘drugs’ to mediate therapeutic benefit; this approach is being pursued 
to reduce levels of vascular endothelial growth factor receptor 1 (vegfrl) mRNA to 
treat the choroidal neovascularisation (CNV) seen in age-related macular 
degeneration (AMD) -  following demonstration of efficacy in mice [224], a Phase I 
clinical trial in AMD patients has been initiated. A more common way of using RNAi, 
however, is to generate short-hairpin RNA (shRNA) molecules from DNA templates; 
this allows the delivery of a DNA template using a viral vector, and the shRNA that is 
transcribed from an RNA polymerase III promoter forms a catalytically active hairpin 
that cleaves a target message. shRNA molecules have been shown to silence more 
than 90% of mutant (P23H) rhodopsin transcript in vitro and in cultured retinal 
explants, which can then be replaced by a rhodopsin gene that isn’t silenced by the 
shRNA [225,226]. Thus it is possible to ablate mutant transcripts that cause retinal 
degeneration, although introducing functional copies of a mutated gene, referred to 
here as gene replacement, has shown more promise as a strategy to treat inherited 
retinal disorders.
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1.12.2 Gene correction -  gene replacement therapy
Early attempts to rescue the rdl mouse using adenoviral [227] and lentiviral 
[228] vectors encoding p-PDE were largely unsuccessful due to the failure of both of 
these vectors to efficiently transduce photoreceptors; vectors based on Ad [229] and 
HIV-1 [199] are known to mediate efficient transgene expression in RPE, but not in 
photoreceptors, hence the paucity of rescue using these vectors for a photoreceptor- 
specific disorder. As AAV2 is known to transduce photoreceptors efficiently [213], it 
is interesting to note that only faint P-PDE immunostaining and a slight shift in in 
vitro electrophysiological response is seen in the rdl mouse following AAV-mediated 
gene replacement therapy [230]. This paucity of rescue is discussed below in the 
context of more successful gene therapy approaches for inherited retinal degeneration.
Several inherited retinal dystrophies are caused by mutations in genes expressed in the 
RPE; specifically, extensive work has been carried out on models for LCA, a severe, 
earl-onset form of retinitis pigmentosa (see Chapter 1.6). One such animal model of 
LCA, the RPE65’/ mouse, loses photoreceptors slowly (>50% photoreceptors survive 
at 4 months of age), has an undetectable scotopic ERG from birth, and a reduction in 
the amount of opsin present in photoreceptors [231]. RPE65"A mice treated in utero 
with AAV2/1.CMV.RPE65 show expression of RPE65 at least 3 months post­
injection, significant improvement in retinal function as assayed by ERG, and 
correction of the biochemical defect caused by the absence of RPE65, as assessed by 
regeneration of rhodopsin following light excitation [232]. The rd l2 mouse is a 
naturally occurring model of LCA which is homozygous null for a C to T mutation 
resulting in a premature stop codon at position 44 of the murine RPE65 gene [74]. 
Gene replacement therapy in rdl2  mice using AAV2/5.RPE65 reduces accumulation 
of lipid droplets in RPE cells, and significantly slows the loss of photoreceptors; rd l2 
mice lose one-third of their outer nuclear layer by 7 months of age, AAV2/5.RPE65- 
treated mice retain near-normal retinal morphology with up to ten layers of 
photoreceptor nuclei [233]. This improved morphology correlates with dark- and 
light- adapted ERG responses being restored to wild-type levels, and the treatment 
with AAV2/5.RPE65 also restores vision-dependent behaviour to wild-type levels 
[233]. Lentivirus-mediated gene replacement therapy in the rd l2 mouse has been
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evaluated as part of the studies presented here (see Chapter 3). Furthermore, several 
groups have demonstrated efficacy of AAV-mediated gene replacement therapy in 
Briard dogs with inherited retinal dystrophy, a large animal model of LCA caused by 
a four base-pair deletion mutation in RPE65 [234]. AAV2.RPE65-mediated gene 
replacement restores RPE65 protein production, and results in an improvement in 
retinal function as assayed by ERG; affected Briard dogs that had virtually 
undetectable b-waves pre-treatment had b-wave amplitudes 3 months post-injection of 
around 120 pV, which is close to one-third of wild-type levels [235]. Importantly, it 
has been demonstrated that AAV-mediated gene replacement therapy in this large 
animal model of LCA results in long-term improvements in retinal morphology and 
function [236,237], indicating that patients with mutations in RPE65 may also benefit 
from AAV-mediated gene replacement; ethical approval for a clinical trial in LCA 
patients with RPE65 mutations has been granted by the appropriate regulatory bodies 
both in the UK and in the USA. Another form of severe, early-onset retinitis 
pigmentosa is caused by mutations in Mertk, as discussed above (Chapter 1.6). The 
RCS rat is a well-characterised rodent model for RP caused by mutations in Mertk, 
and following both AAV-mediated [238] and lentivirus-mediated [205] Mertk gene 
delivery, treated eyes show significantly higher numbers of photoreceptors (2.5-fold 
more) and increased ERG b-wave amplitude (up to four-fold higher) when compared 
to contralateral uninjected eyes, with this treatment effect being enhanced using the 
lentiviral vector. The amelioration in pan-retinal function as assayed by ERG is 
transient, however, with AAV.Mertk-mediated gene replacement resulting in a 
significant improvement in b-wave for 9 weeks post-injection [238], and lentiviral 
gene therapy improving function for up to four months [205]. Despite this, there is 
strong evidence to suggest that gene replacement therapy directed to the RPE 
represents a promising therapeutic strategy for treating RP; as demonstrated by 
studies involving gene replacement of both RPE65 and Mertk, correcting an RPE- 
specific defect can result in excellent functional recovery. This may be because the 
photoreceptors in retinae affected by mutations in RPE-specific genes are healthy, and 
so restoring function to the underlying RPE allows these inherently healthy 
photoreceptors to function normally. Although some forms of RP may benefit from 
gene replacement therapy to the RPE, however, many forms are caused by mutations 
in gene expressed in photoreceptors; gene replacement has proven more challenging
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when this is the case, despite some success in delivering therapeutic nucleic acid to 
photoreceptors.
Recently gene replacement studies carried out in a model of RP have shown that 
AAV-mediated delivery of RPGRIP, whose expression is driven by a novel fragment 
of the murine rhodopsin promoter (mOPS) results in a restoration of RPGR and opsin 
protein localisation to the outer segments of photoreceptors, and a significant slowing 
of photoreceptor loss; the ONL in AAV.mOPS.RPGRIP-treated eyes consisted of up 
to 3 more rows of photoreceptor nuclei when compared to untreated contralateral 
controls [239]. These morphological improvements were accompanied by marked 
electrophysiological improvements; b-waves recorded from AAV.mOPS.RPGRIP- 
treated mice were on average two-fold higher in treated eyes (118 pV) than in 
untreated eyes (66 pV) 5 months post-injection [239]. This study shows that, although 
it is difficult to precisely correlate the number of surviving photoreceptors to ERG 
amplitude, in general if surviving photoreceptors have intact components of 
phototransduction an increase in photoreceptor survival does translate into an 
improvement of function, whilst the reverse is not always the case. A model of an X- 
linked retinal degeneration caused by a mutation in a gene expressed in 
photoreceptors has also been shown to benefit from AAV-mediated gene replacement 
therapy. X-linked retinoschisis causes macular cyst formation and a deficiency in 
inner retinal response to light excitation resulting in an electronegative ERG b-wave 
[240]; this disease was shown to segregate with mutations in RSI, a gene encoding 
retinoschisin [241], a protein thought to be involved in cell-cell interactions between 
various cell types in the inner retina during development and that is expressed in 
photoreceptor inner segments in the adult murine retina [242]. Mice lacking Rslh, the 
murine orthologue of Rsl, have disrupted photoreceptor outer and inner segments, 
disorganised inner nuclear layer and mislocalisation of some retinal ganglion cells to 
the innefr plexiform layer, as well as severely reduced ERG b-wave amplitudes when 
compared to wild-type levels. Intravitreal delivery of an AAV vector encoding the 
Rslh  cDNA restores R slh protein production in all layers of the retina [242], restores 
ERG b-wave with a normal electropositive waveform to near-normal levels up to five 
months post-injection [243]. Thus gene replacement therapy directed towards 
photoreceptors and inner retinal cells can mediate long-term therapeutic benefit, as 
demonstrated by AAV-mediated gene delivery in the RPGRIP'/_ mouse and the Rslh-
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deficient mouse. However, studies using other models of RP caused by mutations in 
photoreceptor-specific genes have shown that gene replacement alone is not always 
sufficient to mediate long-term functional rescue.
Gene replacement has been shown to ameliorate the structure and function of rod 
photoreceptors in the Prph2Rd2/Rdl mouse. The lack of rod outer segments can be 
restored effectively; long-term persistence of newly-formed outer segments has been 
shown [244], with some structural rescue detectable 42 weeks post-treatment. This is 
achieved by rAAV2-mediated delivery of the Prph2 gene driven by a bovine 
rhodopsin promoter (AAV.Rho.Prph2), and the functional benefit following treatment 
with this construct has been demonstrated [245]; b-wave amplitudes from treated eyes 
reach a maximum of 140mV, and resemble the pattern (but not absolute amplitude 
values, which range from 350- to 450 pV) of traces from a wild-type eye in terms of a 
reduction in b-wave latency on increased stimulus intensity. However, this 
restoration of function is seen to be transient when electrophysiological function is 
assessed at longer-term time points [246]; improvement in function peaks six weeks 
after treatment, and b-wave amplitudes decrease from this time point onwards, 
although treated eyes retain statistically significantly improved function in 
comparison to untreated contralateral control eyes until 14 weeks post-injection. 
Following this time-point, AAV-Prph2 treated eyes show no significant improvement 
in their b-wave amplitude over uninjected internal controls [246]. These results show 
that although retinal function can be improved using AAV.Prph2 therapy, this 
improvement is transient. This could be attributable to several factors.
A possible cause of the transient nature of functional improvement, despite newly 
formed outer segments persisting over time, is that the viral titres used to treat the 
Prph2Rd2/Rd2 mouse in previous studies were insufficient to transduce a large enough 
proportibn of the retina, or that the induction of outer segment formation following 
Prph2 gene replacement was not early enough. Whilst previous studies examined 
retinal structure and function following the injection of lxlO10 genome copies of 
AAV per ml, titres two log-fold higher (lxlO 12) are now achieved routinely. It has 
also previously been demonstrated that the quality and quantity of outer segments 
formed following AAV.Rho.Prph2-mediated gene therapy are significantly better 
when treatment is administered at early time points; although treatment of
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Prph2Rd2/Rdl mice up to 40 days old does result in formation of outer segments, sub- 
retinal injection at post-natal day 10 results in more and better organised OS [244]. It 
may be, therefore, that using higher titre virus, and by intervening earlier using sub- 
retinal injection of AAV.Rho.Prph2 at post-natal day seven, better rescue can be 
achieved (see Chapter 4). Another reason for the transient nature of functional 
recovery in the Prph2Rd2/RdI mouse may be that the onset of transgene expression may 
not be early enough to rescue large numbers of cells from apoptosis; the AAV 
serotype used in previous studies, AAV2, is known to take 6 weeks before mediating 
high levels of transgene expression [214], and apoptosis in the Prph2Rd2IRd2 mouse is 
known to peak at post-natal day 18 [102]. Hence as part of these studies we have 
evaluated gene replacement using the same expression cassette used in previous 
studies in the Prph2Rd2/Rd2 mouse, pseudotyped with an AAV5 capsid 
(AAV2/5.Rho.Prph2, see Chapter 4). It remains likely, however, that correction of 
the molecular defect in Prph2Rd2/Rd2 mice does not interfere with the apoptotic cell 
death mechanism. Thus, delivering functional copies of genes mutated in disease can 
be of benefit in certain cases. However, gene correction is not always sufficient to 
mediate long-term therapeutic benefit, particularly in cases where photoreceptor- 
specific genes are mutated. For this, a strategy that promotes cell survival, 
independent of the underlying molecular cause of cell death, needs to be employed.
1.12.3 Neuroprotection
As described in Chapter 1.10, pharmacological interventions designed to 
slow and/or prevent photoreceptor loss are inefficient and require multiple 
administrations of growth factors. Therefore, in order to achieve long-term 
neuroprotection, sustained neurotrophic factor delivery to the eye has been 
investigated. PEDF is one growth factor that has been shown to exert a 
neuroprotective effect in models of retinal degeneration, as evidenced by work using 
recombinant protein [126]. The transient nature of the rescue in this study was due to 
the short ocular half-life of the PEDF protein, and viral delivery of the PEDF gene 
could well circumvent this short-lived aspect of the rescue; this will be investigated as
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part of the studies presented here. More recent work has shown a neuroprotective 
effect of PEDF in the RCS rat, with histological analysis showing significant 
preservation of photoreceptors at four weeks post-injection; in SIV.PEDF-treated eyes 
a local treatment effect is seen, with twice as many photoreceptors present in 
protected regions of the retina compared with untreated areas of the same retina [247]. 
This study also demonstrated a small improvement in electrophysiological function in 
PEDF-treated eyes, but only at four weeks after injection; average b-wave amplitudes 
in SIV.PEDF-treated eyes were 47 pV  ± 15.3 pV, compared with 5.5 pV  ± 3.9 pV  in 
SIV.lacZ-treated control eyes. Thus some neuroprotective nature of PEDF has been 
demonstrated, but this is yet to be validated in other RP models.
The most extensively studied neurotrophic factor in the context of viral vector- 
mediated neuroprotection is ciliary neurotrophic factor (CNTF). CNTF is known to 
play a role in retinal development, where CNTF expression causes a repression of rod 
development from photoreceptor precursor cells [248]. However, the expression of 
CNTF receptor on photoreceptor precursors is lost as the rod cells mature, such that in 
the adult retina photoreceptors do not express CNTFRa. Nonetheless, as CNTF has 
been shown to protect both retinal neurones [124,249,250] and glial cells elsewhere in 
the CNS [251] from cell death, CNTF has been used in attempts to protect 
photoreceptors from apoptosis. As an example of this approach, the rd mouse has 
been shown to benefit from adenovirus-mediated expression of the gene encoding 
CNTF [252]. This study, however, only looked at outer nuclear layer thickness up to 
18 days following treatment; at this very short-term time point, prolonged survival of 
photoreceptors was demonstrated, but neither the long-term morphological effects of 
this treatment, nor the functional consequences, were studied. Liang et al. 
subsequently used two transgenic rat models that carry mutant versions of the 
Rhodopsin gene (P23H and S334-Ter), as well as the Prph2Rd2/Rd2 mouse, to test 
rAAV-niediated CNTF delivery [253]. They showed that intravitreal virus 
administration does allow preservation of photoreceptor cells (treated eyes retain up 
to four layers of photoreceptor nuclei in the ONL 6 to 8 months post-treatment, 
compared with 1-2 layers in untreated eyes), but that it also leads to a deleterious 
effect on retinal function in both rats and mice; CNTF-treated animals showed 
reductions in ERG b-wave, although the b-waves that were recorded appear too small 
to be reliable (average amplitudes of below 10 pV are reported, which in our
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experience is too low to assess the difference between treated and untreated eyes). 
Other rodent models of RP have been used to study the efficacy of CNTF-mediated 
neuroprotection. A study in mice expressing a Prph2 transgene with a P216L 
mutation also showed a reduction in retinal function following CNTF gene delivery 
[254]. A dose-dependent component to the retinal toxicity was proposed by the 
authors; they found that expression of CNTF using the stronger chicken P-actin 
promoter (CA)caused a greater reduction in ERG b-wave than when the weaker CMV 
promoter was used. The CA-driven CNTF expression caused a 74% reduction in b- 
wave amplitude, whereas the CMV-driven gene caused a 54% drop in b-wave. This 
was despite a greater number of cells being preserved in the outer nuclear layer, as 
seen on histology, following CA-driven expression. The authors also reported a re­
modelling of the outer retina, whereby cells in the outer nuclear layer had more 
uncondensed euchromatin and other alterations to nuclear morphology in cells of the 
inner nuclear layer that are indicative of a change in gene expression patterns in these 
cells [254]. These data suggested that expressing CNTF at inappropriately high levels 
may be causing the associated functional detriment. A subsequent study investigating 
the deleterious effects of AAV-mediated CNTF delivery showed that normal retinal 
function is compromised, as well as demonstrating the deleterious effects of CNTF in 
Prph2Kd2IR<i2 eyes treated with AAV-mediated Prph2 gene delivery [255]. Following 
sub-retinal injection of AAV.CMV.CNTF in Prph2Rd2IRdl mice, the small residual b- 
wave recorded (normally around 60 pV at six weeks post-injection) is reduced by 
50%. Indeed, when AAV.CMV.CNTF was used in combination with delivery of 
AAV.Rho.Prph2, previously shown to improve b-wave amplitude, no improvement in 
ERG was seen over internal controls; eyes treated with the combination of viruses and 
those left untreated both had average b-wave amplitudes of around 60 pV. This 
suggested that damage induced by CNTF expression negates any therapeutic effect of 
Prph2 gene delivery. Furthermore, AAV-mediated CNTF delivery to wild-type eyes 
leads to loss of function, indicating an impairment of retinal function induced by 
overexpression of CNTF [255]; wild-type CBA mice showed up to 70% loss of ERG 
b-wave in eyes treated with AAV.CMV.CNTF when compared with untreated 
contralateral control eyes. This loss of function was concurrent with a re-modelling of 
the inner and outer retina that was similar to that seen previously by Bok et al [254], 
and the damage seen after CNTF treatment may originate in the INL. With the 
neuroprotective effect of CNTF on photoreceptors known to be exerted via the Muller
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ganglion cells and the amacrine cells in the inner nuclear layer [92], and with these 
cells known to be responsible for the generation of the ERG b-wave [256], the 
remodelling of the inner retina may be involved in the functional damage reported. It 
is worth noting that studies using encapsulated cell technology (ECT) devices 
engineered to secrete CNTF have been shown to cause similar dose-dependent 
deleterious effects, although as they have been studied in non-degenerating, wild-type 
retinae it is difficult to predict what effect this approach would have on retinae 
undergoing active degeneration. The data discussed above concerning virus-mediated 
CNTF delivery, however, suggests that although CNTF exerts a potent effect on the 
survival of photoreceptors in retinal degeneration , even eight months after treatment 
according to some histological data [253], there is a harmful effect exerted by this 
neurotrophic molecule that reduces overall retinal function. Further work 
investigating these deleterious effects is presented in Chapter 5.
Glial cell-derived neurotrophic factor (GDNF) has also been used as a neuroprotective 
agent, with AAV-mediated gene delivery used in rats transgenic for the S334 ter-4 
mutant version of Rhodopsin [257]. The authors showed both histological 
preservation of the outer nuclear layer and functional improvements in this model; six 
weeks post-injection, eyes treated with AAV.GDNF had an ONL that was 
significantly thicker (up to 28.8 pm) when compared with AAV.GFP-treated controls 
(21.9 pm) and untreated controls (21.4 pm), and significantly increased b-wave 
amplitudes (up to 360 pV) in comparison to both uninjected (298 pV) and GFP- 
treated (315 pV) controls. This work demonstrates the potential of GDNF as a 
neuroprotective agent for retinal gene therapy; to ameliorate or augment function in 
cells harbouring mutations may allow a transient reversal of phenotype, but to prolong 
any improvement it is vital to prevent the death of the cells concerned. Using 
neuroprotection in combination with gene replacement therapy could have a 
synergistic effect, resulting in more potent treatment strategies for RP in which gene 
replacement corrects the underlying pathological defect and neuroprotective agents 
slow or even prevent cell death. Currently, however, further studies using CNTF, 
GDNF, PEDF and others are needed before neurotrophic factors can be considered for 
clinical use alongside gene replacement.
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1.13 Summary
Thus far, gene replacement therapy in models of retinal degeneration has been 
shown to mediate effective long-term disease correction in some cases, whilst other 
models have shown transient structural and functional improvement that needs to be 
improved upon, and other models still have proven difficult to demonstrate any 
efficacy of gene therapy at all. Broadly speaking, the more successful gene therapy 
approaches for retinal degeneration involve correction of molecular defects in the 
RPE, which allows inherently healthy photoreceptors to function as normal; models of 
LCA and other forms of retinal dystrophy caused by RPE-specific defects seem to be 
more amenable to gene replacement therapy, and because lentiviral vectors mediate 
fast onset of transgene expression in the RPE, there may be greater success in 
pursuing gene delivery to the RPE to prevent photoreceptor degeneration. There are 
models of retinal dystrophy caused by mutations in photoreceptor-specific genes that 
do show effective disease correction following gene replacement therapy (e.g. 
RPGRIP'A and Rslh'f' mice), and in these models photoreceptors appear to have more 
subtle defects that are amenable to viral gene therapy. The models that have more 
severe structural and/or biochemical defects in photoreceptors, such as the 
Prph2Rd2rRdl mouse, RhodopsinA mouse and the rdl mouse, seem to be increasingly 
difficult to treat using gene replacement alone; this may be due to the fast kinetics of 
photoreceptor loss that only allows for a narrow treatment window using a very 
efficient viral vector, or it may be that the underlying molecular defects concerned 
commit cells to apoptotic death involving a mechanism which cannot be interfered 
with by simply replacing the missing/mutated gene. In such cases, improved viral 
vectors, along with safer and more potent neurotrophic agents, need to be developed 
in order to successfully treat photoreceptor-specific disorders resulting in retinal 
degeneration.
1.14 Aims and Objectives
As discussed above, viral vector-mediated gene replacement therapy has been 
shown to be partially effective in the Prph2Rd2fRd2 mouse, the RCS rat and other
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rodent models of retinal degeneration. However, the functional improvements seen 
tend to be transient. Neuroprotective gene delivery as been shown to prolong 
photoreceptor survival in certain models of retinal degeneration, but such a factor that 
is neuroprotective without the serious detrimental effects seen with CNTF remains to 
be identified. The aims of these studies are to ameliorate the structural and functional 
outcomes of gene replacement therapy, by developing strategies based on the previous 
work in animal models of retinal degeneration. Specifically, the following areas have 
been addressed:
• How can gene transfer to the retina be improved?
o We have used novel purification methods to produce pseudotyped 
AAV, which has been evaluated in three different models of retinal 
degeneration that require fast onset of transgene expression to achieve 
a therapeutic effect.
o We have evaluated integrase-deficient lentiviral vectors for their ability 
to mediate efficient gene transfer to the retina, and investigated 
whether they can mediate effective gene replacement therapy in 
comparison to integrase-proficient vectors in two different models of 
RP.
• Investigating gene replacement in models of RP caused by mutations in 
photoreceptor-specific genes.
o Outer segments formed following AAV.Rho.Prph2 delivery do persist 
over time, but some are malformed and appear dystrophic [244]. It is 
possible that overexpression of Prph2 is causing this, and so the effects 
of inappropriate levels of PER1PHERIN need to be investigated. For 
this wild-type mice have been treated with an AAV vector encoding 
the Prph2 cDNA, and the long-term impact on retinal function has 
been assessed.
o In previous studies, the most reliable improvement in retinal function 
in the Prph2Rd2IRd2 mouse was achieved following double injections 
(inferior and superior hemispheres) at a single timepoint (post-natal 
day 10). As improvements in surgical techniques now allow subretinal
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injections in younger pups (as early as post-natal day one), the effect of 
earlier and repeated injection has been investigated; this will allow us 
to determine whether transducing a greater proportion of cells in the 
retina leads to a more substantial functional improvement, 
o It is not clear whether individual transduced cells expressing AAV- 
mediated Prph2 survive longer than neighbouring cells that do not 
express viral transgene. We have therefore assessed transduced cells in 
the outer nuclear layer to determine whether or not they carry a 
selective advantage over their non-transduced neighbours. This has 
been achieved by using a bi-cistronic virus that labels Prph2- 
expressing photoreceptors with GFP, allowing us to use this 
fluorescent marker to ascertain whether transduced cells survive 
preferentially.
o Thus far we and others have used the AAV2 serotype to deliver 
therapeutic genes to the eye. With apoptosis peaking in the 
Prph2Rd2/Rd2 mouse retina before AAV2-mediated transgene 
expression reaches its peak, serotypes with different expression 
profiles may be more suitable for such applications. For this purpose 
an AAV2/5 pseudotyped viral vector encoding the Rho.Prph2 
construct has been produced and tested in the Prph2Rd2/Rd2 mouse, to 
assess whether faster onset of gene expression allows an improved 
level of efficacy of gene replacement, 
o AAV2/5-mediated gene replacement therapy in two further models of 
retinal degeneration has been evaluated, to validate the delivery of 
therapeutic genes to the retina using pseudotyped AAV.
• Delivery of genes encoding neurotrophic factors to prevent photoreceptor loss 
has shown that in the case of CNTF, although some protection from cell death 
is achieved, there are detrimental effects on retinal function. It may be possible 
to avoid this reduction in function, whilst retaining the neuroprotective effect 
of CNTF. There may also be alternative neurotrophins that delay 
photoreceptor apoptosis without detrimental side effects. Specifically, the 
following areas have been addressed:
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o We have investigated whether reducing the dose of CNTF 
administered reduces the deleterious effects on normal retinal function 
seen previously, and if so, whether such a dose possesses any 
neuroprotective properties, 
o Other models of RP could be used to thoroughly test the 
neuroprotective capabilities of CNTF. We have used the Prph2Rdll+ 
heterozygote mouse, which has larger residual electrophysiological 
function for longer periods compared to the Prph2Rd2IRd2 homozygote 
mouse, and hence is easier to follow up after treatment with 
neurotrophins. The long-term effects of CNTF expression in this model 
has been evaluated in terms of structure and function, which will aid 
the understanding of the detrimental side effects seen in both wild-type 
and Prph2Rd2/Rd2 mouse, 
o GDNF has been shown to protect the degenerating rat retina in a 
transgenic model of RP (see chapter 1.12). We have evaluated this 
candidate neuroprotective agent by assessing whether it is better 
tolerated than CNTF in murine retina, and whether GDNF gene 
delivery can prolong and enhance rescue mediated by gene 
replacement in the Prph2Rd2/Rd2 mouse and the RCS rat.
2 Materials and Methods
2.1 rAAV plasmid constructs and virus production
2.1.1 Generation of MOPS promoter DNA
Murine genomic DNA isolated from the tail of a wild-type CBA mouse was used to 
amplify Mouse Opsin (MOPS) promoter DNA, using the polymerase chain reaction 
(PCR). A fragment of tail tissue was place in Proteinase K Lysis buffer (100 mM Tris 
@ pH 8.5, 5 mM EDTA, 0.2 % SDS, 200 mM NaCl) with 1 pi Proteinase K enzyme 
(20 pg/ml, Sigma, Dorset, UK) and incubated at 56 °C for two hours. The lysate was 
then spun in a 1.5 ml microfuge tube to remove cell debris, and the supernatant was
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diluted 1/5 and denatured at 95°C for two minutes before use in the following PCR 
protocol.
Using nested primers (see Appendix) a 253 bp fragment of genomic DNA from
murine chromosome 6  was amplified. 2 pi of the denatured genomic DNA was added
to a PCR tube, and the following reagents added: 2pl each forward and reverse primer 
(lOmM, custom-ordered from Sigma-Aldrich, Dorset, UK), 5 pi lOx NH4 Reaction 
Buffer (160 mM (NH4)2S04, 670 mM Tris-HCI (pH 8 . 8  at 25°C), 0.1 % Tween-20), 
2 pi 50 mM MgCb,, 1 pi BioTaq polymerase (all Bioline, London, UK) and 1 pi Vent 
Polymerase (New England Biolabs, Herts, UK) -  the final reaction volume was made 
up to 50 pi using dH2 0 . Following an initial denaturation step (5 minutes at 95 °C), 
30 cycles of PCR were carried using the following conditions:
• Denaturation -  30 seconds at 95 °C
• Annealing -  10 seconds at 51.5 °C
• Extension -  30 seconds at 72 °C
• Final extension -  10 minutes at 72 °C
The PCR product was then electrophoresed and isolated as described below.
2.1.2 Electrophoresis, gel extraction and ligation of DNA
DNA products were separated on agarose gels with 1 % (w/v) ethidium 
bromide using a 1 x TBE buffer (diluted 1/10 from 10 X stock solution, 108 g Tris 
base, 55 g Boric acid, 9.3 g Na^DTA). For resolution of fragments lower than 500 
bp in size, 2 % (w/v) agarose (VWR International, Leicestershire, UK) was added to 
the 1 x TBE, for resolution of larger fragments 1 % was added. The agarose was then 
heated in a microwave oven until the agarose was completely dissolved, and the gel 
was allowed to set in a plastic mould. A 1 kb DNA ladder (Promega, Southampton, 
UK) was run to provide size markers, and both the ladder and all samples were loaded 
using a 6  x Blue/Orange Loading Dye (0.4% orange G, 0.03% bromophenol blue,
0.03% xylene cyanol FF, 15% Ficoll® 400, lOmM Tris-HCI (pH 7.5) and 50mM 
EDTA (pH 8.0 Promega, Southampton, UK). Gels were run at 200 mV for 45
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minutes, or until the required bands could be resolved. Gels were photographed on an 
ultraviolet (UV) transilluminator.
Bands required for ligation were excised using a sterile scalpel blade and placed in a 
1.5 ml microfuge tube. 450 pi QX1 buffer was added (Qiagen, W. Sussex, UK) to the 
gel fragment and the tube was incubated at 55 °C until the gel fragment dissolved. 
150 pi isopropanol was added, the tube was inverted twice to mix, and the sample was 
loaded onto a GenElute HP miniprep column (Sigma-Aldrich, Dorset, UK). The 
column was centrifuged at 12,000 g  for 30 seconds, the flow-through discarded, and 
600 pi Wash Buffer was added to the column. The column was centrifuged (12,000 g, 
30 s) and the flow-through discarded, following which the centrifugation was repeated 
to spin out any residual ethanol in the Wash Buffer. DNA was eluted by adding 50 pi 
distilled H2O and centrifuging for 30 s at 12,000 g. purified DNA was quantified 
using a Nanodrop spectrophotometer (NanoDrop Technologies, Delaware, USA) 
recording UV absorbance at 260 nm.
Fragments purified in this manner were ligated by adding insert DNA to vector DNA 
in a 3:1 molecular ratio. 1.5 pi DNA ligase buffer (50 mM Tris-HCI, 10 mM MgC12, 
1 mM ATP, 10 mM Dithiothreitol, 5 pg/ml BSA, pH 7.5) and 1 pi T4 DNA ligase 
(both New England Biolabs, Herts, UK) were added, and the ligation reaction allowed 
to take place for 30 minutes at room temperature.
2.1.3 Amplification of plasmid DNA in bacteria
Transformation of competent cells
LB-agar plates were made by adding the following to 1 litre distilled water: 10 g 
NaCl, 5 g Yeast extract B, 10 g Tryptone, 14g agar, (all VWR International, 
Leicestershire, UK). This medium was autoclaved at 121 °C for 15 minutes, allowed 
to cool to around 50 °C, and then 50 pg/ml ampicillin (Sigma-Aldrich, Dorset, UK) 
was added. The LB-agar was set in 9 cm diameter plates and stored at 4 °C. For 
transformation, DH5a™ competent cells (Invitrogen Ltd., Paisley, UK), were thawed
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on ice. The cells were incubated with 500 ng plasmid DNA (30 minutes on ice) before 
heat shock at 42 °C in a pre-warmed water bath for 45 seconds. The transformation 
mix was spread onto an LB-agar plate. In cases where a blue-white colony selection 
was required (i.e. when using pGEM®-T Easy plasmids) 50 pi of X-gal solution (20 
mg/ml) was spread over the plate before addition of the transformation mix. Plates 
were incubated overnight at 37 °C to allow the growth of ampicillin resistant colonies.
Amplification and recovery of recombinant plasmid DNA
Bacterial colonies from agar plates were inoculated into 5 ml of LB medium (as above 
for agar plates, without agar) containing 50 pg/ml ampicillin and incubated at 37 °C 
with agitation for 12-16 hours. For small-scale preparations, nucleic acid was 
prepared using a QIAprep® Spin Miniprep Kit (QIAGEN Ltd., W. Sussex, UK). For 
bulk cultures, 200 pi of the 5 ml culture was used to inoculate a further 1 1 of LB, 
which was incubated as above. Plasmid DNA was recovered with a QIAGEN® 
Plasmid Mega Kit (QIAGEN Ltd.).
2.1.4 rAAV production
Recombinant adeno-associated virus particles were synthesised, using the 
constructs described above, based on methods previously described [258] .The 
replicating Herpes Simplex Virus (HSV) amplicon pHAV7.3 was used to provide rep 
and cap genes required for virion production in conjunction with disabled infectious 
single cycle HSV (DISC-HSV) as a helper virus. The pDlO-based plasmid constructs 
described above were transfected in a 1:1 weight ratio with pHAV7.3 amplicon 
plasmid into Baby Hamster Kidney (BHK) cells. BHK cells were cultured to a density 
of around 60 % confluence (~1 0 7 cells per 150mm plate) and were incubated with a 
mixture of Peptide 6  [(K16)GACRRETAWACG], 30 pg construct DNA and 30 pg 
pHAV7.3 DNA, and 45 pi Lipofectin reagent (Invitrogen, Paisley, UK) per 150 mm 
plate. A total of twenty plates was used routinely to produce high-titre rAAV. After 4 
h incubation with the transfection mix (made in Optimem medium, Invitrogen,
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Paisley, UK), DISC-HSV was added to the cells at 10 infectious units (IU) per cell, 
and allowed to drive rAAV production over 36 hours. Cells were then harvested by 
scraping, centrifuged, and three ffeeze-thaw cycles were carried out with vigorous 
vortexing in between to ensure sufficient lysis of the cells. After treating the lysate 
with Benzonase (Sigma, Dorset, UK) to remove DNA persisting in the lysate, and 0.5 
% deoxycholic acid (DCA, Sigma-Aldrich, Dorset, UK) to liberate virus particles 
from cellular membranes, the lysate was filtered through 5 pm and 0.8 pm syringe 
filters (Millipore, Watford, UK). The rAAV particles were purified using a previously 
described heparin column protocol [209] by applying the filtrate to a heparin-agarose 
column that had been pre-washed with 10 ml PBS-MK (phosphate-buffered saline (8 g 
NaCl, 0.2g KC1, 1.44g of Na2HP04, 0.24g, KH2P04 in 1 litre distilled water) + 1 
mM MgCb and 2.5 mM KC1). After washing the column with 10ml PBS-MK + 0.1 
M NaCl solution, the virus was eluted in 6  ml PBS-MK + 0.4 M NaCl (discarding the 
first two ml). The eluate was concentrated into 100 pi using Centricon 10 columns 
(Millipore, Watford, UK), by applying the eluted virus to the column, centrifuging at 
5,000x g  for 75 mins, washing with 2 ml PBS-MK, and spinning to collect the virus 
concentrate. Resulting rAAV preparations were stored at -80 °C, and were quantified 
in terms of genomic titre and, where possible, infectious titre.
2.1.5 Recombinant lentivirus production
The protocol used to produce lentiviral vectors was based on a previously published 
method [259]. Briefly, 293T cells were seeded onto 175 cm2 plates at around 60 % 
confluence. The following day these cells were transfected, using the following 
protocol. Per plate, the following amounts of DNA were added to 5 ml Optimem 
(Invitrogen Ltd., Paisley, UK) and filtered through a 0.2 pm filter (Millipore, 
Watford, UK):
1 pi of a 10 mM stock of polyethylenimine (PEI, Sigma 40, 872-7) was added to 5 ml
of Optimen per plate and filtered through a 0.2 pm filter. DNA and PEI solutions 
were mixed 1:1 and left at room temperature for 20 minutes. The cells were washed in
Vector construct -50 pg 
-17.5 pg 
- 32.5 pg
pMDG
p8.91
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Optimem and then 10 ml of the PEI and DNA were added per plate. The cells were 
incubated at 37 °C, 5% CO2 for 4 hours. The media was then replaced with DIO 
medium (. 24 hours after the transfection the medium was removed and replaced with 
15 ml complete DMEM per plate. The virus was harvested the following day, as 
follows. The medium from the cells was centrifuged at 4000 rpm for 10 minutes and 
then filtered through a 0.22 pm filter. The filtered medium was transferred to 
polyallomer ultra-centrifuge tubes (11.5 ml/tube TH641 rotor or 33 ml/tube Surespin 
rotor). The tubes were placed in the rotor buckets and balanced (including the bucket 
lids). The medium was ultra-centrifuged at 4 °C, for 2-3 hours at 50,000x g  (23,000 
rpm TH641 rotor; 22,000 rpm Surespin rotor). The supernatant was carefully decanted 
off and 50 pi (TH641 rotor) or 150 pi (Surespin rotor) of serum-free medium or 
medium used for transduction was added per tube and pipetted three times. Parafilm 
was placed over the top and the tubes were left on ice for 1 hour. The medium was 
then pipetted 10 times to resuspend the virus and transferred to a 1.5 ml microfuge 
tube. The virus was then centrifuged for 10 minutes at 4000 rpm to remove cell debris 
and aliquoted in 2 ml cryovials. The virus was stored at -70 °C. The DNA present in 
the virus medium was removed to allow transduction efficiency to be measured by 
DNA analysis. For this, before aliquoting the virus was adjusted to 10 mM MgCb 
with 1 M MgCb, and DNAse I (Promega M6101) was added (final concentration 5 
u/ml). The virus was incubated at 37 C for 30 min, aliquoted and frozen.
2.1.6 Genomic titre of rAAV
Each batch of recombinant AAV produced was quantified by dot-blot assay to 
determine the number of genome copies per ml of virus. 1 pi and 5 pi of viral sample 
were digested with 1 pi Proteinase K enzyme (Sigma-Aldrich, Dorset, UK) in 200 pi 
Prot K buffer (10 mM Tris pH 8 , 10 mM EDTA pH8 , 0.5 % SDS) for 30 min at 56 
°C. After adding 20 pg glycogen, 21 pi 3M sodium acetate (NaCH3CC>2) and 260 pi 
100 % ethanol, the digested virus was incubated at -20 °C for 30 min and centrifuged 
at 14000 rpm for 10 min. The precipitated viral DNA was then washed in 70 % 
ethanol and centrifuged again at 14000 rpm for 5 min and resuspended in 200 pi 0.4 
M NaOH +10 mM EDTA. A dilution series of plasmid DNA was prepared, with 1012 
to 105 molecules in 0.4 M NaOH + 10  mM EDTA; these would act as standards on
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the blot. Viral samples and the standards were denatured at 95 °C for 2 min, and then 
placed on ice. A 12 cm x 8  cm piece of nylon transfer membrane (Amersham 
Biosciences, Bucks, UK) was placed in a Dotblot apparatus (BioRad). Wells that were 
to be used were filled with 2 0 0  pi sterile H2O and a vacuum applied to the apparatus. 
Samples and standards were then placed in the wells and applied to the membrane 
under vacuum. The wells were washed with 200 pi 0.4 M NaOH +10 mM EDTA; the 
DNA was cross-linked to the membrane on a sheet of 3 MM Whatman paper (VWR, 
Leicestershire, UK) by incubating at 37 °C for twenty minutes. A hybridisation bottle 
was pre-heated in a hybridisation oven at 65 °C, together with 50 ml Church mix 
(0.24 M SDS, 2 ml 0.5 M EDTA, 0.34 M Na2HP04, 0.16 M Na2H P04). The blot 
membrane was placed in water and transferred to the pre-heated bottle and pre­
hybridised for 30 min. During this incubation the DNA fragment to be used as a probe 
for the blot was isolated from an agarose gel and DNA isolated in QX1 buffer 
(Qiagen) using mini-prep columns. The isolated probe DNA was resuspended in 65 pi 
of water, and 34 pi was placed in a fresh microfuge tube and denatured at 95 °C for 
two minutes. After incubation on ice for 2 minutes, the tube was centrifuged briefly to 
collect the evaporated liquid from lid. The following reagents were added from the 
NEBlot Phototope Kit (New England Biolabs, Herts, UK), in order: 10 pi 5x 
Labelling mix (contains random octomers), 5 pi dNTP mix (contains biotin-dATP), 1 
pi Klenow. The probe was ncubated at 37 °C for between 1 hr and overnight, as 
convenient. The biotinylation reaction was terminated by adding 5 pi 0.2 M EDTA, 
pH 8 . To precipitate the probe, the following was added: 5 pi 3 M sodium acetate, 150 
pi 100 % ethanol; this was incubated at -20 °C for 20 minutes. After centrifugation at 
14000 rpm for 10 minutes, at 4 °C, the precipitated probe was washed with 70 % 
ethanol, centrifuged and resuspended in -20 pi TE or water. 5 pi was to probe blot, 
the rest was reserved at -20 °C.
5 pi of purified probe DNA was added to the hybridisation bottle containing the blot, 
and was allowed to hybridise to the samples and standards overnight at 65 °C. The 
Church mix containing the probe was discarded and he blot was washed three times 
with 50 ml 33 mM sodium phosphate buffer at pH 7.2 (a 1 M stock of 0.68 M 
Na2H P0 4 and 0.32 M Na2H P04 was diluted 1 in 30) for five minutes per wash. The 
blot was then processed using the Phototope-Star Detection kit (New England 
Biolabs, Herts, UK) as follows: the blot was blocked by placing in small plastic tray
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and adding Block Solution (5% SDS, 125mM NaCl, 25mM sodium phosphate @ pH 
7.2) -  20-30 ml to cover blot. The blot was incubated at room temperature on a 
shaking platform, and the block solution was drained. The blot was then incubated 
with Streptavidin, diluted 1:1000 in block solution (15 to 20ml in total). Streptavidin 
solution was then drained. After washing twice for 5 minutes each with Wash 
Solution I (which is Block solution diluted 1/10), the blot was incubated with biotin- 
conjugated alkaline phosphatase, diluted 1:1000 in 20 ml Block Solution. After 5 
minutes at room temperature, with shaking, this solution was drained and the blot 
washed once with Block Solution, then wice with Wash Solution II (10 mM Tris-HCI, 
10 mM NaCl, 1 mM MgCh pH 9.5) -  20 ml per wash was used, and all washed were 
5 minutes at room temperature with shaking. During second and final wash, CDP-Star 
reagent was made up from the Phototope Detection Kit (New England Biolabs, Herts, 
UK). The assay diluent is 25x concentrate, so first this was diluted 1/25 dilution (2.5 
ml needed per blot). Then CDP-Star reagent was diluted 1:100 in the lx diluent (i.e. 
25 pi in 2.5 ml). The blot was placed face upwards on a sheet of clingfilm, and the 
diluted CDP-Star reagent pipetted carefully onto the blot, ensuring area with dots is 
well covered. The blot was wrapped in clingfilm to ensure no leakage of CDP-Star 
reagent, and an X-ray film was exposed to the blot to determine viral titre.
2.1.7 Infectious titre of rAAV
A cell-based in vitro assay was also used for all vectors encoding a GFP gene 
to determine how many infectious particles of virus were produced. 293T cells were 
seeded onto 24-well plates at approximately 50 % confluency, and were infected with 
a serial dilution of AAV ranging from lpl to 1/1,000,000th pi of virus (infections were 
carried out in duplicate). Wells were superinfected with wild-type adenovirus to 
provide helper functions to the infecting AAV particles, and infectious titre was 
calculated after two days of incubation at 37 °C by multiplying number of GFP- 
positive cells in the well with least green fluorescence by the relevant dilution factor.
2.2 Subretinal injection of viral vector
96
Injections were performed in either CBA mice of 6 - 8  weeks or in ten-day-old 
Prph2Rd2IM2 mice as described previously [213]. Surgery was performed under direct 
retinoscopy through an operating microscope. The tip of a 1.5 cm, 34-gauge 
hypodermic needle (Hamilton) was guided in-between a cover slip and a rubber 
sleeve to the sclera of the right eye and then inserted tangentially through it, causing a 
self-sealing wound tunnel. The needle tip was brought into focus between the retina 
and the RPE and approximately 2pl of virus suspension was injected to produce a 
bullous retinal detachment in the superior hemisphere. A second injection was 
performed subsequently to produce a similar detachment in the inferior hemisphere.
2.3 Electrophysiological analysis of treated mice
ERGs from treated rats and mice were recorded in a standardised fashion at 
various time points after injection. All animals were dark-adapted overnight (16 
hours) and Ganzfeld ERGs were obtained simultaneously from both eyes of each 
animal in order to provide an internal control. All procedures for recording were 
carried out under dim red light. Mice were anaesthetised with a single i.p. injection of
0.15 ml of a mixture of Domitor (1 mg/ml medetomidine hydrochloride, Pfizer 
Pharmaceuticals, Kent UK), ketamine (100 mg/ml, Fort Dodge Animal Health, 
Southampton, UK) and water in the ratio 1:0.6:84. Rats were anaesthetised with an
1.p. injection of 0.15 ml solution of Domitor and ketamine in water in the ratio 
2:3:600. The pupils were dilated using one drop each of Phenylephrine 2.5 % and 
Tropicamide 1 % to each eye. A single drop of 2 % hydroxy-propyl-methyl-cellulose 
(HPMC) was placed on each cornea to keep it moisturised. ERGs were recorded using 
commercially available equipment (Toennies Multiliner Vision, Jaeger/Toennies, 
Germany) after placing corneal contact lens-electrodes (type Henkes, Jaeger- 
Toennies, Germany) and midline subdermal reference and ground electrodes. 
Bandpass filter cut-off frequencies were 1 and 300 Hz for all measurements. Great 
care was taken to keep electrode impedances symmetrical and low (between 5 and 8  
kOhm). Single flash recordings were obtained at light intensities increasing from 0.1 
mcds/m2 to 3000 mcds/m2. Ten responses per intensity level were averaged with an 
inter-stimulus interval of 5 s (0.1, 1, 10, 100 mcds/m2) or 5 responses per intensity
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with a 17 sec interval (1000 and 3000 mcds/m2) to try and minimise the dark adapted 
conditioning flash effect. All data was analysed using the Toennies Multiliner Vision 
program.
2.3.1 Statistical analysis
For each animal the b-wave amplitude at 100 mcds/m was used for statistical 
analysis. The b-wave values (a-wave through to b-wave peak) of the treated (right) 
eye were paired with the untreated contralateral (left) eye to provide an internal 
control. A paired Student’s t-test was used to evaluate significance (p< 0.05). This 
method controls for inter animal variance and test-retest variance present in rodent 
ERGs.
2.4 in vivo  evaluation of transgene expression
Eyes injected with virus containing a GFP reporter gene were evaluated in 
vivo for transgene expression using a slit lamp microscope adapted for rodents. Mice 
were anaesthetised as described above (2.3) and the eyes that were to be examined 
dilated with 1 % Tropicamide; the mouse was then placed on a platform to allow 
illumination of the eye via the slit lamp. Dilated eyes were kept moist by placing a 
drop of Viscotears carbomer gel (Novartis, Hants, UK) on the cornea, and a glass 
cover slip was placed in contact with the gel to aid visualisation of the retina. A light 
image was first captured using a Leica DC500 digital camera, following which a 
blocking filter was applied to the light source which allowed visualisation of GFP 
fluorescence from the retina.
2.5 Histological analysis
2.5.1 Cryosections
At various timepoints mice treated with viral vectors were anaesthetised with a 
single intra-peritoneal injection of 0.2 ml sodium pentabarbitone (Euthatal). The 
animal was then perfusion-fixed; the right atrium was opened with a single cut and 1 0  
ml 4 % paraformaldehyde was injected into the left ventricle for pre-fixation of the 
tissue until most of the blood was exchanged. Eyes were taken and immediately
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immersion fixed in 4 % paraformaldehyde for 4 hours. After fixation the eyes were 
cryoprotected in 10 % sucrose solution for 20 min at room temperature. Eyes were 
then embedded in O.C.T. (R A Lamb, E. Sussex, UK) and frozen in iso-pentane 
which had been pre-cooled in liquid nitrogen. Specimens were stored at -80 °C and 12 
pm thick sections were cut using a Bright cryostat. Propidium iodide (PI) was added 
to fluorescent mounting medium (Dako, UK), and this was added to the slides prior to 
placing a coverslip on top; the PI acts as a red counterstain for nuclear material, 
allowing identification of cells on the section.
2.5.2 Paraffin sections
Animals were sacrificed according to Schedule 1 of the Animals (Scientific 
Procedures) Act 1986. After enucleation eyes were fixed in 1 % buffered formalin 
overnight. Eyes were then placed in 70 % ethanol to dehydrate them, and embedded 
in paraffin and sectioned at 5 pm.
2.5.3 Immunohistochemistry
Frozen sections were taken as described above, and air-dried for 10 minutes. After re- 
hydrating the sections in water for five minutes, the sections to be stained were 
marked with a hydrophobic marker pen and were blocked using 1 % bovine serum 
albumin (BSA) and 3 % normal goat serum (NGS) in TBS-T for an hour at room 
temperature. Sections were then incubated with primary antibody diluted in block 
solution overnight at 4 °C. After washing three times with TBS-T, sections were 
incubated with secondary antibody diluted in TBS-T for two hours at room 
temperature. After washing twice with TBS-T sections were counterstained with 
propidium iodide or DAPI diluted 1/1000 in TBS-T, washed once with TBS-T and 
mounted in fluorescent mounting medium. For all antibody dilutions, please see 
Appendix.
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3. Improving gene delivery to the retina
3.1 Introduction
Viral gene delivery to the eye was first attempted using a recombinant 
adenoviral vector encoding a 0-Gal reporter gene, which resulted in short-term 
transgene expression in RPE cells and in a few photoreceptors [229,260]. However, 
this transgene expression is lost over time as the episomal Ad genome is lost, and an 
immune response to the adenoviral vector eliminates transduced cells [168]. In 
disease paradigms in which high-level, short-term transgene expression is enough to 
mediate a therapeutic effect, Ad-based vectors may be of benefit; for the majority of 
ocular gene therapy applications, however, longer-term, stable transduction of cells is 
required. As discussed previously, two types of viral vector have shown efficacy in 
delivering therapeutic nucleic acids to the retina -  those based on the adeno- 
associated virus (AAV) and those based on HIV-1 (lentivirus, see Chapter 1.11). Not 
only is long-term, stable transgene expression achieved using both recombinant AAV 
[214] and recombinant lentivirus [199], both vectors can restore structure and function 
to various models of retinitis pigmentosa [204,205,235,238,245,261].
Vectors based on adeno-associated virus are the most widely used viral gene transfer 
agents in ocular therapy; following extensive work in animal models of retinal disease 
(reviewed in [215]), an AAV-based vector is currently being used in two clinical gene 
therapy trial for LCA patients carrying mutations in RPE65 [262]. As discussed in 
Chapter 1.11, ease of production, a well characterised transduction profile and the 
highly efficient transduction of both photoreceptors and RPE (following sub-retinal 
delivery) contribute to AAV2 being the most widely used serotype for retinal gene 
therapy. However, with the development of pseudotyped vectors, it is possible to 
transduce more cells, achieve a faster onset and higher maximal levels of transgene 
expression, and circumvent the possibility of an immune reaction against a serotype 
that patients may have been previously exposed to [263]. Pseudotyping produces 
AAV virions consisting of a genome based (generally) on AAV2, encapsidated by
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proteins from a different serotype; such hybrid virions can be made because the cap 
gene that encodes viral capsid proteins is provided in trans to the transgene cassette 
during virus production, meaning the cap gene from (for instance) AAV4 can be co­
transfected with a transgene cassette flanked by AAV2 ITRs, resulting in AAV2/4 
being made. Pseudotyped viruses based on AAV2 have different transduction profiles 
to AAV2 itself following intraocular delivery, as summarised in Table 3.1. By 
exploiting the specific transduction pattern of a given pseudotype, transgene delivery 
can therefore be targeted to the tissue of interest; for instance, AAV2/4 would be 
appropriate for RPE-specific expression of a secreted growth factor [264], whereas 
AAV2/5 mediates transgene expression in both photoreceptors and RPE [265]. 
Another feature of pseudotyped vectors is the faster onset of transgene expression 
following sub-retinal delivery when compared with AAV2; previously published data 
suggests that AAV2-mediated transgene expression takes up to six weeks to reach 
maximal levels [214], whereas strong, near-maximal levels of reporter gene 
expression are seen between two and three weeks post-injection following AAV2/5 
mediated transgene delivery [265]. Considering that AAV2-mediated gene 
replacement therapy in the Prph2Rd2IRd2 mouse results in transient improvement in 
retinal function and no slowing of photoreceptor loss, we decided to pseudotype the 
AAV2.Rho.Prph2 expression cassette [245,246] with an AAV5 capsid, to determine 
whether faster onset and more efficient transduction kinetics of transgene expression 
using this pseudotype would allow prolonged improvement in function and a slowing 
of photoreceptor loss (Chapter 4). However, as well as changing the transduction 
profile of vectors, pseudotyping also alters the biochemical properties of the mature 
virions produced. Whilst AAV2 can be purified using a heparin-agarose column 
[209], it has been demonstrated that AAV2/4 and AAV2/5 are both unsuitable for 
purification using this affinity chromatography strategy [264]. Described in this 
chapter are two different purification methods used to produce AAV2/5.Rho.Prph2, 
and in vivo evaluation of this pseudotyped virus as a gene replacement vector is 
described in Chapter 4.
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Table 3.1: Tropism of pseudotyped AAV vectors following sub-retinal delivery. Taken 
from Rolling, et al, 2004.
Mouse Rat Dog Primate
rAAV-2/2 RPE+PR RPE+PR RPE+PR RPE+PR
rAAV-2/1 RPE — ----- —
rAAV-2/4 — RPE RPE RPE
rAAV-2/5 RPE+PR RPE+PR RPE+PR —
rAAV-5/5 RPE+PR — — RPE+PR
RPE, retinal pigmented epithelium. PR, photoreceptors.
3.2 Improved purification of recombinant AAV vectors
Recombinant AAV2 can be purified using a variety of techniques, including 
caesium chloride density gradients [266], iodixanol gradients [267] and the current 
method of choice, heparin affinity chromatography [209]. These methods are difficult 
to scale up for the production of large quantities of virus, and heparin columns are 
only efficient at purifying AAV2 and not other serotypes. Hence alternative methods 
for the purification of AAV-based vectors have been developed that are applicable for 
more than one serotype and are potentially useful for large-scale vector production. A 
two-column purification protocol that is suitable for AAV2 and AAV2/5 has 
previously been described, whereby cell lysates from 293T cells transfected with 
AAV production plasmids (including the transgene cassette flanked by AAV2 ITRs, a 
packaging plasmid containing the AAV5 cap gene, and a plasmid containing HSV 
helper functions) was firstly bound to a cationic exchange column, followed by 
further chromatography on an anionic exchange column [268]. To validate this 
purification system using packaging plasmids, transgene cassettes and tissue culture 
methods used routinely in our hands, we attempted to optimise the purification of both 
AAV2 and AAV2/5 using the previously-described methodology.
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Two days after transfection of AAV2 production plasmids, cells were harvested by 
scraping and resuspended in 1 ml per 15 cm2 plate of 25 mM NaHP0 4 , pH 7.4/ 20 
mM NaCl, 2 mM MgCh (Buffer A). The cells were then freeze-thawed three times 
and prepared for cationic exchange as previously described [268]. We performed the 
chromatographic steps using an Akta Prime FPLC system controlled and monitored 
by PRIMEVIEW software (both Amersham Biosciences, UK), that follows the pH, 
conductivity (measured in siemens (S) per area, and proportional to salt 
concentration) and UV absorbance of the flow-through from the columns. We initially 
made AAV2 using twenty 15 cm plates of 293T cells, and processed the lysates as 
above. The crude cell lysate was applied to the cationic SP Sepharose column in 
Buffer A (see above) adjusted to 150 mM NaCl, washed with one column volume (in 
our case 5ml) of the same buffer, and was eluted from the column using Buffer A 
containing a linear gradient of NaCl ranging from 150 mM to 500 mM. We followed 
conductivity and UV280 absorbance of the solution that flowed through the column, 
and were able to obtain traces similar to those published by Brument et al [268]. 
Examples of these traces are shown in Fig. 3.1 A; note the point at which the elution 
buffer is added, and the subsequent rise in conductivity and UV absorbance 
corresponding to eluate that contains AAV2 particles. The eluate was collected in 1 
ml fractions automatically, and these fractions were assessed by dot blot to determine 
at which point in the elution gradient most AAV2 particles were being recovered. 
Generally we found that AAV2 genome copies were most abundant between fractions 
13 and 17 (Fig. 3.2 A), which correspond to a conductivity reading of between 20 and 
26 mS/cm and a concentration of Buffer B of between 55 % and 70 %. However, on 
occasion we found a peak of UV absorbance immediately following the addition of 
Buffer B (Fig. 3.1B), which corresponded to elution of some virus particles, which 
was followed by elution of further AAV2 in downstream fractions (Fig. 3.1B). This 
indicated that the purification of AAV particles from the cationic chromatography 
column was not as reliable as purification using heparin columns, as elution from 
these columns occurs at a known salt concentration consistently (0.4 M NaCl).
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Fig. 3.1: Representative traces from FPLC purification o f AAV2.CMV.hfGFP; (A) As
the concentration of Buffer B increases, the conductivity (a measure o f salt concentration) 
also increases. A rise in UV absorbance (peak indicated by black arrow) begins shortly after 
this, corresponding to AAV2 particles being eluted from the column; m ost AAV2 particles 
were found in Fractions 13-17 by dot-blot analysis. (B) Plots from a separate purification. A 
sharp peak in UV absorbance (black arrow) is seen as Buffer B is added, and dot-blot 
analysis showed that some virus was eluted at this point. AAV2 genomes were also detected 
in Fraction 8, which was after the expected rise in conductivity in this elution. (C) Plots 
from second, anionic column; despite a sharp peak in UV absorbance (black arrow), poor 
recovery o f AAV2 was seen on dot-blot analysis, suggesting the UV absorbance was not due 
to virus being eluted.
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Fig. 3.2: Dot blot of eluted fractions from FPLC purification o f AAV2.CMV.hfGFP;
(A) Blot o f fractions obtained from purification shown in Fig. 3.1 A. Plasmid standard 
containing CMV.hrGFP cassette shown alongside 30 fractions o f  eluate collected from 
cationic column; CMV.hrGFP probe hybridises well to fractions 13-17. (B) Blot from 
purification shown in Fig. 3.IB. AAV genomes are detected in fraction two, corresponding 
to the sharp peak in UV absorbance seen during purification. Further AAV was also 
detected in Fraction 8, which was after the expected rise in conductivity in this elution. The 
elution o f  AAV genomes in fraction 15 corresponded to non-infective AAV, as shown by in 
vitro cell culture experiments (data not shown).
Nonetheless we were able to attempt the second chromatographic step described by 
Brument et al, who found that following the cationic step, viral preps still contained a 
significant amount of contaminating protein as determined by silver-staining proteins 
following SDS-PAGE [268]. We therefore applied the fractions from the cationic 
exchange column that were identified by dot blot as containing most AAV2 to a 
Resource-Q anionic exchange column (Amersham Biosciences) in Buffer B (20 mM 
Tris, pH 8.2, 2 mM MgCl2, 1 mM CaCh) adjusted to 50 mM NaCl. The bound 
fraction was eluted using a gradient of Buffer B containing 500 mM NaCl, and we 
obtained FPLC plots similar in profile to those published previously, but with lower 
absolute values for UV absorbance (Fig. 3.1C); our absorbance peaked at less than 25
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mAu, whereas Brument et al describe a peak of UV absorbance at around 55 mAu. It 
is not clear whether this discrepancy correlates to the relatively poor purification of 
AAV2, but dot blot analysis of the fractions eluted from this second column revealed 
that very little AAV2 was recovered, in the order of lxlO6 particles per ml (Brument 
et al purified around 2x1012 particles using a similar number of transfected 293T 
cells). We therefore took aliquots of the fractions from both chromatographic steps 
where we expected virus to be present (from dot blot analysis and from conductivity 
and UV absorbance traces from the monitoring software) and added them to 293T 
cells in vitro to confirm whether we had purified any infections particles of AAV. As 
shown in Fig. 3.3A, following the first, cationic exchange column, infectious particles 
of AAV were able to drive reporter gene expression, and an infectious titre assay 
showed that we had purified lx l0 7 infectious particles of AAV (considerably lower 
than the lx l011 routinely purified from heparin columns, shown in Fig. 3.3B). 
However, infection using eluate from the second, anionic exchange column did not 
result in transduction of 293T cells in vitro. We therefore concluded that although we 
were able to produce infectious AAV2 particles using the first column, attempts to 
further purify this virus using anionic exchange were unsuccessful. In view of this the 
AAV2/2 that was used in the experiments described in Chapter 4 was isolated using 
a previously described heparin-agarose column chromatography technique that results 
in reliable and efficient purification.
As this two-step chromatography protocol was designed to purify AAV independent 
of serotype, purification of AAV2/5 was also attempted using cationic/anionic 
exchange chromatography. Firstly, we found that co-transfection of our pDlO-based 
AAV2 ITR plasmids with an AAV5 packaging plasmid (kind gift from JA 
Kleinschmidt, Heidelberg, Germany) did not adversely affect transfection efficiency, 
and allowed transient expression of reporter gene (hrGFP) in vitro as seen during 
production of AAV2 (Fig. 3.3C).
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Fig. 3.3: in vitro GFP expression using AAV expression cassettes; all im ages taken 
using a fluorescent microscope with a 20X objective lens. (A) 293T cells infected with 
AAV2/2.CM V.hrGFP purified using two-step ion exchange chromatography. Low 
transfection efficiency is seen. (B) For comparison, 293T cells infected with 
AAV2/2.CM V.hrGFP purified using heparin column are shown. Cells appear rounded due 
to superinfection with wild-type adenovirus. (Q  Co-transfection o f pDlO.CMV.hrGFP and 
AAV5 packaging plasmid does not prevent GFP expression during virus production. (D) 
293T cells infected with AAV2/5.CMV.hrGFP purified using sepharose-mucin 
chromatography shows efficient transduction in the absence o f Ad-mediated superinfection.
Lysates from transfected cells were prepared as above, with Buffer A being adjusted 
to 100 mM NaCl for chromatography of AAV2/5 instead of 150 mM for AAV2 (this 
is because AAV2/5 has been shown to bind the SP Sepharose column efficiently at 
this lower salt concentration [268]). Cationic exchange chromatography was again 
performed using an SP Sepharose column, and the bound fraction was eluted using 
Buffer A containing a gradient of NaCl up to 100 mM. Fractions were collected and 
aliquots were analysed by dot blot to assess the efficiency of virus purification. 
Representative traces from the FPLC system are shown in Fig. 3.4; despite a peak in 
UV absorbance following addition of Buffer B, dot-blot analysis of the collected 
eluate showed poor purification from the first, cationic column. Nonetheless the 
fractions that contained AAV genomes were applied to the second, anionic column
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and eluted using Buffer B with a gradient of NaCl up to 500 mM. No AAV genomes 
above the detection limit of the dot blot assay were found. We concluded that using 
this two-step purification method we were unable to purify sufficiently high-titre 
AAV2/5, and so an alternative purification method was investigated.
We decided to purify AAV2/5 using a method based on a previously-published 
protocol that uses mucin coupled to sepharose to purify recombinant virus particles 
[269]. As we were adapting this methodology for use with the FPLC system described 
above, the first step was to couple mucin, which is a protein rich in sialic acid, to the 
sepharose that was to form the matrix of our purification column. This was done by 
dissolving 240 mg of mucin type IS in 4 ml ddFLO and mixing this with 6.0 g of 
CNBr sepharose that had been washed three times with 50 ml of ImM HC1. pH was 
adjusted to 8.0 and the sepharose-mucin mixture left overnight at 4 °C. To block non 
reacted groups, the mixture was then washed with 1 M Tris HC1 pH 8.0 for 2 hours, 
and then washed three times with 4 ml 1 M Tris HC1, pH 8 followed by 3 washes with 
1 M sodium acetate pH 3-4. The coupled sepharose-mucin was then packed into an 
XK 16/20 column (Amersham) which was equilibrated with two column-volumes 
(i.e., 36 ml) Buffer A (20 mM Bis Tris Propane, 20 mM Tris, pH8) containing 45 mM 
NaCl, using the Akta prime FPLC system. AAV2/5 was produced using transient 
transfection in 293T cells as previously described [269], and the lysate applied to the 
equilibrated column as a l-in-3 dilution to dilute the salt concentration and allow 
virus to bind to the column. The column was washed using two further column 
volumes of Buffer A containing 45 mM NaCl, and virus was eluted using Buffer A 
containing 450 mM NaCl. Virus produced using this methodology was concentrated 
using a Centricon-100 column, and by infecting 293T cells in vitro (Fig. 3.3D) we 
showed that around 2x1011 infectious particles of AAV2/5.CMV.hrGFP had been 
isolated. We therefore used this sepharose-mucin chromatography method to make 
AAV2/5.Rho.Prph2 and evaluated this as a gene replacement vector as described in 
Chapter 4.
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Fig. 3.4: Representative traces from FPLC purification o f AAV2/5.CMV.hfGFP; (A)
AAV2/5 particles were found by dot blot in fractions 13 and 14, where UV absorbance 
shows a small increase (small peak indicated by black arrow), and in Fractions 19 and 20. 
However, the total number of virus particles purified was relatively low compared to 
purification o f AAV2. (B) Plots from the second, anionic exchange column. Despite small, 
erratic increases in UV absorbance (black arrows, note the Y axis scale in comparison to 
previous traces), very little AAV2/5 was recovered from the second column.
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4 Evaluating integrase-deficient lentiviral 
vectors for use in the eye
4.1 Introduction
Although vectors based on both AAV and lentiviruses mediate effective 
treatment in models of RP, safety might be improved by employing novel techniques 
designed to minimise the risk of side effects resulting from vector administration. One 
way of improving the safety of lentivirus-mediated gene delivery would be to achieve 
stable transgene expression in the absence of proviral integration into host DNA. As 
discussed in Chapter 1.11, insertional mutagenesis has been shown to cause 
neoplastic transformation in patients treated with a retroviral vector encoding the yc 
cytokine receptor gene [185]. This was shown to be a direct result of proviral 
integration near the LM02 promoter which activated inappropriate expression of this 
oncogene, leading to clonal proliferation of T-cells. The need to develop vectors that 
do not activate host oncogenes had been recognised prior to the initiation of the X- 
SCID trials, and had resulted in the production of self-inactivating (SIN) HIV-1 based 
vectors [270,271]. Nonetheless, the potential remained for proviral integration to 
cause insertional mutagenesis; disruption of normal host gene expression, or 
inappropriate activation of host genes near the insertion site would pose a significant 
risk even in the absence of promoter activity in the viral LTR sequences. Integration 
of lentiviral provirus DNA is mediated by integrase (IN), encoded by the viral 
integrase gene provided in trans during recombinant virus production. This approach 
allows production of replication-defective lentivirus particles, which contain reverse 
transcriptase (RT) and IN proteins (to allow efficient proviral synthesis and 
subsequent integration) without the rt and integrase genes being incorporated into the 
vector genome [196]. Mutagenesis experiments were used to identify which protein 
domains and which amino acid residues within IN are essential for viral integration; 
these studies identified two classes of IN mutant, referred to as Class I and Class II. 
Class II mutants have pleiotropic effects on the HIV-1 life cycle, with various 
processes including Gag/Pol precursor processing, reverse transcription of the viral 
genome and nuclear entry of the pre-integration complex (PIC) being inhibited; Class
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I mutants are specifically blocked at the integration stage, with only the catalysis of 
proviral integration inhibited whilst all other viral functions remain intact [272]. Thus, 
the viral genome remains within the host cell as an episome, which is able to direct 
transgene expression but is lost as a result of successive cell divisions [273]. Despite 
this, previous studies using a non-human lentivirus vector (based on feline 
immunodeficiency virus, FIV) showed paucity of transgene expression using a vector 
carrying a D66V amino acid substitution [202]. Subsequently, an IN-deficient HIV-1 
vector that included an origin-of-replication from the SV40 virus was shown to 
mediate long-term transgene expression in vitro. In permissive cell lines that co­
expressed the SV40 Large-T antigen, the non-integrated proviral episomes were able 
to replicate extra-chromosomally and sustain viral transgene expression for up to 60 
days [203]. This study demonstrated that episomal proviral DNA can drive efficient 
transgene expression, and because the majority of cell types that are targeted by 
ocular gene therapy strategies are non-dividing, we chose to evaluate a Class I IN 
mutant for its ability to mediate stable transgene expression in the eye.
4.2 Integrase-deficient lentiviral vectors drive efficient
reporter gene expression in vitro and in vivo
We used a mutant integrase gene harbouring a D64V amino acid substitution, 
provided in trans to the HIV-1-based expression plasmid, and made recombinant self- 
inactivating virus using a previously-described method [274]. The integrase-deficient 
vectors were titre-matched to integrase-proficient vectors, and were evaluated for 
efficacy of transgene delivery in vitro and in vivo. The integrase-deficient reporter 
gene constructs were able to drive stable, long-term transgene expression in murine 
RPE (Fig. 4.1). This was independent of whether they the contained c/s-acting 
Woodchuck post-transcriptional regulatory element (WPRE, included in lentiviral 
vectors to enhance transgene expression), using either the cytomegalovirus (CMV) 
promoter or the spleen focus-forming virus (SFFV) promoter (both known to drive 
ubiquitous expression) and with or without the central poly-purine tract (CPPT) from 
the HIV-1 genome (which aids nuclear transport of the vector genome in host cells) 
(Fig. 4.1a). Reporter gene expression was equivalent in eyes injected with integrase-
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deficient vectors as compared with integrase-proficient titre-matched controls; eGFP 
fluorescence was noted on in vivo fundoscopy at seven days post-injection (p.i.) and 
remained strong until 9 months p.i, the longest time point assessed (Fig. 4.1a, b). Six 
months post-injection, strong eGFP expression was seen in the RPE (Fig. 4.1c), 
consistent with previous studies using integrating lentiviral vectors [199,205]. In vitro 
transduction of human RPE cells was also demonstrated; ARPE-19 cells, an 
immortalised human RPE-derived cell line [275], showed strong eGFP expression 
when transduced with integrase-deficient vectors (Fig. 4.2a, b), as did cultured 
primary human RPE taken from an AMD patient following short exposure to vector 
suspension (Fig. 4.2c-f); this demonstrates the potential for ex vivo transduction of 
human RPE, which could be transplanted back into the recipient to mediate a 
therapeutic effect.
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Fig. 4.1: Reporter gene expression in the eye following administration o f integrase- 
deficient lentiviral vectors; independent o f vector configuration (a), integrase-deficient 
vectors were able to mediate strong, long-term G FP expression in the eye as shown by 
fluorescent fundus photographs taken at various time points (b) and by cryosections 
counterstained with propidium iodide (red). The route o f administration determined viral 
trdpism, with sub-retinal injection leading exclusively to RPE transduction and intracameral 
injection resulting in comeal endothelial transduction.
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Fig. 4.2: Reporter gene expression in vitro following administration o f integrase- 
deficient lentiviral vectors; (a) efficient reporter gene expression following infection of 
human ARPE-19 cells with an integrase-deficient lentivirus encoding GFP driven by an 
SFFV promoter, (b) CMV prom oter drives similar levels o f expression in ARPE-19 cells, 
(c) Primary human RPE cell derived from AMD patient transduced with integrase-deficient 
lentivirus encoding GFP. (d) Transduced primary RPE cells show hexagonal morphology 
expected o f macular RPE. (e) Patient-derived RPE cells have many auto-fluorescent 
lipofuscin granules, shown in red.
4.3 Integrase-deficient lentiviral vectors m ediate effective 
gen e therapy in anim al m odels o f retinal degeneration
Integrating lentiviruses have been shown to mediate effective gene therapy in 
rodent models of retinal degeneration [205,276]. We therefore investigated whether 
our integrase-deficient vectors could improve retinal function in two models of retinal 
degeneration, the Rpe65Rdl2/Mn mouse and the RCS rat, both of which have been 
previously shown to benefit from viral gene therapy [205,233]. Rpe65Rdl2/Rdn mice 
received sub-retinal injection of an integrase-deficient lentivirus encoding the human
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RPE65 gene. Rpe65RdI2/Rd12 eyes treated with the integrase-deficient hRPE65 vector 
showed substantially improved ERG waveform, and significantly greater b-wave 
amplitudes, than untreated contralateral eyes (Fig. 4.3a, b). No improvement in ERG 
was seen following sub-retinal administration of an integrase-deficient virus encoding 
eGFP (Fig. 4.3c, d). Another group of Rpe65Rdl2/Rd12 mice received integrase-deficient 
RPE65 virus in the right eye and integrase-proficient virus in the left; eyes treated 
with integrase-deficient virus showed a trend towards higher b-wave amplitudes than 
eyes treated with integrase-proficient, with improved waveform and more pronounced 
oscillatory potentials (Fig. 4.3e, f). These functional improvements remained until at 
least two months post-injection, the latest time point studied; at this stage the b-wave 
amplitudes recorded from Rpe65M12/M12 mice treated with integrase-deficient RPE65 
virus were around 50 % of those seen in age-matched wild-type mice.
To validate this novel gene delivery system in another model of retinal degeneration, 
we used an integrase-deficient virus encoding the Mertk gene to rescue the RCS rat; 
this model of severe early-onset retinitis pigmentosa has previously been shown to 
benefit from lentiviral gene therapy [205]. Compared with uninjected controls, eyes 
treated with the integrase-deficient Mertk vector showed improved ERG waveform 
and amplitude at six weeks post-injection (Fig. 4.4a, b); the average b-wave 
amplitudes recorded from the treated eyes was equivalent to amplitudes seen in the 
previous study using integrating vectors, being around 100 pV (or around 25 % of 
wild-type rat amplitudes). One group of RCS rats received sub-retinal injections of 
integrase-deficient virus in one eye and integrase-proficient virus in the other; both 
eyes showed a comparable treatment effect, with an average b-wave amplitude of 
around 120 pV being recorded from both eyes (Fig. 4.4c, d). As previously reported, 
a small, not statistically significant, sham treatment effect was noted using an 
integrase-deficient virus encoding eGFP (Fig. 3.8a, b); this is a result of the injection 
fluid flushing away the debris layer that accumulates in the sub-retinal space of the 
RCS rat [205].
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Fig. 4.3: Effective restoration of retinal function following administration of 
integrase-deficient lentiviral vector encoding human RPE65; (a, b) sub-retinal delivery 
o f  integrase deficient lentivirus encoding hRPE65  results in significantly im proved ERG  
waveform and b-wave amplitudes three weeks post-injection com pared to untreated 
contralateral eyes (» = 5). (c, d) no improvement in E R G  is seen following administration o f 
an integrase-deficient vector encoding G FP {n — 4). (e) eyes treated with integrase-deficient 
virus show improved ER G  waveform, particularly in m ore pronounced oscillatory 
potentials, when com pared with eyes treated with integrase-proficient virus; (f) the 
difference in average b-wave potential was no t statistically significant (n — 6).
These data demonstrate that in the absence of proviral integration into host 
chromosomal DNA, lentiviral vectors are able to drive stable and long-term transgene
116
expression which can mediate a therapeutic effect in two rodent models of retinal 
degeneration. This is the first study to demonstrate in vivo efficacy of vectors 
harbouring a mutation in integrase, and as such represents an important step in the 
development of lentiviral gene therapy vectors; in non-dividing cell types the use of 
episome-derived transgene expression is a promising approach that would allow 
delivery of therapeutic gene without the risk of insertional mutagenesis seen with 
integrating viruses.
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Fig. 4.4: Restoration of function in RCS rats following integrase-deficient lentivirus- 
mediated gene replacement; Representative ER G  traces (a, c, e) and averaged b-wave 
amplitudes (b, d, f) from RCS rats treated with integrase deficient virus encoding Mertk. (a 
and b) show that following monocular treatm ent with integrase deficient virus encoding 
Mertk ERG  waveform and b-wave amplitude is restored to levels seen in previous studies (n 
= 6). (c and d) RCS rats injected with integrase-deficient Mertk virus in the one eye and 
integrase-proficient virus in the left eye show that integrase-deficient virus results in 
equivalent ERG  waveform and similar averaged b-wave amplitudes when com pared to 
integrase-proficient virus (n — 6). (e and f) show that there is a small bu t n o t statistically 
significant sham effect on ER G  caused by administration o f control vector encoding GFP, 
as described previously (n = 4).
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5. Improving gene replacement therapy in 
rodent models of retinal degeneration
5.1 Introduction
The primary aim of gene replacement therapy is to restore structure and 
function to cells directly affected by a disease-causing mutation. The earliest studies 
in gene therapy established proof-of-concept that either lipid-based non-viral vectors 
[277] or recombinant viruses [278] could be used to deliver genes to host cells. The 
remaining challenge was to achieve levels of transduction that would produce a 
therapeutic effect in an in vivo model of disease, and ultimately in patients. Whilst this 
has not been straightforward, much progress has been made in improving the delivery 
of transgenes to target cells, with improvements made in efficiency of gene transfer, 
safety of the vectors used and biological efficacy in disease (see Chapter 1.11,1.12).
There have been significant advances in ocular gene therapy since the first studies 
involving reporter gene transfer to the retina [213,279]. Indeed, many studies have 
shown physiological disease correction mediated by viral gene delivery in animal 
models of disease [205,233,235,238,239,245]. Nonetheless, in many cases the 
improvements in structure and function are transient, largely owing to the failure of 
gene replacement therapy to delay or prevent photoreceptor apoptosis. Previous 
studies in rodent models of retinal degeneration have shown that although gene 
replacement can slow the rate of photoreceptor loss in some cases [205,239], most 
models fail to show long-term preservation of photoreceptors or amelioration of 
retinal function following gene replacement therapy [228,246]. As discussed in 
Chapter 5, strategies to enhance photoreceptor survival have focussed on delivery of 
genes encoding neurotrophic factors to the retina; these have had varying degrees of 
success, and in the absence of gene replacement therapy often mediate little functional 
benefit. The aim of the work in this chapter is to investigate whether by improving the 
efficiency of gene delivery to rod and cone cells, we could increase the duration of 
improved function in the Prph2Rd2fR<n mouse, the Rhodopsin knockout mouse (Rho'f )
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and the rdl mouse by gene replacement therapy. Specifically, we have investigated 
the long-term effects of AAV-mediated Prph2 expression in wild-type retinae, and 
determined whether overexpression of this gene causes any functional deficit. We 
have also investigated whether using an alternative promoter sequence to drive Prph2 
expression would improve gene replacement therapy and the subsequent functional 
recovery in Prph2Rdl/Rd2 mice. Although AAV-mediated gene replacement therapy 
results in significant functional improvement in the Prph2Rd2/R<n mouse, apoptotic cell 
death is not slowed as assessed by outer nuclear layer thickness [244]. There are two 
possible reasons why gene replacement in this model may not lead to a significant 
reduction in photoreceptor loss. If gene replacement therapy does not confer a 
selective survival advantage to an individual transduced photoreceptor that expresses 
Prph2, transduced cells would not survive longer than untransduced neighbouring 
cells. Conversely, if cells expressing Prph2 do survive longer than their untransduced 
neighbouring cells, it may be that using pan-retinal ERG or ONL thickness 
measurements are not sensitive enough to show enhanced survival. In order to 
investigate the effects of AAV-mediated Prph2 expression on individual transduced 
Prph2Rd2/Rdl photoreceptors, we needed to mark photoreceptors that express the AAV- 
mediated Prph2 cDNA. Hence a construct was developed that included an IRES.GFP 
sequence downstream of the Prph2 expression cassette. This enabled Prph2- 
expressing transduced cells to be easily marked with GFP expression; using this 
construct, the proportion of GFP-positive (and hence Prph2-positive) cells in the outer 
nuclear layer was quantified, and this analysis was repeated at a later time-point to 
determine whether transduced cells survive longer than untransduced cells.
We also treated Prph2Rd2/Rdl mice with AAV2/5.Rho.Prph2 (described in Chapter 
3.4) and investigated whether this pseudotyped vector lead to improved ultrastructure, 
histological preservation and electrophysiological function of photoreceptors when 
compared to treatment with AAV2/2. In addition we have tested AAV2/5-mediated 
gene replacement therapy in two other murine models of RP -  the rdl mouse, which 
has been difficult to rescue because of the fast kinetics of degeneration, and the Rho'1' 
mouse, which requires high levels of transgene expression in order to achieve 
functional rescue.
119
5.2 AAV-mediated overexpression of Prph2 is well tolerated
Sub-retinal delivery of the AAV.Rho.Prph2 that was being made using the 
pD10.Rho.Prph2 plasmid available in the laboratory was resulting in poor functional 
improvement in Prph2Rd2/Rdl mice, almost certainly because the 3’ ITR in the 
available pD10.Rho.Prph2 clone had become shortened through recombination as we 
identified by restriction digestion. Therefore before the following experiments using 
AAV2/2.Rho.Prph2 could be attempted, the Prph2 cDNA had to be sub-cloned into 
pDlO-based plasmid in which the ITR sequences were known to be intact. Hence the 
pD10.Rho.Prph2 plasmid was digested with BamHI and Agel to excise the Prph2 
cDNA. Another pDlO-based plasmid containing the rhodopsin promoter, 
pD10.Rho.RP2, was digested with BamHI and Notl, and an oligonucleotide adapter 
ligated to this to convert the Notl overhang to an Agel site. After digesting this 
plasmid with Agel, the BamHI/Agel-digested Prph2 cDNA fragment was ligated to 
give pD10.Rho.Prph2 (Fig. 5.1). We verified the new construct by restriction digest 
analysis to show that the restriction sites missing in the original construct had been 
restored once the Prph2 cDNA was sub-cloned into a new pDIO backbone (Fig. 5.2). 
Having shown that this new pDlO.Rho. Prph2 clone has the expected restriction sites 
in the expected orientation, we proceeded to make virus with this plasmid and test it 
in the experiments described below.
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Fig. 5.1: Cloning strategy used  to  sub-clone Prph2  cD N A  into pD lO -based plasm id 
w ith in tact IT R  sequences; the Prph2 cDNA was excised from the existing 
pD10.Rho.Prph2 plasmid using BamHI and Agel digests. The pD10.Rho.RP2 plasmid was 
digested with BamHI and Notl, and an oligonucleotide adapter that changed the Notl 
overhang to an Agel site was ligated. The Prph2 cDNA was then ligated to this to give a 
novel pD10.Rho.Prph2 plasmid.
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Fig. 5.2: R estriction d igest analysis com paring  old and  new  pD 10.R ho.Prph2 clones;
(A) Smal digests are routinely used by our laboratory to verify ITR sequences; old clone gave 
fewer bands o f (approximately) 700 bp, an unexpected band at 1800 bp, and a smaller band 
from the vector backbone at 3.3 kbp, whereas the new pD10.Rho.Prph2 clone gave the 
correct pattern of bands at 3.5 kbp, 1500 bp and three bands at —700 bp (bands in both 
lanes at —400 bp are not visible on this 1 % EtBr agarose gel). (B) A combined digest using 
Pad and Ncol enzymes shows that one Pad  recognition site is missing in the old plasmid, 
hence there are two bands at —900 bp and —6.5 kbp, whereas the new clone gives the 
expected bands at around 4 kbp, 2.7 kbp and 700 bp.
Previous reports investigating the overexpression of Prph2 indicated that mice 
carrying a Prph2 transgene on a Prph2+I+ wild-type background showed no signs of 
rod or cone dysfunction [280]. However, the suggestion by Sarra et al that AAV- 
mediated Prph2 overexpression in wild-type mice lead to the loss of photoreceptors 
was of major concern [244]. In order to investigate the consequences of AAV- 
mediated Prph2 overexpression in wild-type retinae, we delivered as high a dose of
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AAV.Rho.Prph2 as we could achieve by unilateral sub-retinal injection into wild-type 
C57B1/6 mice. We purified AAV using heparin columns as previously described 
[209], and concentrated the eluate using Centricon-10 spin columns to de-salt the 
virus suspension and to obtain the highest possible concentration of virus to inject into 
the wild-type mice. Dot-blot analysis of this virus showed that there were 2x10 
genomes per ml, 100-fold higher titre than has been used in previous studies [246]. A 
group of wild-type mice received sub-retinal injections of this high-titre 
AAV.Rho.Prph2, and a control group received sub-retinal injection of 
AAV.CMV.GFP to control for the effects of AAV transduction. ERG recordings 
taken 3- and 8-months post-injection indicated no significant reduction in function in 
treated eyes compared with untreated contralateral eyes in both Prp/22-treated and 
GFP-treated groups (Fig. 5.3), a finding that suggests that both injection of high-titre 
AAV and overexpression of Prph2 are well-tolerated for long periods of time without 
detrimental effects on pan-retinal function.
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Fig. 5.3: AAV-mediated Prph2  overexpression is w ell tolerated: sub-retinal delivery o f 
AAV.Rho.Prph2 to wild-type mice (n=8) does not result in significant reduction in ERG b- 
wave amplitudes. A t three and eight months post-injection, a small reduction in b-wave is 
seen in eyes injected with AAV.Rho.Prph2 (Prph2 treated) when compared with uninjected 
contralateral control eyes (Prph2 untreated, p=0.09), which is also seen following sham 
injection o f control vector (GFP treated) compared with uninjected contralateral control 
(GFP untreated).
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5.3 Early and repeated injection of high-titre 
AAV2.Rho.Prph2 does not enhance gene replacement therapy 
in Prph2Rd2/RdZ mice
Previous studies investigating gene replacement therapy in Prph2RdllRdl mice 
have shown that by treating mice at post-natal day (PND) 10 and again at PND 15, an 
improvement in retinal function is seen that lasts for over three months post-injection 
[246]. Having shown that administration of high-titre AAV.Rho.Prph2 (2x1012 
particles per ml) does not reduce retinal function in wild-type mice (see above), we 
decided to investigate whether earlier intervention using this virus would result in 
enhanced functional improvement in Prph2RdllRd2 mice. Hence double sub-retinal 
injections of AAV.Rho.Prph2 (2xl012 particles per ml) were performed in the dorsal 
and ventral quadrants at PND 7, earlier than previously attempted in this model and 
before significant apoptosis is detected in the outer nuclear layer [72]. Five days later 
sub-retinal injections were performed in previously untreated quadrants of the retina 
(nasal and temporal) such that approximately 60 % of the retina had a sub-retinal bleb 
raised allowing photoreceptors to be exposed to virus. ERG recordings were taken six 
and eight weeks post-injection, and we found a variable degree of improvement in b- 
wave at 100 mcds/m between animals; at six weeks, two mice had b-wave 
amplitudes in their treated eyes that were comparable to those found in treated eyes 
from previous studies (86.2 pV and 113 pV), whereas the other mice in this treatment 
group had lower amplitudes (27.6 pV, 32.8 pV, 69.0 pV and 70.0 pV) in their treated 
eyes. Overall, there was a trend towards higher b-waves in treated eyes (average b- 
wave in treated eyes was 66.4 pV ± 32.3 pV) when compared with untreated 
contralateral eyes (35.5 pV ± 11.7 pV) (Fig. 5.4), although the difference between the 
treated and untreated eyes was not statistically significant (p > 0.05).
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Fig. 5.4: Sub-retmal delivery of AAV.Rho.Prph2 to Prpb2Rd2/Rd2 mice at PND 7 and 
PND12 does not result in significant improvement in retinal function; (A) Six weeks 
post-injection, scotopic ER G  recordings show that eyes treated with AAV.Rho.Prph2 do 
no t have significantly improved b-wave amplitudes (66.4 pV +  32.3 pV and 56.35 pV + 27 
pV at 100- and 1000 m cds/m 2 respectively) com pared to untreated contralateral eyes (35.5 
pV ± 11.7 pV and 53.8 pV ±  31.8 pV) (p > 0.05, n — 7)). (B) Eight weeks post-injection, 
there is still no statistically significant rescue o f E R G  b-wave in treated eyes (65.8 pV ±  33.0 
pV at 100 m cd/m 2 and 56.2 pV + 22.6 pV at 1000 m cds/m 2) com pared to untreated 
contralateral eyes (35.4 pV ±  10.5 pV at 100 m cd /m 2  and 50.5 pV +  29.8 pV at 1000 
m cds/m 2, p > 0.05).
'■y
At 1000 mcds/m we saw virtually no improvement in ERG b-wave across the 
group; treated eyes had an average b-wave of 56.35 pV ± 27 pV, and untreated eyes 
had an average of 53.8 pV ± 31.8 pV. At eight weeks post-injection, there was still no 
statistically significant difference between treated eyes (65.8 pV ± 33.0 pV at 100 
mcd/m2 and 56.2 pV ± 22.6 pV at 1000 mcds/m2) compared with untreated control 
eyes (35.4 pV ± 10.5 pV at 100 mcd/m2 and 50.5 pV ± 29.8 pV at 1000 mcds/m2, p > 
0.05). From this we can conclude that the extra trauma caused by two surgical 
interventions at early time points negates any benefit there may be from having an 
earlier onset of gene expression; the lack of improvement in b-wave amplitude is less
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likely to be caused by the use of higher titre virus, as we have shown that delivery of 
AAV.Rho.Prph2 at this titre is tolerated in wild-type mice. The fact that some 
Prph2Rd2/Rdl eyes showed an improvement in ERG following early and repeated 
injection suggests that this treatment can be tolerated in some cases, but that overall 
the strategy of treating mice at PND 7 and again at PND 12 was liable to causing 
more damage to the retina and a subsequent absence of the functional improvement 
seen after surgery at PND 10 and PND 15. In the following experiments involving 
Prph2Rd2/Rd2 mice, therefore, we decided to treat Prph2Rd2/Rd2 mice at PND 10, and to 
use high-titre AAV to mediate gene therapy.
5.4 Prph2 expression driven by a novel fragment of the 
mouse opsin promoter results in efficient transgene 
expression in rods, but not cones
As discussed previously, it is not clear whether gene replacement therapy in 
the Prph2Rd2/Rdl mouse has any effect on the apoptotic mechanism within individual 
transduced photoreceptors. To investigate this, a construct with a smaller promoter 
fragment driving Prph2 expression was required, in order that a multi-cistronic 
expression cassette including an IRES.GFP sequence could be accommodated within 
the 4.8 kb packaging limit of AAV2. As the full-length bovine rhodopsin promoter 
(referred to as Rho) used in previous studies [244-246] is over 2.2 kb, a novel 235bp 
fragment of the mouse opsin promoter (referred to here as the MOPS promoter, 
spanning nucleotides -218 to +17 relative to the start codon of the opsin gene) was 
isolated from mouse genomic DNA (Fig. 5.5, see Appendix for primer sequences). 
As this fragment of the MOPS promoter had not previously been validated in vivo, 
this promoter fragment was cloned into an AAV plasmid in place of the CMV 
promoter to make pD10.MOPS.GFP. An untranslated 1.9 kb fragment of the bacterial 
P-Galactosidase gene was cloned downstream of the SV40 polyadenylation signal, to 
act as a ‘stuffer’ sequence; the addition of this sequence meant the final 
pDlO.MOPS.GFP.STUFF plasmid had 3.5 kb of DNA between the AAV2 ITR 
sequences, which allows the expression cassette to be efficiently packaged into AAV 
virions.
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Fig. 5.5: (A) Cloning strategy to  used  to  AAV p lasm id  contain ing  novel m ouse opsin 
prom oter (MOPS) fragm ent driving G FP; (i) A 234 bp fragment o f the mouse opsin 
promoter was isolated using PCR on murine genomic DNA. This was ligated to the linear 
pGEM -T easy cloning vector (Promega, UK); double-headed arrows indicate multiple cloning 
sites (MCS). The MOPS promoter was then excised from this vector using Spel and SacII 
restriction enzymes, (ii) The CMV prom oter in pD10.CMV.GFP was excised using Spel and 
SacII digests, and the MOPS promoter cloned in its place to generate pD10.MOPS.GFP. (iii) 
To ensure efficient packaging o f this expression cassette into rAAV, pD10.MOPS.GFP was 
digested with Aj/II  and Spel and the expression cassette excised. This was ligated to 
pDlO.CMV.GFP.STUFF that had been digested with AjJII and Spel, which replaced 
CMV.GFP.PolyA with MOPS.GFP.PolyA. This resulting plasmid, 
pDlO.MOPS.GFP.PolyA.STUFF, included the non-coding B-gal stuffer fragment. Black 
arrows represent AAV2 inverted terminal repeat (ITR) sequences.
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(B) To use the MOPS promoter to drive Prph2 and GFP expression, (i) The Prph2 cDNA 
was excised from pD10.Rho.Prph2 using Xhol and Agel restriction enzymes. This fragment 
was used to replace the CN TF  cDNA in pD10.CMV.CNTF.IRES by ligating to an 
Xhol/Agel fragment o f this plasmid, (ii) This gave pD10.CMV.Prph2.IRES.GFP.PolyA, 
from which the Prph2.IRES.GFP sequence was excised using Agel,/Muni restriction 
enzymes; this was used to replace the GFP.PolyA fragment in pD10.MOPS.GFP to give the 
AAV plasmid pD10.MOPS.Prph2.IRES.GFP.PolyA.
Recombinant AAV2/2 using the pDlO.MOPS.GFP.PolyA.STUFF plasmid 
(AAV.MOPS.GFP) was made as previously described [238], and the titre was 
determined by dot blot analysis as being lx l0 12 genomes per ml. Wild-type C57B1/6 
mice received sub-retinal injection of 2 pi in one eye as previously described [246], 
and six weeks post-injection fundus examination revealed strong GFP fluorescence 
from the retina (Fig. 5.6, n = 4). The mice were sacrificed at this time point and 
assessed histologically to determine whether the MOPS promoter was driving
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photoreceptor-specific transgene expression. Fluorescent micrographs of frozen 
retinal sections reveal strong GFP expression that was photoreceptor-specific; no RPE 
cells were GFP-positive, and as AAV2 normally transduces the RPE this result 
indicates that this novel fragment of the MOPS promoter drives photoreceptor- 
specific transgene expression (Fig. 5.6). In order to determine whether MOPS drives 
expression in cones, the eyes we treated with AAV.MOPS.GFP were stained with 
peanut agglutinin (PNA). PNA is a lectin molecule that binds specifically to 
galactose-galactosamie disaccharide residues found on the sheaths that surround cone 
inner and outer segments [281], and as such is used to stain for cone photoreceptors. 
We found that although there was efficient photoreceptor transduction, no GFP- 
positive cells were co-stained with PNA, suggesting that no cones were transduced 
using the AAV.MOPS.GFP construct (Fig. 5.7).
AAV-mOps-GFP
Fig. 5.6: N ovel M OPS prom oter m ediates efficient photoreceptor-specific GFP 
expression; (A) six weeks after sub-retinal delivery o f AAV2.MOPS.GFP to wild-type mice, 
fundus examination shows transduction o f more than 50% of the retina. (B) Representative 
photomicrograph (20X objective lens) o f cryosections from an eye injected with 
AAV2.MOPS.GFP. Efficient photoreceptor-specific transduction was seen, with absence o f 
G FP expression in the RPE. Green, GFP; red, propidium iodide nuclear counterstain; RPE, 
retinal pigment epithelium; OS, outer segment; IS, inner segment; ONL, outer nuclear layer; 
OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GC, 
ganglion cell layer.
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Fig. 5.7: M OPS prom oter drives efficient transgene  expression in  rod photoreceptors
b u t not in cones; (image A taken using 16X objective lens, B using 40X lens, C is a 
magnified area of B) six weeks post-injection, confocal laser scanning microscopy shows 
that there is efficient transduction o f photoreceptors as evidenced by GFP expression. 
However, there is no co-localisation o f G FP with cone opsin staining (shown in red), 
indicating that all none o f the transduced cells are cones. The only cell in which red and 
green signals are apparently seen was shown to be two distinct cells in different slices o f a Z- 
stack image.
5.5 Investigating the effect o f  Prph2 expression on  
individual photoreceptors fo llow ing A AV-m ediated gene  
delivery
In order to follow whether individual photoreceptors survive for longer than 
untransduced neighbouring cells, we cloned the Prph2 cDNA downstream of the 
MOPS promoter described above, and in place of the p-Gal stuffer sequence an 
IRES.GFP sequence was sub-cloned; this gave pD10.MOPS.Prph2.IRES.GFP (Fig. 
5.5B). The MOPS promoter fragment was chosen as it has been previously validated 
in an AAV vector in terms of driving effective transgene expression in photoreceptors
[239]. Also, the MOPS promoter fragment, at less than 250 bp, was the only 
available promoter fragment that was small enough to allow the Prph2.IRES.GFP 
expression cassette to be packaged into the 4.8 Kbp AAV genome. The IRES was 
included in order to drive GFP expression and thus mark transduced cells, which by 
extension were expressing Prph2. Wild-type C57B1/6 mice received sub-retinal 
injection of recombinant AAV made using the MOPS.Prph2.IRES.GFP construct 
( lx l0 12 particles/ml); although fundoscopy showed extensive GFP expression in the 
retina (Fig. 5.8 A), injected eyes showed damage to retinal function as assayed by 
ERG (Fig. 5.8 B). A new batch of rAAV was made, and was shown not to reduce 
ERG b-wave amplitudes in wild-type mice eight weeks post-injection (data not 
shown). Hence this virus was used to treat Prph2Rd2mi mice. Six weeks after sub- 
retinal delivery of AAV.MOPS.Prph2.IRES.GFP (surgery performed at PND10), 
injected eyes had significantly higher b-wave amplitudes than uninjected control eyes 
(Fig. 5.9), and the average b-wave amplitudes obtained were comparable to those 
seen following treatment with AAV.Rho.Prph2. Four mice were sacrificed and their 
eyes processed for cryosectioning. In order to determine the proportion of GFP- 
positive (and hence Prph2-positive) photoreceptors in treated retinae, serial 
cryosections were taken at 10 pm thickness and at fixed positions in each eye 
confocal microscopy was used to generate images of equivalent areas in treated 
sectors of retina (Fig. 5.10A). By quantifying the average number of photoreceptors 
present (propidium iodide counter-stained nuclei, five images per eye), we confirmed 
that between the two time-points assessed, degeneration of the ONL was taking place; 
at six weeks post-injection there were 233.7 ± 27.7 photoreceptor cells per field of 
view, whereas at 12 weeks post-injection there were 174.7 ± 3.7 photoreceptors per 
field of view (Fig. 5.10B, p=0.02). The number of GFP-positive photoreceptor nuclei 
in the ONL of each image was quantified, and 10 images per eye were analysed in 
this manner. This gave an average number of GFP-positive nuclei per eye, which was 
plotted as a percentage of total cells in the same eye (Fig. 5.IOC). At six weeks post­
injection, 48.9 % ± 2.6 % of photoreceptors were GFP-positive (and, by extension, 
expressing Prph2). At 12 weeks there was a small reduction in the percentage of 
transduced cells, with 41.4 % ± 4 % of photoreceptors being GFP-positive; an 
unpaired Student’s T-test showed that this difference was statistically significant, 
albeit marginally so (p=0.04). This result indicated that individual photoreceptors that 
express AAV-mediated Prph2 do not survive for longer than untransduced
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neighbouring cells, and that there may be a small negative effect whereby transduced 
cells survive less when compared to untransduced cells. Overall this suggests that 
Prph2 expression does not confer a selective advantage to photoreceptors in 
Prph2Rdl,Kd2 retinae.
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Fig. 5.8: Sub-retinal delivery o f AAV.MOPS.Prph2.IRES.GFP to wild-type mice results in 
strong GFP expression and reduction in function; (A) six weeks post-injection, fundus 
examination of wild-type mice shows strong transduction o f over half the retinal area (left 
panel, light image; right panel, fluorescent image). (B) Average b-wave amplitudes recorded 
at 100- and 1000mcds/m2 show significant reduction in retinal function in eyes injected 
with AAV.MOPS.Prph2.IRES.GFP (235.5 pV ±  92 pV and 276.9 pV ± 90 pV at the 
respective intensities) compared to untreated contralateral eyes (372.5 pV ± 58.5 pV and 
445.3pV ±108  pV respectively, n — 6).
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Fig. 5.9: Sub-retm ai delivery oi A A V .M U t'& .t'rpnz.iK iiD .u^i' to r r p n z ^ 1*61 m ice 
results in significant im provem ent in retinal function; six weeks post-injection, scotopic 
ERG recordings show that eyes treated with AAV.MOPS.Prph2.IRES.GFP have 
significantly improved b-wave amplitudes (98 pV ±  31.4 pV) compared to untreated 
contralateral eyes (57.3 pV ± 22.6 pV) (p < 0.02, n — 8).
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Fig. 5.10: Sub-retinal delivery o f A A V .M O PS.Prph2.IR ES.G FP does no t confer 
selective advantage to transduced  cells in  P rpb2Rd2/Kd2 m ice; six-weeks post injection, 
cryosections were taken from treated eyes and confocal images taken at fixed positions in 
each eye. (A) representative image showing GFP-positive photoreceptors within PI- 
cunterstained outer nuclear layer. (B) Average number o f photoreceptors per field o f view at 
6 weeks post injection (235.7 ±  27.7) is significantly greater than at 12 weeks post-injection, 
demonstrating that between the two time-points analysed the outer nuclear layer was 
degenerating (p = 0.02, n — 4). (C) As a percentage o f total photoreceptor cells, there are 
fewer transduced cells surviving at 12 weeks post-injection (41.4 % + 4 %, p =  0.04, n — 4) 
than at six weeks post-injection (48.9 % + 2.6 %), suggesting there is no selective advantage 
conferred to cells that express Prph2 compared to non-transduced neighbouring cells.
5.6 A A V 2/5-m ediated  gene replacem ent therapy results in  
enhanced Prph2-m ediated functional im provem ent in  
Prph2Rd2/Rd2 m ice
In this chapter we have shown that Prph2 expression mediated by high-titre 
AAV2/2 is well tolerated in wild-type mice, but that sub-retinal delivery of this virus 
in PND7 mice did not result in enhanced improvement of retinal function compared to 
previous studies (Chapters 5.2, 5.3). We have also shown that reporter gene 
expression from an AAV2/5 vector encoding GFP is strong 15 days post-injection and 
reaches maximal levels 28 days post-injection (Fig. 5.11), whereas AAV2/2 is known 
to mediate only weak expression at these time-points and to give maximal expression 
six weeks post-injection [214,265]. We therefore decided to investigate whether a 
pseudotyped vector encoding Prph2 could mediate enhanced functional improvement 
in Prph2Rdl/Rd2 mice when compared directly with AAV2/2.
Fig. 5.11: AAV2/5 encoding G FP m ediates strong  transgene expression two weeks 
post-injection, earlier than  AAV2/2; cryosections taken from wild-type mouse eyes 
following sub-retinal delivery o f AAV2/5.CM V.GFP showing onset o f reporter gene 
expression at 15 days post-injection (A), and strong expression 21 days (B) and 28 days (C) 
post-injection. Courtesy o f Dr. M Rajah.
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Using the Sepharose-mucin FPLC protocol described in Chapter 3.4, 
AAV2/5.Rho.Prph2 was produced in order to validate this pseudotyped virus as a 
gene replacement vector in the Prph2Rd2IRdl mouse. AAV2/2.Rho.Prph2 was produced 
as previously described [246] as a control virus, and the titre of both AAV2/2- and 
AAV2/5.Rho.Prph2 was determined on the same dot blot to obtain an accurate 
measure of the number of genome particles produced; the AAV2/5 titre was shown to 
be 2x l013 genomes per ml, and the AAV2 titre was 2xl012 genomes per ml. In order 
to assess whether treatment with AAV2/5.Rho.Prph2 would result in enhanced 
functional rescue compare with AAV2/2.Rho.Prph2, Prph2RdlfRdl mice (post-natal 
day 10, n = 8) received sub-retinal injections of these viruses at equal titre (AAV2/5 
was diluted 1/10), with right eyes treated with AAV2/5 and left eyes with AAV2/2. 
Four weeks post-injection (this is the earliest time point at which ERG recordings can 
be reliably made in young mice) both AAV2.Rho.Prph2-treated eyes (96.2 pV ± 
31pV at 100mcds/m2) and AAV2/5-treated eyes (125.7 pV ± 22pV) showed b-wave 
amplitudes greater than those expected from untreated eyes (usually between 40 and 
60 pV at this age in Prph2Rd2/Rd2 mice) (Fig. 5.12). ERGs were then recorded every 
two weeks for 16 weeks, at which time point the animals were sacrificed. At all time 
points eyes treated with AAV2/5.Rho.Prph2 showed higher average b-wave 
amplitudes than those treated with AAV2.Rho.Prph2; this difference was statistically 
significant at weeks 8 (p=0.001), 10 (p=0.007), 12 (p=0.02) and 16 (p=0.04) post­
injection, and returned to being non-significant (p=0.055) at week 20 (Fig. 5.12). This 
indicates that AAV2/5 is able to mediate significantly enhanced functional 
improvement in this model of retinal degeneration when compared to titre-matched 
AAV2 that contains the same expression cassette. Following the final ERG recording 
20 weeks post-injection, the mice were sacrificed and processed for histological 
analysis by resin-embedded sectioning. Sections from AAV2/5-injected and AAV2/2- 
injected eyes were compared, there did not appear to be a greater number of cells 
surviving in eyes treated with AAV2/5 (Fig. 5.13A, B). We were unable to show 
intact outer segments persisting at this stage on electron microscopy (Fig. 5.13C, D).
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Fig. 5.12: A A V 2/5.R ho.Prph2 m ed iates enhanced  im provem ent in retinal function in
Prph2Kd2/Rd2 m ice w hen  com pared  to AAV2/2.Rho.Prph2; averaged b-wave amplitudes 
taken after injection o f  either AAV2/5.Rho.Prph2 (right eye) or AAV2/2.Rho.Prph2 (left 
eye) show that AAV2/5 results in higher amplitudes at all time points assessed.
Fig. 5.13: AA V2/5.Rho.Prph2 does not appear to delay photorecep tor cell loss w hen 
com pared to A AV2/2.Rho.Prph2; at five months post-injection, there are no more 
photoreceptors surviving in AAV2/5-treated eyes (B) compared with AAV2/2-treated eyes 
(A) as seen on semi-thin resin-embedded histological section. We were unable to show 
persistence of organised outer segments at this time-point upon electron microscopy in eyes 
treated with AAV2/2 (C) or AAV2/5 (D).
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5.7 Gene replacement therapy in the rdl and Rho/m models 
of retinitis pigmentosa
We decided to evaluate AAV2/5-mediated gene replacement therapy in the 
rdl mouse and the Rho1' mouse, two further models of retinal degeneration caused by 
mutations in photoreceptor-specific genes. A construct containing the canine P-PDE 
cDNA under the control of the CMV promoter was available, so rAAV was made 
using caesium chloride density centrifugation (courtesy of Dr. F. Rolling, INSERM 
Nantes, France), as previously described [268]. This virus was evaluated in vivo as a 
gene replacement vector. PND1 rdl mice (on a C3H genetic background) received 
double sub-retinal injections of 1 pi AAV2/5.CMV.pPDE virus suspension (5xlOn 
genomes/ml). Five and seven days post-injection, mice were sacrificed and their eyes 
processed for cryosectioning. Immunohistochemistry on 10 pm sections using a rabbit 
anti-serum raised against murine P-PDE revealed no staining in both treated and 
untreated eyes, whereas wild-type mice showed diffuse staining in the outer segments 
of photoreceptors (Fig. 5.14A and B). To ascertain whether the rabbit anti-serum 
cross-reacts with canine P-PDE, immunohistochemistry was performed on sections 
taken from wild-type and rcdl dogs. This revealed faint but apparently specific 
staining in the outer segments of wild-type dog retinae, with absence of staining in the 
diseased retinae (Fig. 5.14C and D). This indicated the absence of p-PDE 
immunostaining in the AAV2/5-treated rdl eyes was not due to the 
immunohistochemistry failing to detect canine P-PDE protein, but due to a likely 
failure of the AAV2/5 to efficiently produce transgene. A new batch of 
AAV2/5.CMV.PPDE was isolated, this time using the sepharose-mucin purification 
method described in Chapter 3. This virus was evaluated in vitro for its ability to 
produce p-PDE protein; we were able to use a newly available polyclonal antibody 
(AbCam, Cambridge, UK) raised against p-PDE to detect expression. 293T cells were 
seeded at an approximate density of 50,000 cells per well in a 24-well plate and 1 pi 
AAV2/5.CMV.PPDE (2xl012 genomes/ml) was added in triplicate. As controls, wells 
were transfected with pD10.CMV.pPDE, to verify whether the expression cassette 
itself was able to produce mature protein in vitro.
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Fig. 5.14 A A V 2/5-m ediated gene rep lacem ent therapy in  r d l  m ouse does no t result 
in  detec tab le  (3-PDE pro tein  production; immunohistochenistry performed on frozen 
sections taken from (A) wild-type mouse (diffuse green staining in outer segments is (3- 
PDE); (B) rdl mouse treated with AAV2/5.CMV.(3PDE at P I and sacrificed at P l l  (no 
immunostaining is seen in any retinal layers); (Q  wild-type dog section (faint punctuate 
green immunofluorescence corresponds to (3-PDE; (D) rcdl dog, in which absence o f green 
staining seen in (C) indicates that the antibody used cross-reacts with canine p-PDE protein.
Infection of 293T cells using AAV2/5.CMV.pPDE did not result in detectable levels 
of p-PDE protein, whereas plasmid transfection using pD10.CMV.pPDE (the plasmid 
containing AAV2 ITRs that was used to make rAAV) does result in specific pPDE 
staining, indicating that the expression cassette is able to drive production of PPDE 
protein (Fig. 5.15A-C). The pPDE cDNA was also sequenced, which confirmed that 
the full-length coding sequence had been cloned into the pDIO plasmid. 
AAV.CMV.hrGFP was also infected into 293T cells at the same time, to confirm that 
in vitro infection of virus leads to transgene expression (Fig. 5.15D). Because the 
sequence of the cDNA was correct, the plasmid construct was shown to give 
transgene expression and the titre of the rAAV was high (5x10 genomes/ml), we 
decided to administer the AAV.CMV.pPDE by sub-retinal injection to PI rdl mice, 
to evaluate its efficacy in this model of RP. As seen previously, no pPDE expression 
was seen on cryosections of rdlmicQ sacrificed ten days post-injection. Interestingly,
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no immunostaining was detected in the RPE; as AAV2/5 is known to transduce the 
RPE, and a ubiquitous promoter sequence was used in the expression cassette, we had 
expected to see some transgene expression in the RPE.
Fig. 5.15: Infection of 293T cells w ith  AA V2/5.CM V.pPD E does no t result in 
detectable P-PDE protein  production  in  v itro , w hereas p lasm id transfection  w ith 
pD10.CM V.pPDE does; in vitro immunocytochemistry performed on 293T cells following 
(A) infection with AAV2/5.CMV.pPDE; (B, C) plasmid transfection with 
pD10.CMV.pPDE; (D) infection with AAV2/5.CMV.hrGFP; (E) no treatment. (A) shows 
no cells stained with anti~P-PDE antibody, only DAPI counter-stained nuclei (blue). (B) 
shows P-PDE staining in cell bodies o f approximately 20% o f cells following plasmid 
transfection; (C) is higher-magnification view o f cells in (B). (D) shows that AAV2/5 is able 
to efficiently infect 293T cells, with hrGFP fluorescence (green) in approximately 50% of 
cells. All cells counterstained with DAPI, images taken at 20X magnification except (C), 
which is at 40X.
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We also attempted to rescue the Rho'' mouse by using sub-retinal delivery of AAV2/5 
encoding the human Rhodopsin cDNA. The cDNA was obtained as a kind gift from P. 
Humphries (Trinity College, Dublin, Ireland), and was sub-cloned into our AAV2 
ITR plasmid pDIO to give AAV.boRho.huRho, in which the human Rhodopsin gene 
is driven by the same bovine rhodopsin promoter that is used in our AAV.Rho.Prph2 
construct (sub-cloning carried out by Dr. A. MacNeil). rAAV was produced and 
purified using the sepharose-mucin chromatography method described in Chapter 3. 
Mice were treated at PND 10, and ERG recordings taken 10 days post-injection 
showed that at 100 mcds/m2, both treated and untreated eyes had negligible b-wave 
amplitudes characteristic of the rhodopsin knock-out mouse (Fig. 5.16A). We were 
unable to detect rhodopsin immuno-staining in treated eyes sacrificed 21 days post­
injection (Fig. 5.16C), whereas sections from wild-type mice showed strong staining 
in photoreceptor outer segments (Fig. 5.16B).
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Fig. 5.16: Sub-retinal injection of AAV.boRho.huRho does not result in improved 
retinal function as assessed by ERG; (A) ten days post-injection, ERG recordings taken 
from Rho1' mice treated with AAV.boRho.huRho showed no improvement in b-wave 
amplitudes in treated eyes when compared with untreated contralateral eyes. At 1000 
m cds/m 2 there are cone-derived b-waves recorded from both eyes, but treated eyes do not 
have greater amplitudes than untreated eyes. (B) Whereas wild-type eyes show strong 
staining in the inner/outer segments for Rhodopsin (red), Rho1 eyes treated with 
AAV.boRho.huRho show no Rhodopsin staining.
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4.8 Discussion
Having established that high-titre AAV-mediated Prph2 expression does not 
significantly reduce retinal function as assayed by ERG, we used several approaches 
to improve the efficiency of Prph2 gene delivery to the Prph2Rd2fRdl retina. The first 
approach was to use these higher-titre viral preparations, and to perform sub-retinal 
injections at earlier time-points than previously attempted to initiate therapeutic gene 
expression earlier. However, there was no additional benefit of this strategy in terms 
of improved ERG b-waves; the extra trauma of surgical intervention at an earlier age 
seems to negate the benefit of having an earlier onset of gene expression. This finding 
is corroborated by data from experiments investigating the consequences of sub- 
retinal injections in both neonatal and adult mice; it was determined that injection of 
more than 1.5 pi PBS in PND 10 mice caused significant damage to retinal function as 
assessed by ERG, as did repeated injections at PND 10 and PND 15 (personal 
communication, Dr. M. Rajah). This damage was greater if the injection volume was 
increased, or if the surgery was performed at earlier time-points. Therefore in all 
subsequent experiments we used an injection volume of 1.5 pi to deliver high-titre 
virus and performed sub-retinal surgery in two hemispheres of the eye at PND 10 to 
ensure minimal damage was caused; this enabled optimal b-wave amplitudes to be 
recorded, as seen in Chapters 5 and 6.
We have described the use of a novel promoter derived from the proximal region of 
the mouse opsin gene to drive transgene expression in photoreceptors. This expression 
is restricted to the outer nuclear layer, with no RPE expression detected. The MOPS 
promoter was subsequently evaluated in a gene replacement strategy in which 
efficient RPGRIP expression was seen in rods that lead to restoration of the 
connecting cilium trafficking defect and long-term improvement in ERG in the 
RPGRIP'/_ mouse [239]. The data from that study confirmed that the MOPS promoter 
drives strong transgene expression in rod cells. The lack of transgene expression in 
cone cells that is described above appears to contradict a previous report suggesting 
that a similar fragment of the mouse opsin promoter does drive expression in cones 
[282]. However this study differed from ours in certain respects. Firstly, we used a 
different fragment of the proximal region of the mouse rhodopsin gene (nucleotides -
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218 to +17 relative to start codon) than the authors of this study used (-385 to +86). It 
is difficult to say whether this affected the ability of our promoter to mediate 
transgene expression in cone cells. In addition our method of analysing cone-specific 
gene expression was also different; whereas it appears that Glushakova et al used 
standard fluorescent microscopy and a digital camera for imaging their cryosections, 
we used a confocal scanning laser microscope, which provides greater resolution 
within single optical slices of 1 pm in thickness. This technique allows greater 
certainty in co-localisation studies, meaning that whilst on a fluorescent micrograph a 
cell may appear to be expressing both PNA and GFP, the two fluorescent signals may 
originate in two different cells that lie adjacent to or above one another. We therefore 
report that, using confocal imaging, we were unable to see any PNA-positive cone 
cells that co-expressed GFP, whereas upon light microscopy some cells did appear to 
express both markers.
By investigating the effect of transduction with a Prph2 cDNA on the survival of 
photoreceptors over time, our findings suggest that there is no selective advantage 
conferred to transduced rod cells when compared with untransduced neighbouring 
cells. Indeed, there may be a small effect to the contrary, as it appears that 7.5 % 
fewer surviving cells are transduced at 12 weeks post-injection than at 6 weeks post­
injection. Although it is not likely that this small reduction in survival of transduced 
cells is due to a specific toxic effect of Prph2 cDNA expression, it does warrant 
further investigation. It may be that the GFP expression driven by our 
MOPS.Prph2.IRES.GFP construct causes some toxicity, as has been seen with high- 
level GFP expression in the past [283].
We have also shown that AAV2/5 mediates efficient gene replacement therapy in 
Prph2Rd2IRd2 mice, which results in significantly better ERG b-wave amplitudes than 
seen with AAV2. This result validates the use of AAV2/5-mediated gene replacement 
for photoreceptor-specific disorders, although there does not appear to be any effect 
on the rate of photoreceptor cell loss; this is discussed in more detail in Chapter 7. 
Despite the enhanced functional rescue seen in this model following treatment with 
AAV2/5.Rho.Prph2, using pseudotyped AAV does not appear to result in efficient 
gene replacement therapy in the rdl mouse or the Rho'1' mouse. We have shown that 
the expression cassette drives efficient gene expression following in vitro plasmid
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transfection, but that in vivo we see no photoreceptor cells expressing P-PDE 
following administration of virus. It is therefore not possible to conclude whether the 
rdl mouse can be effectively treated using a pseudotyped AAV vector, and this 
warrants further investigation as discussed in Chapter 6. Similarly, the apparent 
failure of AAV2/5.boRho.huRho to mediate efficient transgene expression in the 
rhodopsin knock-out mouse warrants further investigation; although the sequence of 
both the promoter element in the construct and the cDNA have been verified, it is not 
clear whether the rAAV drives expression of Rhodopsin in vitro. The use of a 
photoreceptor-specific promoter makes it technically challenging to assess this 
construct in vitro, as we are unable to reliably culture photoreceptor-derived cell lines. 
Cell lines such as Y79 cells have been described [47], which if cultured successfully 
would allow in vitro testing of constructs driven by photoreceptor-specific promoters 
such as MOPS and Rho.
143
6 Neuropfotection in combination with gene 
replacement therapy in rodent models o f RP
6.1 Introduction
As discussed in Chapter 1.14, many gene replacement strategies provide only 
transient improvement in retinal function, and, with a few notable exceptions are 
unable to delay or prevent the apoptotic loss of photoreceptors. With delivery of 
recombinant growth factors failing largely due to their very short ocular half-lives, 
viral vectors have been used to deliver genes encoding neurotrophic factors to delay 
apoptosis in retinal degeneration. However, of major concern is the deleterious effect 
on retinal function, both in models of retinitis pigmentosa and in wild-type rodents, 
that results from AAV-mediated CNTF delivery [253-255]. The aim of the 
experiments in this chapter is to investigate whether the reduction in ERG b-wave 
mediated by CNTF is dependent on the dose administered, and if so whether a dose 
can be identified that does not reduce normal retinal function but that enhances gene 
replacement therapy by delaying photoreceptor loss. In addition, the long-term 
consequences of CNTF gene delivery are investigated in a model of retinal 
degeneration in which retinal function and photoreceptor numbers decline gradually 
over a period of one year.
Glial cell line-derived neurotrophic factor has shown much promise in gene therapy 
applications in the CNS, but is yet to be extensively studied as a neuroprotective agent 
in retinal degeneration. Therefore we have evaluated GDNF in terms of its effect on 
normal retinal function, in order to determine whether GDNF exerts similar 
deleterious effects to CNTF. We have also evaluated the efficacy of AAV-mediated 
GDNF expression to enhance gene replacement therapy in two rodent models of 
retinitis pigmentosa, in order to assess whether GDNF is able to enhance the 
morphological and electrophysiological improvements seen following gene 
replacement.
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6.2 Deleterious effects of AAV-mediated CNTF expression 
are dose-dependent
In order to investigate whether the detrimental side effects of AAV-mediated 
CNTF expression are dose-dependent, we carried out a dose response experiment in 
vitro and in vivo. To determine whether a reduction in particle titre of 
AAV.CMV.CNTF results in a reduction of CNTF production, a sandwich ELISA was 
performed to determine the level of CNTF protein produced. 50,000 293T cells were 
seeded per well of a 24-well plate, and 5x108, 5x107 and 5x106 particles of 
AAV.CMV.CNTF were added to the wells in triplicate. The amount of CNTF protein 
present in the supernatant was dependent on the dose of virus (Fig. 6.1); the cells 
infected with 5x108 particles gave the highest level of CNTF protein (20.6 ng/ml ±1 
ng/ml), with a 1/10 dilution giving an intermediate amount (8 ng/ml ±2.1 ng/ml) and 
the 1/100 dose resulting in the lowest amount of CNTF protein produced (3.4 ng/ml 
±0.4 ng/ml). We injected three groups of two month-old wild-type CBA mice with a 
dilution series of AAV.CMV.CNTF virus; (lxlO 10 genomes/ml, as used previously 
[255], and 10- and 100-fold dilutions of this stock). Right eyes were injected in 
superior and inferior hemispheres with 2 pi of the appropriate dilution, with left eyes 
serving as uninjected controls. Six weeks and two months post-injection, pan-retinal 
function was assessed by ERG. A severe deleterious effect on retinal function was 
observed in the group of mice injected with the highest concentration of virus (Fig. 
6.2); injected right eyes showed a 40 % reduction in ERG b-wave amplitude as 
compared with uninjected contralateral control eyes (p=0.01). Mice injected with a 
1/10 dilution of the neat virus showed a smaller decrease in b-wave amplitude (24 %), 
whilst the group of mice that received a 1/100 dilution showed no significant change 
in ERG. This clearly demonstrates the dose-dependent relationship between AAV- 
mediated CNTF expression and reduction in retinal function.
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Fig. 6.1: Amount o f CN TF protein produced in vitro following infection with 
AAV.CMV.CNTF is dose-dependent; 50,000 293T cells were infected with 5xl08, 5xl07 
or 5xl06 virus particles, and CNTF production assessed by sandwich ELISA. CNTF was 
significantly higher in cells that received the highest dose compared with the 1/10 dilution 
(p<0.02) and with the 1/100 dilution (p<0.01).
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Fig. 6.2: Reduction in retinal function following AAV-mediated CNTF delivery is 
dose-dependent; In wild-type mice sub-retinal injection o f AAV.CMV.CNTF at the 
highest dose (CNTF 1, 5x l010 particles per ml) resulted in a large reduction in ERG b-wave 
amplitude (40 %, n = 4, p = 0.01) in treated eyes when compared with untreated eyes. A ten­
fold dilution o f the virus (CNTF 1/10) resulted in an intermediate level o f reduction in 
function (24 %, n -  4, p =  0.009), and a 100-fold dilution (CNTF 1/100, n — 4) resulted in 
no significant reduction in function. ERG recordings taken at (A) six weeks and (B) eight 
weeks post-injection.
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6.3 Reducing the dose of CNTF vims precludes 
neuroprotection
Having demonstrated that the deleterious effects mediated by CNTF are dose 
dependent in wild type mice, we used the lowest titre of AAV.CMV.CNTF (CNTF 
1/100, equivalent to 1x10s genomes/ml) to determine whether this dose was able to 
enhance gene replacement therapy in the Prph2R<niM2 mouse. At post-natal day 10 
Prph2R61/RA1 mice received double sub-retinal injections of a combination of the 
diluted AAV.CMV.CNTF virus and AAV.Rho.Prph2 in the right eye, with left eyes 
receiving AAV.Rho.Prph2 only (n = 6, total volume injected per hemisphere 1.5 pi). 
No significant increase in b-wave amplitude was noted in eyes treated with a 
combination of AAV.CMV.CNTF and AAV.Rho.Prph2 over eyes treated with gene 
replacement only (Fig. 6.3A). This suggests that treatment with the reduced dose of 
CNTF does not result in enhanced function when compared with gene replacement 
alone.
An additional group of Prph2Rd2/Ri2 mice (n = 4) received sub-retinal injections of the 
diluted AAV.CMV.CNTF virus alone in their right eyes, with left eyes remaining 
uninjected; these eyes were assessed histologically two months post-injection, to 
determine whether the reduced dose of CNTF still allows enhanced photoreceptor 
survival in this model. No increase was seen in the numbers of photoreceptor cells 
surviving in treated eyes (Fig. 6.3B). These data suggest that when delivered at a 
lower dose, although CNTF causes no detriment to function in wild-type retinae, it no 
longer prolongs photoreceptor cell survival in the Prph2Rd2/Rdl model of retinal 
degeneration.
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Fig. 6.3: Reducing CNTF dose precludes neuroprotection in Prpb2Kd2/Kd2 mouse; (A)
there is no  significant difference in ER G  b-wave amplitudes in Prph2Rd2^ Rd2 mice following 
co-injection o f  AAV.CMV.CNTF (CNTF 1/100) and AAV.Rho.Prph2, when compared 
with injection o f  AAV.Rho.Prph2 alone (» =  4). (B) There is no significant difference in the 
num bers o f  surviving photoreceptors in Prph2Rd2/Kd2 mice following injection o f diluted 
AAV.CM V.CNTF (CNTF 1/100) when compared with uninjected control eyes. 
Photoreceptor numbers were quantified by taking photomicrographs o f sections at fixed 
positions from  a serially sectioned orientated eye.
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6.4 Long-term CNTF expression in Prph2?d2U mice results 
in reduced function and photoreceptor damage
CNTF gene delivery that prevents photoreceptor death also results in a 
diminished ERG, but if this is stably maintained until beyond the point at which 
untreated eyes have no function, RP patients may benefit from CNTF-mediated 
photoreceptor survival. In order to determine whether this might be the case, we 
evaluated the effects of AAV-mediated CNTF expression in Prph2R<n/+ mice, a 
murine model of RP with a slow rate of degeneration. In Prph2Rd2l+ mice, 
photoreceptors are lost gradually, with the ERG declining from near wild-type levels 
to around 50 % thereof at one year of age [284]. We treated Prph2Rd2l+ mice with 
intravitreal injection of AAV.CMV.CNTF (at a titre of lxlO10 genomes/ml, which has 
been shown to prevent cell death whilst reducing retinal function) and followed the 
animals’ retinal function, as assayed by ERG, over nine months. Five months post­
injection the damage to retinal function was apparent; ERG traces were markedly 
reduced in CNTF-treated eyes as compared with uninjected internal control eyes and 
eyes that had received intravitreal injection of AAV.CMV.GFP as a control (Fig. 
6.4A). Rather than observing a diminished ERG that is stably maintained, we 
observed that retinal function in CNTF-treated eyes became progressively worse over 
time with decreased b-wave amplitudes even at long-term time-points five and nine 
months post-injection (Fig. 6.4B).
Twelve months post-injection the mice were sacrificed and enucleated, and the eyes 
were processed as follows: after eyecup dissection where the lens and cornea were 
removed, half of the neurosensory retina was processed for cryosections and half for 
resin-embedded semi- and ultra-thin sections. Immunohistochemistry performed on 
cryosections (see Chapter 2.5.3 and Appendix I) showed that eyes treated with 
AAV.CMV.CNTF had greatly reduced levels of cone opsin staining (Fig. 6.5B, C) 
when compared with untreated eyes (Fig. 6.5A); some sections taken from CNTF- 
treated eyes contained one or two opsin-positive cells only (Fig. 6.5B), whereas most 
sections had no cone opsin immunopositivity at all (Fig. 6.5C). Even where there was 
cone opsin staining in CNTF-treated eyes, the cone opsin was often mis-localised in 
the inner segment and the cell bodies, an example of which is shown in Fig. 6.5D.
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Fig. 6.4: AAV-mediated CNTF expression reduces retinal function in Prpb2K62/Jr 
mice; (A) E R G  intensity series, from  a Prph2Kd2/+ mouse five m onths after intravitreal 
injection o f AAV.CMV.CNTF (1 x 1010 genom es/m l) in one eye. There is a decline in 
function in the injected eye (left panel) when compared with the uninjected contralateral eye 
(right panel). Light intensity shown to the right o f each trace in m cds/m 2. (B) b-wave 
amplitudes from  Prph2Kd2/+ mice following monocular intravitreal injection o f either 
AAV.CM V.CNTF or AAV.CMV.GFP (6 animals in each group). A t one m onth post­
injection, CN TF treated eyes have lower b-wave amplitudes than their uninjected 
contralateral eyes (CNTF untreated), as well as G FP treated eyes and their uninjected 
contralateral eyes (GFP untreated). These reduced amplitudes continue to deteriorate and 
remain lower than controls.
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Fig. 6.5: AAV-m ediated C N T F  expression causes loss of cone opsin  expression bu t 
no t loss o f cone cells in  P rph2nd2/+ m ice; (A) Cone opsin staining in untreated Ptph2Kd2/+ 
eye at 15 months o f age. Some sections from Ptph2Rd2/+ eyes treated with AAV.CMV.CNTF 
have small numbers o f cone opsin-positive photoreceptors (B), but most sections show no 
cone opsin staining at all (C). Where cone opsin is present in CNTF-treated eyes it is 
mislocalised to the inner segment and cell body (D). (E) Peanut agglutinin (PNA) staining in 
untreated Pfpb2Kd2/+ eye (green) that localises to the inner and outer segment sheaths. PNA 
staining in CNTF-treated eyes is disorganised and some staining is seen in the outer nuclear 
layer (F). PNA and cone opsin staining can be co-localised in untreated Prph2Kd2/+ eyes (G), 
but not in CNTF-treated eyes.
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In addition, the outer nuclear layer in CNTF-treated eyes appeared thinner and 
contained fewer photoreceptor nuclei, which was subsequently confirmed using resin- 
embedded sections (see below). To determine whether the reduction in cone opsin 
staining was due to loss of cone photoreceptors, or due to cones no longer expressing 
opsin despite surviving, peanut agglutinin (PNA) staining was combined with cone 
opsin staining. PNA is a lectin molecule that binds specifically to galactose- 
galactosamie disaccharide residues found on the sheaths that surround cone inner and 
outer segments [281], and as such is used to stain for cone photoreceptors. PNA 
staining was found to be largely normal in untreated Prph2Kd2l+ retinae, with cone 
inner- and outer segments being clearly demarcated by this lectin (Fig. 6.5E). CNTF- 
treated eyes showed PNA staining that was disorganised, with no defined inner and 
outer segments visible and mis-localised in the outer nuclear layer (Fig. 6.5F). The 
inner and outer segments may have appeared disorganised because the photoreceptors 
in the CNTF-treated eyes seem to be at a more advanced stage of degeneration, with 
more cells having been lost. However, we were able to detect cone opsin and PNA 
double stained cells in the untreated eyes (Fig. 6.5G), indicating that cone cells were 
surviving and continued to express cone opsin at this time point in Prph2R<n/+ mice. 
However, in CNTF-treated eyes, virtually no PNA-positive cells co-expressed cone 
opsin; the number of PNA-positive cone cells in comparable regions of the retina 
appeared similar, but these cones were no longer expressing cone opsin. Using semi- 
thin resin-embedded sections the number of photoreceptors in the outer nuclear layer 
of CNTF-treated eye was determined; when compared with untreated eyes, CNTF- 
treated eyes had fewer photoreceptors surviving, indicating that rather than 
prolonging photoreceptor survival, long-term CNTF expression causes accelerated 
degeneration in this model of RP.
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6.5 AAV-mediated GDNF expression enhances retinal 
function in combination with gene replacement in Prph2Rd2/Rd2 
mouse and RCS rat
In order to assess the potential of GDNF as a neuroprotective agent, we 
constructed an AAV vector containing a mouse GDNF cDNA under the control of a 
CBA promoter. The GDNF gene was available in an AAV2 plasmid downstream of a 
CMV promoter; however, there was also another CMV sequence and the eGFP gene 
in the same expression cassette. This repetition of the CMV promoter within the 
expression cassette meant the pD10.CMV.GDNF.CMV.GFP plasmid was highly 
prone to recombination, and previous attempts to produce rAAV using this construct 
resulted in infectious virus that expressed GFP in vitro, but GDNF protein production 
was below the detection limit of the sandwich ELISA used to assess GDNF levels 
(data not shown). The GDNF cDNA was therefore sub-cloned from this plasmid by 
digestion with SphI, followed by Vent polymerase end-filling, and Not I  digestion; this 
gave a 1400 bp fragment consisting of the proximal CMV immediate early enhancer 
and the GDNF cDNA. This was ligated to a 7.3 kb fragment derived from 
pD10.CBA.IGFl.IRES.GFP, that had also been digested using the same enzymes, in 
place of the IGF1 cDNA. As the CBA promoter fragment is made up of the proximal 
CMV enhancer sequence and the promoter region from the chicken fi-actin gene, 
ligating the two fragments together reconstituted the full-length CBA promoter (Fig. 
6.6). This new plasmid, pD10.CBA.GDNF.IRES.GFP, was used to make recombinant 
AAV, and this was assessed in vitro for its ability to produce GDNF protein. An 
ELISA was performed on supernatants collected from 293T cells infected with 
AAV.CBA.GDNF; supernatants from uninfected cells and cells infected with an 
unrelated virus (AAV.CMV.IL10) were used as control samples. Both control groups 
showed no detectable GDNF production above the lower detection limit of the assay 
(8 pg/ml). In contrast, cells infected with 2xl09 particles of AAV.CBA.GDNF gave 
3074 pg/ml (±130 pg/ml), and those infected with 2xl07 particles gave a lower level 
of GDNF protein (1012 pg/ml, ± 146 pg/ml). This showed the vector is effective at 
producing high levels of GDNF protein.
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Fig. 6.6: Sub-cloning strategy used to  generate AAV plasm id contain ing G D N F  
cD N A  upstream  of IR E S.G FP sequence; the G D NF  cDNA was excised from 
pD10.CM V.GDNF.CM V.GFP along with part o f the CMV promoter, and ligated to a 
fragment o f pD10.CBA.IGFI.IRES.GFP, which reconstituted the full-length CBA promoter 
and gave pD10.CBA.GDNF.IRES.GFP.
To assess the impact of this vector on normal retinal function in vivo, wild-type 
C57/B16 mice received sub-retinal injections of AAV.CBA.GDNF (2x1012 
particles/ml) in the right eye (2 pi), with left eyes left untreated. ERG recordings from 
dark-adapted mice were taken eight weeks post-injection. AAV-mediated GDNF 
expression did not affect normal retinal function as assayed by electroretinography 
(Figs. 6.7A and B); GDNF-treated eyes had ERGs with normal waveform and a- and 
b-wave amplitudes, with no statistically significant reduction in average b-wave 
following AAV-mediated GDNF expression.
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Fig. 6.7: AAV-mediated GDNF expression is well-tolerated in wild-type mice;
Representative (A) and averaged (B) ERG  recordings from six wild-type mice six weeks 
after sub-retinal injection o f AAV.CBA.GDNF show normal waveform and a- and b-wave 
amplitudes in injected eyes (A left panel) when compared with uninjected contralateral eyes 
(A right panel). (B) N o significant difference is seen between averaged b-wave values from 
the animals described in (A) (p > 0.05).
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We therefore treated both Prph2Rd2/Rdl mice and RCS rats with the same vector. At 
post-natal day 10 one group of Prph2RdirRdl mice received sub-retinal injections of 
AAV.CBA.GDNF alone in the right eye (1.5 pi), with the left eyes serving as 
uninjected controls. The GDNF-treated eyes showed no significant functional 
improvement as compared with the control eyes (Figs. 6.8A and B); this is to be 
expected, as in the absence of gene replacement therapy, Prph2Rd2fRdl mice have 
negligible retinal function owing to the absence of photoreceptor cell outer segments. 
A further group of Prph2Rd2/Rdl mice received sub-retinal injections of a combination 
of AAV.CBA.GDNF and AAV.Rho.Prph2 viruses in the right eye, and of 
AAV.Rho.Prph2 virus alone in the left eye (n = 6). These mice were treated at post­
natal day 10, and received a total of 1.5 pi of virus solution per hemisphere. At two 
and three months post injection, the eyes that received gene replacement in 
combination with GNDF show significantly enhanced b-wave amplitudes when 
compared with contralateral control eyes that received gene replacement alone; 
Prph2Rd2IRdl eyes treated with combination of AAV.CBA.GDNF and 
AAV.Rho.Prph2 show 51 % higher b-wave amplitudes (p=0.007) than eyes injected 
with AAV.Rho.Prph2 only (Fig. 6.8A and B). When ERG recordings were taken four 
months post injection, despite a small b-wave being recorded from both eyes, there 
was no longer a significant difference between b-wave amplitudes from eyes treated 
with the combination of GDNF and gene replacement when compared with and eyes 
treated with gene replacement only (Fig. 6.8C).
156
GDNF + Prph2 Prph2 only
20 ms per division 20 ms per division
B
3  20
(8 1 0 0  i
Treatment Groups
o
a  eo
t  ■ Prph2
■ rL^ ~ d
Treatment Groups
GDNF only 
l Untreated 
GDNF + Prph2 
 only
C 70
5  30
■ GDNF ONLY
□ Untreated
□ Rph2 + GDNF
■ RDS ONLY
Treatment Groups
Fig. 6.8: AAV-m ediated G D N F  delivery enhances im provem ent in  retinal function 
following gene rep lacem ent therapy in Prpb2Kd2/Rd2 m ice; (A) Representative ERG 
traces recorded 2 months post-injection from Prpb2Kd2/Kd2 mice treated with combination of 
AAV.CBA.GDNF and AAV.Rho.Prph2 in one eye (left panel) and AAV.Rho.Prph2 only in 
the contralateral eye (right panel). For reference, traces at 100mcds/m2 from a Prph2Kd2/Kd2 
mouse treated with G D N F only are shown (*). (B) Averaged b-wave values taken from the 
mice described in (A) (« = 6). Upper graph is from two months post-injection, lower graph 
is three months post-injection. (C) Four months post-injection, there is no longer a 
significant difference in b-wave amplitude between eyes treated with the combination of 
AAV.CBA.GDNF and AAV.Rho.Prph2 and those treated with AAV.Rho.Prph2 only
(p>0.06).
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RCS rats were also treated with AAV.CBA.GDNF, to assess the ability of GDNF to 
slow PR cell death in another model of RP. The first group of rats (n=6) received sub- 
retinal injections of AAV.CBA.GDNF in the right eye (5 pi per hemisphere, superior 
and inferior hemispheres injected) whilst the left eye was left uninjected (injections 
performed at post-natal day 12). Eyes treated with AAV.CBA.GDNF alone (66.8 pV 
± 27.6 pV) show a four-fold increase in ERG b-wave amplitude when compared with 
untreated contralateral eyes (16.2 pV ± 5.9 pV) at six weeks post-injection (p = 
0.007) (Fig. 6.9A and B). At eight weeks post-injection there is no longer a 
significant difference between GDNF-only treated eyes and untreated contralateral 
eyes. When used in combination with gene replacement therapy, however, AAV- 
mediated GDNF expression does produce a potent functional benefit when compared 
with gene replacement alone. We used a combination of Lenti.Mertk (50 ng p24 per 
ml) and AAV.CBA.GDNF, injected into the sub-retinal space of post-natal day 12 
RCS rats, with the left eyes receiving the Lenti.Mertk virus alone. In all cases the rats 
received 5 pi of total virus in both the superior and inferior hemispheres. At six weeks 
post-injection, significantly enhanced ERG b-wave amplitudes were recorded from 
eyes treated with the combination of AAV.CBA.GDNF and Lenti.Mertk (159.1 pV ± 
36 pV) when compared with internal control eyes that received Lenti.Mertk only 
(105.9 pV ± 23.4 pV, p = 0.002) (Figs. 6.9A and B). This remained the case at eight 
weeks post treatment, with eyes treated with the combination of GNDF and Mertk 
showing significantly higher b-wave amplitudes than eyes treated with Mertk alone 
(Fig. 6.9C).
This enhanced function at six and eight weeks post-injection suggests that GDNF is 
able to exert an additive effect on the functional the benefit mediated by gene 
replacement in the RCS rat, as is seen in the Prph2RdllRd2 mouse. The effect of using a 
combination of neurotrophic gene delivery and gene replacement is marked in both 
models tested. In the Prph2R<32/Rd2 mouse, the combination of AAV-mediated GDNF 
expression and gene replacement therapy results in a 2.5-fold improvement in ERG b- 
wave amplitude when compared with no intervention, whereas treatment with the 
combination of AAV.CBA.GDNF and Lenti.Mertk results in almost an ten-fold 
increase in retinal function as compared with untreated eyes.
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Fig. 6.9: AAV-mediated G D N F  delivery enhances im provem ent in  retinal function 
following gene rep lacem ent therapy in RCS rats; (A) Representative traces from RCS rats six 
weeks post-injection. Upper panel, traces from AAV.CBA.GDNF-only treated eye (left) and 
untreated control eye (right) from one rat. Lower panel, traces from an eye treated with a 
combination o f AAV.CBA.GDNF and Lenti.Mertk (left), compared with traces from 
Lenti.Mertk-only treated eye (right). (B) Averaged b-wave amplitudes from animals described in 
(A). AAV-mediated G D N F  delivery alone results in a four-fold increase in b-wave amplitude 
over untreated control eyes (p=0.007). When combined with Lenti-Mertk-mediated gene 
replacement, AAV-mediated G D NF  expression results in a 50 % increase in b-wave amplitude (p 
= 0.002) as compared to gene replacement alone. (C) A t 8 weeks post-injection, combination- 
treated eyes still show significantly higher b-wave amplitudes (p = 0.03) compared to 
Lenti.Mertk-treated eyes.
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The later time points used in this study show that the enhanced function resulting 
from AAV-mediated GDNF delivery is not maintained beyond two months in the 
RCS rat and three months in the Prph2Rd2/Rdl mouse. This may be primarily due to the 
use of a pan-retinal measure of retinal function being assayed; the area of the retina 
treated with the gene replacement and neurotrophic vectors may well retain higher 
levels of function than can be determined by a pan-retinal ERG, and the histological 
preservation of photoreceptors seen following sacrifice at these time points suggests 
this could be the case.
6.6 AAV-mediated GDNF expression enhances 
photoreceptor survival in combination with gene replacement 
in Prph2Rd2/Rd2 mouse and RCS rat
The treated Prph2Rd2/Rd2 mice were assessed histologically following their 
final ERG recordings, at four months post-injection. Mice were sacrificed, their eyes 
processed for paraffin sectioning and cell numbers in treated areas were quantified 
and compared with corresponding areas in untreated or control eyes. For the 
quantification, photomicrographs were taken at fixed positions within injected areas 
using a 20x objective lens, and the number of photoreceptors in the field of view 
counted. Five images were taken per eye, and equivalent areas were used from 
internal control eyes; four eyes were used per group. When Prph2Rd2/R<n mice were 
treated with AAV.CBA.GDNF alone, 25 % more photoreceptors were present in 
treated eyes when compared with untreated controls (p=0.009) (Figs. 6.10A, 6.10B 
and 6.12A). This effect is even more pronounced when AAV.CBA.GDNF is used in 
combination with gene replacement therapy in this model. Eyes treated with a 
combitiation of AAV.CBA.GDNF and AAV.Rho.Prph2 have on average 74 % more 
photoreceptors surviving at four months post-treatment than contralateral eyes that 
were treated with AAV.Rho.Prph2 only (p=0.04) (Figs 6.1C, 6.10D and 6.12B).
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Fig. 6.10 — E n h an ced  preservation of photorecep tors in Prph2Rd2/Ri2 m ice following 
A A V -m ediated G D N F  delivery: Representative photomicrographs o f H & E stained 
paraffin sections, taken using a 20X objective lens, from: (A) Untreated Pfpb2Rd2/Kd2 eye; (B) 
AAV.CBA.GDNF-treated Prpb2Kd2/Rd2 eye; (C) AAV.Rho.Prph2 treated Prph2Rd2/Kd2 eye; 
(D) AAV.CBA.GDNF and AAV.Rho.Prph2 combination-treated Prph2KA2/Rd2 eye. Greatest 
num ber o f photoreceptors are present in the eyes treated with a combination o f G D N F and 
gene replacement (D), more so than when eyes are left untreated (A), or when gene 
replacement alone is used in either model (C). INL, inner nuclear layer; RPE, retinal pigment 
epithelium; ONL, outer nuclear layer; IS, photoreceptor inner segments. Scale bar 25pm.
Again, comparing the combination of neuroprotection and gene replacement shows 
how potent this approach can be in this model, and supports the data from the 
assessment of retinal function; there is a four-fold increase in the number of 
photoreceptor cells surviving in eyes that received sub-retinal injection of the 
combination of AAV.CBA.GDNF and AAV.Rho.Prph2 when compared to untreated 
eyes. Importantly, the overall retinal morphology in eyes treated with GDNF, whether 
on by itself or in combination with gene replacement, was similar to that seen in wild- 
type mice.
RCS rat eyes were assessed three months post-injection to determine the histological 
effect of AAV-mediated GDNF expression in this model. Again, AAV-mediated
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GDNF expression results in a greater number of photoreceptors surviving; in eyes 
treated with AAV.CBA.GDNF alone 64 % more photoreceptors were present than 
untreated contralateral eyes (Figs. 6.11 A, 6.1 IB and 6.12C, p=0.006). Moreover, 
when used in combination with gene replacement therapy, AAV-mediated GDNF 
delivery allows a greatly enhanced survival of photoreceptor cells; Figs. 6.11C, 6.1 ID 
and 6.12C show that in RCS rat eyes treated with a combination of 
AAV.CBA.GDNF and Lenti.Mertk, 72 % more photoreceptor cells are present when 
compared with eyes treated with MERTK only (p=0.0004).
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Fig. 6.11 -  E n h an ced  preservation  o f photoreceptors in  RCS rats following AAV- 
m ed iated  G D N F  delivery: Representative photomicrographs o f H & E stained paraffin 
sections, taken using a 20X objective lens, from: (A) Untreated RCS eye; (B) 
AAV.CBA.GDNF-treated RCS eye; (C) Lenti.Mertk-treated RCS eye; (D) 
AAV.CBA.GDNF and Lenti.Mertk combination-treated RCS eye. Greatest number of 
photoreceptors are present in the eyes treated with a combination o f G D N F and gene 
replacement (D), more so than when eyes are left untreated (A), or when gene replacement 
alone is used in either model (C). INL, inner nuclear layer; ONL, outer nuclear layer; RPE, 
retinal pigment epithelium; DEBRIS, layer of photoreceptor debris that accumulates due to 
Mertk mutation in RCS rat. Scale bar 25pm.
162
There is a five-fold increase in the number of photoreceptors surviving when 
comparing eyes treated with the combination of AAV.CBA.GDNF and Lenti.Mertk to 
untreated eyes (Fig. 5.12C). This again emphasises the potent neuroprotective effect 
exerted by GDNF, in particular in combination with gene replacement therapy.
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Fig. 6.12: Quantification o f histological preservation o f photoreceptors following 
AAV-mediated GDNF delivery; (A) In Pfpb2Kd2/Kd2 mice, AAV-mediated G D NF  delivery 
results in 25 % more photoreceptors surviving four months post-injection when compared 
with untreated internal control eyes (p=0.01). (B) Treatment with a combination of 
AAV.CBA.GDNF and AAV.Rho.Prph2 results in 74 % more photoreceptors surviving 
when compared with AAV.Rho.Prph2-mediated gene replacement therapy alone (p=0.04). 
(C) Sub-retinal injection o f AAV.CBA.GDNF alone results in 64 % more photoreceptors 
surviving in the RCS rat when compared with uninjected eyes at three months post-injection 
(p=0.006), whilst injection o f a combination o f AAV.CBA.GDNF and Lenti.Mertk results 
in 72 % more cells surviving at the same timepoint when compared with contralateral eyes 
given Lenti.Mertk-mediated gene replacement therapy alone (p=0.001).
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6.7 Discussion
CNTF is perhaps the most extensively studied neurotrophic molecule in the 
context of ocular therapeutics [125,252-255,285-287]. Transplantation into the 
vitreous of encapsulated cells stably transfected with the CNTF gene [287] or 
intraocular injection of viral vectors expressing CNTF have prolonged photoreceptor 
cell survival by up to three months [253-255]. Indeed, a small phase I clinical trial of 
an encapsulated cell-technology (ECT) device secreting CNTF has recently been 
initiated [288]. Whilst CNTF has a potent effect on photoreceptor survival in animal 
models, the detriment to normal retinal function is a cause for concern in terms of 
clinical application; Bok et al [254] and Schlichtenbrede et al. [255] both showed a 
major reduction in pan-retinal function following administration, with the former 
study suggesting a dose-dependent element to the detrimental side effects of CNTF. 
In this study we have shown that the detrimental effects of CNTF are dependent of the 
dose administered, whilst administering a dose of CNTF that does not adversely affect 
normal retinal function precludes its ability to delay photoreceptor cell death.
Our study in Prph2RA2l+ mice also indicates that reduced function resulting from 
vector-mediated CNTF delivery is not stably maintained, but continues to decline over 
time and is always lower than in untreated and sham-treated controls. It is therefore 
unlikely that patients treated with an ECT device secreting CTNF would benefit in 
any way from preservation of photoreceptors despite loss of function. Moreover, 
long-term histological and immunohistochemical analysis of Prph2RA2l+ eyes treated 
with CNTF demonstrated damage to photoreceptors; specifically, the shutoff of cone 
opsin expression is of concern in terms of clinical application, as patients receiving 
CNTF-mediated treatment depend on a central island of cone-rich macula for residual 
vision.
Further work is required to investigate the causes of this long-term deleterious effect 
on photoreceptors. We need to determine whether long-term CNTF expression 
actively induces photoreceptor apoptosis, or whether another mechanism is 
responsible for fewer photoreceptors surviving in Prph2RA2l+ eyes treated with CNTF 
than in untreated eyes. The mechanism behind cone opsin shutoff is also unclear;
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previous studies using AAV-mediated CNTF expression have reported morphological 
changes in inner retina nuclei, suggestive of a change in the gene expression in these 
cells. In all, these data suggest that the deleterious effects of CNTF outweigh any 
potential beneficial effects, and urge caution against the use of CNTF-mediated 
treatment for retinal degeneration in patients.
In the case of GDNF, a strong neuroprotective effect has also been demonstrated in 
rodent and primate models of Parkinson’s disease [289]. However, Phase II clinical 
trials in which Parkinsonian patients received intracranial infusion of recombinant 
GDNF protein were halted as no clinical benefit was observed. Evidence from another 
study suggested that long-term GDNF infusion was well tolerated and efficacious in 
ameliorating symptoms [290], suggesting that the decision to discontinue the larger- 
scale trial may have been premature. Viral vector-mediated delivery of GDNF has 
been used to delay Parkinsonian symptoms in rodents and non-human primates, 
although GDNF gene delivery appears to cause overexpression-related side effects in 
both Parkinsonian and normal brain tissues [291]; components of the dopamine 
synthesis pathway in striatal neurones are directly downregulated by GDNF, leading 
to reduced dopamine production. This has lead to the development of inducible viral 
vectors to deliver the neurotrophic factor [292] the use of which is designed to prevent 
the effects of continuous GDNF expression.
Previous studies that have examined the effects of prolonged CNTF transgene 
expression in the eye have reported changes in the morphology of photoreceptor cell 
nuclei and have suggested that effects on the outer retina or re-modelling of the inner 
retina might be responsible for the reduction in retinal function [254,255]. We did not 
notice any obvious changes in the inner or outer retinal appearance following 
injection of vector expressing GDNF. This suggests that AAV-mediated GDNF 
expression is better tolerated than AAV-mediated CNTF expression, and supports 
evidence from previous work that the mechanisms of action of GDNF are distinct 
from those of CNTF [293]. Evidence from our study further demonstrates that whilst 
exerting a neuroprotective effect on degenerating photoreceptors, CNTF causes loss 
of retinal function, whereas GDNF is able to significantly slow photoreceptor loss 
without the concomitant detrimental side effects. These data represent the first 
evaluation of a combination approach to viral vector-mediated retinal gene therapy,
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whereby a neurotrophic factor is shown to act synergistically with gene replacement 
to provide enhanced cell survival over gene replacement or growth factor alone. Due 
to its apparent lack of deleterious side effects GDNF may in fact be a more 
appropriate candidate to be carried through into large animal models and eventually 
patient trials, although further work dissecting the precise mechanisms underlying the 
neuroprotective effect exerted by GDNF is needed before such a clinical application 
can be considered.
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7. D iscussion
7.1 Improving gene replacement therapy in rodent models of 
retinal degeneration
The experiments discussed in Chapters 3 and 4 were aimed at developing 
improved gene replacement strategies in five clinically applicable models of retinitis 
pigmentosa: the RCS rat, the rdl2  mouse, the Prph2Rd2/Rdl mouse, the rdl mouse and 
the Rho'1' mouse. One of the major objectives, that of demonstrating efficient 
transgene expression using novel integrase-deficient viral vectors in rodents, was 
achieved. We were also able to show efficacy of these integrase-deficient vectors in 
mediating gene replacement therapy in the RCS rat and rdl2  mouse. In the first 
instance, these data are to our knowledge the first example of effective, stable gene 
replacement therapy mediated by integrase-deficient vectors. The use of lentiviral 
vectors carrying pleiotropic integrase mutations has several advantages over both 
integrating lentiviruses and over other vectors whose genomes remain episomal. 
Because these novel lentiviral vectors mediate gene transfer to post-mitotic cells in 
the absence of integration into host chromosomal DNA, they represent a significant 
advance in the biosafety of lentiviral vectors; the risk of insertional mutagenesis is 
greatly reduced compared to integrating retroviral and/or lentiviral vectors, such that 
these novel vectors have much less oncogenic potential. Unfortunately the gene 
replacement therapy in which insertional oncogenesis was shown to cause significant 
adverse effects (IL2RG gene replacement in patients with X-SCID, see Chapter 1) 
would presumably not be a suitable application for integrase-deficient lentiviral 
vectors, as the episomal vector DNA would be lost from the rapidly dividing 
haematopoietic stem cells transduced in this therapeutic regimen. Nonetheless, there 
is great potential for the use of integrase-deficient vectors in the treatment of diseases 
affecting post-mitotic tissues such as muscle, the CNS and the eye, whereby the lack 
of integration does not reduce the high efficiency and stability of gene expression that 
make lentiviral vectors very efficient gene therapy agents. It is this combination of 
increased biosafety and preservation of therapeutic efficacy that is most promising in 
terms of applying lentiviral gene therapy to humans.
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We showed that by using an AAV2 vector pseudotyped with the AAV5 capsid, we 
were able to enhance the functional improvement following gene replacement therapy 
in the Prph2Rd2/Rd2 mouse (Chapter 5); based on studies comparing the kinetics of 
transgene expression between different AAV serotypes [265], this was likely due to a 
higher proportion of cells being transduced, and the onset of transgene expression 
from AAV2/5.Rho.Prph2 being faster than that from the AAV2/2.Rho.Prph2 used in 
previous studies. Pseudotyped AAV vectors have been previously shown to mediate 
rapid, stable reporter gene expression in the eye following sub-retinal delivery in 
wild-type mice [264,265], and in the muscle using intra-articular delivery in a model 
of arthritis [294]. Therapeutic gene delivery using AAV2/5 has also been investigated; 
GALC gene replacement therapy in twitcher mice, which are a model of inherited 
globoid-cell leukodystrophy, results in higher GALC protein production, greater 
preservation of CNS morphology and greater longevity of mice when mediated by 
AAV2/5 when compared with AAV2/2 [294]. Also, AAV2/5 was shown to mediate 
effective gene replacement in RPE65'1' dogs [295], a model of LCA caused by RPE65 
deficiency. Thus, the therapeutic potential of AAV2/5 has been established, and the 
data presented here comparing AAV2/5.Rho.Prph2 with AAV2.Rho.Prph2 (Chapter 
5) confirm that gene replacement therapy using AAV2/5 results in significantly 
improved function when compared with AAV2/2. Notwithstanding this finding, we 
report that there does not appear to be significantly more photoreceptors surviving in 
AAV2/5-treated eyes when compared with AAV2/2-treated eyes. A study in which 
AAV2/5 and AAV2/2 were administered to murine CNS would seem to support our 
data. The authors of this study conclude that although more efficient transduction was 
achieved with AAV2/5 encoding a reporter gene when compared to AAV2/2, 
protection from cell death following axotomy was no greater following therapeutic 
gene delivery of nerve growth factor (NGF) by AAV2/5 than by AAV2/2 [296]; this 
was attributed to having reached a ceiling of NGF protein levels with the AAV2/2 
vector, meaning that the more efficient pseudotyped vector is unable to mediate 
enhanced production of NGF, which prevents AAV2/5-treated neurones from 
surviving longer. It would be of considerable interest to see whether the expression of 
Peripherin had reached a similar peak using AAV2/2, or whether treatment with 
AAV2/5 does lead to increased Prph2 transcipt production. Despite having shown 
that there is a significant improvement in the ERG b-wave obtained from 
AAV2/5.Rho.Prph2-treated eyes compared with AAV2/2-treated eyes, our study
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suggests that there is not a reduced loss of photoreceptors in eyes treated with 
AAV2/5. It would appear that this is because gene replacement therapy does not stop 
photoreceptors from dying by apoptosis in this model of retinal degeneration. 
Nonetheless, further investigation of the effect of AAV2/5-mediated gene 
replacement therapy in this model is warranted. We sacrificed the treated animals five 
months after injection, at a time when the AAV2/5-treated eyes did not have 
significantly better ERG b-wave amplitudes than AAV2/2-treated eyes. It is 
conceivable that we may have seen more photoreceptors surviving in AAV2/5-treated 
eyes than in AAV2/2-treated eyes had we examined a cohort of eyes at 10 weeks 
post-injection, when the former had on average 27% greater b-wave amplitudes than 
the latter. This will be investigated as part of the studies that follow the work 
presented here. In addition, we were unable to fully test the effect of gene replacement 
therapy on cone function as part of the studies presented here. The ERG equipment 
used to monitor retinal function in our treated mice has now been improved in order 
to investigate cone function, and in addition the use of novel LED-based ERG 
techniques enables reliable measures of cone function to be taken. We have 
demonstrated that the novel fragment of the mouse opsin promoter (MOPS) described 
in Chapter 5 drives transgene expression in rods, but not in cones. As part of the 
further work to be carried out following the studies presented here, alternative 
promoter sequences that mediate expression in both rods and cones need to be 
investigated, with the aim of administering gene replacement to models such as the 
Prph2Rd2IRd2 mouse and assaying their cone function. As many RP patients in end- 
stages of disease depend on their cone-mediated vision once the peripheral retina has 
atrophied, it is of great importance from a clinical perspective to develop gene 
replacement therapies that specifically enhances cone function.
Whilst were able to demonstrate that AAV2/5 mediates enhanced functional 
improvement in the Prph2RdlfRdl mouse, the other models of retinal degeneration we 
studied appear to benefit less from AAV2/5-mediated gene replacement therapy. The 
failure of AAV2.5.CMV.pPDE to mediate efficient transgene expression in vivo in 
the rdl mouse, despite the expression cassette being effective in vitro, shows that 
certain models of retinal degeneration may be less amenable to gene replacement than 
others. We cannot rule out the possibility that our particular rAAV preparation was 
either rendered non-infectious or contaminated with toxic by-products during
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preparation, although we did repeat the virus isolation and obtained the same result. 
Previous attempts at treating the rdl mouse using gene replacement therapy have also 
proved largely unsuccessful, either through use of adenoviral vectors [178,227] which 
have subsequently been shown not to transduce photoreceptors [168], through use of 
lentiviral vectors [228] for which the same applies [199] or through low-level protein 
production following administration of relatively low-titre AAV (lx l0 7 infectious 
particles per ml, [230]). It appears, therefore, that achieving rescue in the rdl mouse is 
challenging, and that both more comprehensive reporter gene studies and further 
advances in vector production may be necessary to rescue this model of retinal 
degeneration.
7.2 Neuroprotection in combination with gene replacement 
therapy may be an effective treatment strategy for retinitis 
pigmentosa
Preventing photoreceptor cell death is vital to the success of any treatment for 
retinal degeneration; correcting a molecular defect, even if it results in ameliorating 
the function of the tissue being treated, will only produce a transient treatment effect 
if photoreceptors continue to die at the same rate as before or without treatment. This 
has been effectively demonstrated with gene replacement studies in the Prph2Rd2/Rd2 
mouse, whereby an initial improvement in retinal function begins to decline nine 
weeks post-treatment [246], caused by the failure to slow photoreceptor loss [244]. 
Hence, a large number of studies have investigated a different approach to gene 
therapy for retinitis pigmentosa, neuroprotection -  the delaying or preventing of 
photoreceptor apoptosis by the use of neurotrophic factors. Many of the first studies 
using this approach were concerned only with allowing photoreceptors to survive for 
longer following administration of a neurotrophic factor, either as recombinant 
protein [124,125] or by vector-mediated delivery of the gene encoding the 
neurotrophic factor [247,252]. These studies demonstrated that, amongst others, 
ciliary neurotrophic factor can mediate some protection from cell death in models of 
retinal degeneration, but that this protection is short-term. Longer-term protection 
from cell death has been demonstrated in rodents that carry mutant human transgenes
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for Rhodopsin [253] and Peripherin [254], but these studies also demonstrated that 
CNTF has detrimental effects on retinal electrophysiology that cased major concern in 
terms of translating this type of therapy to a clinical setting. One crucial aspect of 
these studies is that no correction of the underlying molecular defect was attempted 
alongside the administration of the neurotrophic agent; the aim of these studies was 
simply to prolong photoreceptor cell survival, but a treatment in which cells survive 
longer but still have little or no function is unlikely to be of benefit to patients. 
Attempts were therefore made to assess the effect of combining neuroprotection and 
gene replacement therapy. In this study Schlichtenbrede et al. showed that CNTF 
administration resulted in reduced retinal function both in normal animals and in 
Prph2Rd2fRd2 mice that had received gene replacement therapy. The experiments 
described in Chapter 6 follow on from these previous studies by demonstrating that 
CNTF causes dose-dependent detrimental side effects to retinal function, and that 
reducing the dose of CNTF abrogates its neuroprotective function. Moreover, we 
report long-term detrimental effects on cone opsin expression, electrophysiology and 
retinal morphology following long-term exposure to CNTF in Prph2Rd2l+ mice. It 
remains to be seen whether these finding will be replicated in the patients that have 
received CNTF as part of a clinical trial, although our findings do not support this 
approach as a clinical therapy.
We have shown, nonetheless, that neuroprotection in combination with gene 
replacement therapy is feasible, and that slowing of photoreceptor cell death can be 
combined with restoration of an underlying molecular defect without detrimental side 
effects. Our results using AAV-mediated GDNF expression indicate that GDNF may 
be a more suitable candidate than CNTF for further investigation as a neuroprotective 
agent; we have shown that expression of GDNF does not reduce normal retinal 
function, and enhances gene replacement as shown by significantly higher ERG b- 
wave amplitudes and significantly more photoreceptors surviving at the latest time 
points assessed. Nevertheless, many more issues need to be addressed before the use 
of GDNF in clinical trials can be considered. The improvement in retinal function 
appears to remain transient, despite there being more photoreceptors present in 
GDNF-treated eyes than in untreated eyes or those that received gene replacement 
alone. There are a number of alternative explanations for this finding. It may be that 
by using a pan-retinal measure of retinal function, we may be unable to detect an area
171
of GDNF-treated retina that has preserved function for longer than in other areas in 
the same eye. Consider that some patients with a completely extinguished pan-retinal 
scotopic ERG retain photoreceptor function in a small sector of retina, meaning their 
visual acuity is preserved in a narrow visual field to the extent that their quality of life 
is maintained [297]. It is conceivable that a therapy such as AAV-mediated GDNF 
expression, in combination with an efficient gene replacement therapy, could achieve 
preservation of structure and function in given areas of the retina (of particular 
interest would be the preservation of photoreceptors in the macula), and this could be 
sufficient to constitute an effective clinical therapy. The use of visual acuity tests, 
multifocal ERG and microperimetry would aid the assessment of whether this is the 
case in patients. To do the same in rodents is more challenging, as most measures of 
visual function used in rats and mice average measurements from across the retina. 
One technique that may allow function in discrete areas of the retina to be measured 
and compared would be the use of a multi-electrode array (MEA) on retinal explants 
to record the response from the ganglion cells or inner retina following stimulation 
with light [298].
As the studies presented here demonstrate, the success or otherwise of gene 
replacement therapy and neuroprotection in animal models of retinal degeneration 
depend upon several factors. The development of novel vector systems that mediate 
increasingly efficient and safe transgene delivery is of great importance, but is not the 
only factor involved. Certain models of disease appear to be more amenable to viral 
gene therapy than others, and it may be that the nature of the causative mutation 
underlies this. Some models of RP have shown long-term protection from cell death 
following gene replacement therapy alone; disease correction in models of RP caused 
by mutations in Rpe65, RPGRIP and Rsl results in retardation of apoptotic cell death. 
Models of RP caused by more severe biochemical insults to photoreceptors and/or the 
RPE are inherently difficult to treat, because it appears that photoreceptors commit to 
apoptotic cell death if they have severe disturbances in their metabolic capabilities or 
structure, whereas those models that have more subtle insults to photoreceptor 
metabolism appear easier to treat. This is where neuroprotection may have most 
impact; we have seen that gene replacement alone is not capable of slowing cell death 
in the Prph2Rdmd2 mouse, and is not effective at doing so to any great extent in the 
RCS rat. Our studies show that by using a combination of gene replacement and
172
neuroprotection, long-term preservation of photoreceptors can be achieved. Thus a 
similar combination may be useful in other models of disease in which gene 
replacement therapy does not appear sufficient to mediate long-term rescue.
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Appendix I
PCR primer sequences, MOPS promoter:
Outer pair: 5’ TTTAGGGCCCAAGGGTTCCAGTCG 3’, TM = 64.7 °C 
5’ CGTTCATGGCTGCGGCTCTCG 3’, TM = 64.5 °C 
Inner pair: 5’ CAGACTGACATGGGGAGGAAT 3’, TM = 57.2 °C 
5’ CTCCCACAGCGCAACTCC 3’, TM -  53.7 °C
Immunohistochemistry conditions:
Chicken anti-mouse cone opsin (mixture of anti-S-opsin and anti-L/M-opsin 
antibodies, Fig. 5.7 and Fig. 6.5): 1/5000 in TBS-T. Secondary antibody: Alexa 546- 
conjugated goat anti-chicken IgG (Molecular Probes, UK), 1/200 in TBS-T.
Biotinylated peanut agglutinin (PNA, Fig. 5.7 and Fig. 6.5): 1/200 in TBS-T. 
Streptavidin-conjugated Alexa 488,1/250 in TBS-T
Mouse monoclonal anti-Rhodopsin (Fig. 5.16): 1/100 in TBS-T. Secondary 
antibody: Alexa 546-conjugated goat anti-mouse IgG 1/500 in TBS-T
Rabbit anti-mouse (3-PDE serum (Fig. 5.14): 1/500 in TBS-T. Secondary 
antibody: Alexa 546-conjugated goat anti-rabbit IgG 1/150 in TBS-T.
Rabbit polyclonal anti-mouse |3PDE antibody (5.15): 1/500 in TBS-T. 
Secondary as above.
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